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Abstract 
  The nuclear receptor PPARγ is a lipid-dependent transcription factor which 
regulates many pathways in lipid metabolism. Due to functions in adipogenesis, 
glucose uptake and insulin sensitivity it has been a target of type II diabetes 
mellitus therapeutics since the 1990s. Due to a poorly understood anti-
inflammatory pathway it is also an emerging target in neurodegenerative disease. 
Despite extensive research the majority of the structural mechanism underlying 
the regulation of this proteins’ function is poorly understood. It is often thought 
that nuclear receptors function in a simple two-state model with defined on and 
off states. This model only considers one region of the protein, the coregulator 
interaction surface. In this mechanism ligands function only to modulate the 
equilibrium population of the active and inactive states. In this work we examine 
the conformational ensemble of PPARγ in response to the binding of a wide 
variety of structurally and functionally diverse ligands and find clear evidence 
that this model is only correct for the most efficacious activating ligand. In all 
others the ligand induced conformational ensemble is highly diverse and contains 
multiple populations. Additionally, the mechanisms of inverse agonism and 
agonism are examined. Through this a novel mechanism of inverse agonism is 
determined. As well we demonstrate that the mechanistic underpinnings of 
agonism are not strictly through the coregulator interaction surface. The most 
efficacious ligands also make important interactions in other regions of the 
protein which are often disregarded. Among the most interesting findings is the 
identification of a highly conserved motif on helix 4 of the ligand binding domain 
of nuclear receptors. We demonstrate that this motif is responsible for a large 
degree of the specificity observed in coactivator interactions. This provides a 
substantial amount of insight into the mechanism by which these proteins function 
as it had previously been observed that coactivator recruitment was exceptionally 
specific, but no mechanistic reason was known. Through this work we have 
gleaned a deeper understanding of the mechanism of specific ligand-dependent 
conformations in this important protein. This fundamental understanding allows 
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Chapter 1 Introduction 
1.1 Nuclear Receptors 
  The nuclear receptors (NR) are a diverse family of transcription factors 
that regulate a wide variety of signaling pathways. In the human genome there are 
48 recognized NR proteins in this superfamily which make up the largest group of 
known transcription factors1,2. These proteins are highly sequence divergent but 
structurally conserved3. All members of this superfamily share a very modular 
fold wherein they contain an N-terminal intrinsically disordered region known as 
either the A/B domain or the activation factor 1 region (AF-1). This domain has 
very low homology between nuclear receptors and like many intrinsically 
disordered regions appears to function primarily in the recruitment of regulatory 
proteins. Though there is an emerging role for this domain in the modulation of 
drug response. Thus far this has only been reported with estrogen receptor alpha 
(ERα)4,5 but this may also be true for other members of this superfamily. The next 
domain is the C domain or DNA-binding domain (DBD). This approximately 80 
residue domain is highly conserved between nuclear receptors, ~80%, and 
contains two tetra-cysteine zinc fingers. This domain mediates the interaction 
with the respective response element for each of the NR. Receptors will bind to 
their response element as either heterodimers, most often dimerized with retinoid 
x receptors (RxR), homodimers or as half-site binders. This leads to highly 
divergent sequences for the response elements, but they are most often  direct 
repeats for heterodimeric binding proteins or an inverted repeat if the receptor 
binds as a homodimer. The next domain, D,  is the flexible hinge region of 
approximately 20 residues which connects the DBD to the following domain and 
allows conformational freedom between the domains of the protein. For many 
nuclear receptors the E domain or ligand-binding domain (LBD) is the C-terminus 
of the protein. This domain has a very conserved fold made up of approximately 
12 α-helices and a single region which typically contains three β-sheets. Not all 
nuclear receptor LBDs have exactly 12 helices, but they are numbered as if they 
do. The LBD contains the ligand binding pocket as well as the major coregulator 
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interaction surface known as the activation factor 2 (AF-2). In some receptors, 
primarily the hormone receptors, there is an additional F domain which is 
moderately structured and makes up the C-terminus of the protein. The role of the 
F domain is not known but has been shown in some receptors such as ERα or 
glucocorticoid receptor (GR) to be essential for protein stability. Recent data in 
ER α and β indicates this domain may also be required for agonist behavior of 
certain ligands6,7. 
 
Figure 1. Conserved structure of nuclear receptors. A: Primary structure of nuclear receptors 
showing the four conserved domains seen in nuclear receptors. Domain F is unique to hormone 
receptors and is not present in the majority of nuclear receptors. B: Crystal structure of the DBD of 
GR bound to a response element of DNA (PDB 1GLU). C: Crystal structure of the LBD of GR 
bound to a peptide of the coactivator TIF2 (PDB 1M2Z). Both the DBD and LBD have a 
conserved fold in nuclear receptors, so the representative structures shown will be very similar to 
those of other nuclear receptors. Figure was adapted from Carter et al8. 
 
These receptors are primarily divided into three families (NR1, NR2 and 
NR3) which respond to different types of ligands. The NR1 family is primarily 
lipid-dependent and binds either fatty acids or cholesterol metabolites. The NR2 
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family is by majority vitamin-dependent and binds a variety of essential vitamins 
such as retinoic acid (vitamin A). There are exceptions to this however, as the 
vitamin D receptor (VDR) is a member of the NR1 family while the orphan 
receptor testicular receptor 4 (TR4) which has no known ligands specific to this 
protein but can bind peroxisome proliferator-activated receptor gamma (PPARγ) 
synthetic ligands is a member of NR2. The NR3 family is composed primarily of 
hormone receptors and include heavily studied receptors such as GR or ERα. 
There are three additional small families which are the NR0, NR4 and NR5 
families. These are all orphan receptors, with no known ligands, and several, 
including all members of the NR4 family, are considered to be constitutively 
active and ligand-independent9,10. This is based on crystallographic observations 
that these proteins do not contain a true ligand binding pocket due to impingement 
by helix 3 and a large number of bulky hydrophobic side chains in the ligand 
binding pocket9. However, a recent paper examining the LBD of Nurr1, NR4A2, 
showed that the residues around what would be the ligand binding pocket are 
highly plastic11. This may indicate that what is observed in crystal structures is 
only one of several accessible conformations in this region and that in some 
accessible conformations there is a properly formed ligand-binding pocket. The 
NR0 family is also interesting, these proteins have lost the AF-1 and DBD 
through the evolutionary process and now function more in the manner of a 
coregulator. They still form heterodimers with other nuclear receptors but due to 
the lack of their own DBD they are almost exclusively transrepressive12,13.  
1.2 Mechanism of transcriptional regulation 
Nuclear receptor function is regulated through the recruitment of 
coregulator complexes. These occur through direct interactions between the 
nuclear receptor and either a coactivator or a corepressor protein in a ligand-
dependent manner. The binding of a coregulator to a NR will then nucleate the 
formation of a large complex which regulates the transcription of downstream 
genes in a variety of ways. It is generally thought that in an apo state of the 
nuclear receptor it is almost exclusively bound with corepressors and when bound 
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to an endogenous ligand or a synthetic agonist, corepressors are displaced and 
coactivators are recruited. These interactions are primarily mediated by small 
motifs on the coregulator protein. In a coactivator this interaction motif is 
comprised of an LxxLL sequence known as an NR box14–16 (In this work referred 
to as an LxxLL box to avoid confusion with the abbreviation for nuclear 
receptor). For a corepressor this motif is a somewhat longer and there is less 
clarity in what makes up the sequence, but it is postulated that this motif contains 
at least I/LxxI/VIxxxF/Y/L, LxxxL/IxxxL/I or L/VxxI/VI and is referred to as a 
CoRNR box17–20. The LxxLL or CoRNR box interacts most often on the AF-2 
surface of the nuclear receptor in a conserved manner where the interaction is 
mediated primarily by a single α-helix of the coregulator protein. These 
interactions are exceptionally specific with each NR binding only certain 
coregulators and often only specific LxxLL or CoRNR boxes within a 
coregulator. Currently, little is known of how these interactions are specific but in 
chapter three of this work we present evidence for a helix 4 motif on the AF-2 
surface of nuclear receptors which appears to be responsible for the majority of 
the specificity observed in coactivator binding. 
What is known about coregulator recruitment is almost completely in the 
context of coactivators. It has been shown that the AF-2 surface of a nuclear 
receptor has a hydrophobic cleft which allows a docking event between the 
leucine residues in the LxxLL box and the nuclear receptor21. Following this 
docking the most common hypothesis for interaction is from the “mousetrap 
model” of the charge clamp. The charge clamp is made up of a glutamate on helix 
12 and a lysine on the C-terminus of helix 3 which are conserved in almost all 
nuclear receptors22. In this model helix 12 relocates into a conformation where it 
is more proximal to the coactivator LxxLL box. This moves the coactivator into a 
conformation where it is located near both charge clamp residues and allows for 
the formation of extensive hydrogen bonds between the charge clamp residues 
and the peptide backbone of the LxxLL box. These interactions have been shown 
experimentally to convey the bulk of the binding energy for the coregulator but as 
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stated earlier confer no selectivity since they are to a conserved region of the 
peptide backbone of the coactivator. 
 Additionally, there are several nuclear receptors which have been shown 
to interact with coregulators through the intrinsically disordered AF-1 region23,24. 
The nature of this interaction is not well understood. The hypothesis for how this 
binding leads to a functional output is by driving a self-association between the 
AF-1 and the LBD which is required for activity, but why this is required for 
activation is not currently clear. This often leads to coregulators binding to both 
the AF-1 and AF-2 surface simultaneously25,26. It has been demonstrated that 
these spanning interactions are important for function but the structural reason 
why remains unclear. In the case of a small number of nuclear receptors, the NR4 
family and the testicular receptors (TR2 and 4)27,28, the AF-2 surface is degenerate 
and unsuitable for coactivator binding, so all coactivator interactions are mediated 
purely through the AF-1. For the NR4 proteins this is primarily thought to be due 
to a reversal of the charge clamp residues. In all three members of this family the 
helix 12 charge clamp residue is instead a lysine and the helix 3 charge clamp 
residue is a glutamate. This is in contrast to all other nuclear receptors which have 
the conserved lysine on helix 3 and the glutamate on helix 12. It is not totally 
clear why this change prevents coactivator recruitment on the AF-2 as these 
residues are only involved in non-specific hydrogen bonds to the backbone of 
coactivators but it has been shown experimentally that only the AF-1 contributes 
to coactivator binding in Nur77 and that the presence of the LBD actually lowers 
coactivator affinity29. For the other nuclear receptors which do not bind 
coactivators through the AF-2, TR2 and TR4, the reason appears to be due to a 
change in the polarity of the normally hydrophobic cleft where the leucines in the 
LxxLL box interact. In these proteins this cleft is much shallower and more polar 
which creates an unfavorable environment for these hydrophobic interactions27,28. 
Interestingly, in at least Nurr1, NR4A2, it has been found that not only do 
coactivators not bind in the AF-2 region but corepressors may also bind in a novel 
position which is located in a cleft between helices 11 and 1230. 
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1.2.1 Transcriptional activation through the recruitment of coactivator 
complexes 
 
Coactivator proteins recruit large complexes which depending on the 
coactivator have distinct functionality and regulate different pathways31. The 
largest family of coactivator proteins is the p160 family32. This includes the most 
commonly studied coactivator proteins nuclear receptor coactivator 1 and 2 
(NCoA 1 and 2), also commonly known as SRC 1 and 2, as well as several other 
proteins. These proteins function primarily through the formation of histone 
acetyltransferase (HAT) complexes which covalently modify histone proteins and 
lead to the release of DNA thereby making it more accessible for transcription33. 
Other common coactivators such as p300 and creb-binding protein (CBP) 
nucleate the formation of similar HAT complexes34. There is significant crosstalk 
between the NCoA proteins and CBP or p300 as it has been shown for each they 
are often in the complexes assembled by the other35 leading to a synergistic 
activation. In addition, the yeast HAT protein GCN536, closely related to the 
human analog KAT2A, has been shown to directly bind some nuclear receptors in 
a drug dependent manner as a coactivator. This implies that the formation of large 
complexes may not always be necessary for coactivator function, but it should be 
stated that it is not clear that if these HAT proteins were directly recruited they 
would not nucleate larger complexes as well.  
Not all coactivators are dependent on histone modification for function. 
Two examples of this are the mediator of RNA polymerase II transcription 
subunit 1 (MED1, also known as TRAP220 and DRIP205) and PPARγ 
coactivator 1α (PGC1α)37–39. With these coactivators the mechanism operates 
through a direct interaction with the promoter rather than through the recruitment 
of HAT proteins. Both of these proteins function in the same manner where upon 
binding  of the nuclear receptor they assemble the 33-protein mediator complex. 
This complex will then interact directly with the promoter of the gene to be 
transcribed and facilitate the assembly of the RNA polymerase II holoenzyme.  
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There may also be other activity with two specific coactivator proteins, 
NCoA140 and MED141. These have been shown in cell-based assays to increase 
gene expression when overexpressed. The mechanism of this is not fully clear as 
it occurs in the absence of stimulation of any ligand for receptors which interact 
with these proteins. The most likely hypothesis for this observation is that the 
higher concentration of overexpressed MED1 or NCoA1 led to more instances 
where the NR was bound to the coregulator even in the absence of ligand. This is 
consistent with the observation that NR have an innate low affinity for 
coactivators when the NR is in the apo state. However, this hypothesis has not 





Figure 2. Nuclear receptor activity is mediated by coregulator recruitment. Nuclear receptor 
regulated transcription of downstream genes is mediated by the recruitment of coregulators. For 
most nuclear receptors depending on the ligand bound state either coactivator complexes (top) will 
be recruited to drive transcription. Alternatively, when bound to an inverse agonist or in the apo 
state there is a preference for corepressor binding which will downregulate the transcription of 
most downstream genes (bottom). Figure was adapted from Parissi et al42. 
 
1.2.2 Transcriptional repression and corepressor complexes 
Nuclear receptor corepressors are a much less diverse group. In humans 
there are two primary corepressors, nuclear receptor corepressor 1 and 2 (NCoR 1 
and 2, NCoR2 is often referred to as SMRT)43,44. These are both structurally 
similar large proteins, approximately 2500 residues, which are primarily 
intrinsically disordered. They share a mechanism of action whereby they nucleate 
the formation of complexes which contain one or more histone deacetylase 
(HDAC) proteins. The activity of HDAC will induce compression of genomic 
DNA and thereby reduce transcription of nearby genes. It is generally thought that 
the resting state of nuclear receptors in the absence of ligand is bound to one of 
these corepressors. Due to somewhat high structural similarity and a similar 
mechanisms of action it is often thought that these proteins are redundant and 
perform the same role. However, this seems unlikely mostly due to the high cost 
of producing such large and complex proteins. If these two NCoR proteins did not 
have discrete roles it is likely that one would have since been selected against and 
become a pseudogene. As well, there is some literature that suggests that one 
cannot compensate for the absence of the other. For instance, it was shown in 
mouse adipocytes that the selective ablation of NCoR1 created a phenotype very 
similar to that seen with treatment by a PPARγ activating drug45. If it were the 
case that NCoR1 and NCoR2 were redundant than it would be expected that the 
ablation would have had minimal effect due to compensation through NCoR2. 
There is a third less well understood corepressor, nuclear receptor 
interacting protein 1 (NRIP1). This protein is particularly interesting as it does not 
contain a CoRNR box like the other corepressors but rather contains the LxxLL 
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box seen in coactivators46,47. It has been shown to bind in a ligand-dependent 
manner with a binding preference for agonist bound receptors. It has similar 
corepressor activity as is seen with NCoR1 and SMRT arising primarily through 
the assembly of corepressor complexes containing HDAC proteins. However, it 
also has been shown to have some coactivator characteristics. This mechanism is 
not well understood but it is thought that the regulation of NRIP1 activity as either 
a coactivator or corepressor is regulated through post-translational modification of 
the NRIP1 protein or by the sequence of the DNA the nuclear receptor is bound 
to. The presence of an LxxLL box instead of a CoRNR box would also suggest 
this protein would have a distinct binding mode from the NCoR proteins. This is 
due to the fact that the CoRNR box has a much larger footprint on the nuclear 
receptor and binding is thought to require either displacement of helix 12 or as has 
more recently been shown a relocation of helix 1248. This implies that despite 
primarily having corepressor activity this protein likely binds in a manner similar 
to coactivators. 
1.3 Peroxisome proliferator-activated receptor gamma (PPARγ) 
The work in this project focuses on the nuclear receptor PPARγ. This 
protein along with PPAR α and δ (PPARδ is also referred to as PPARβ) make up 
the NR1C family. All the PPAR proteins function as lipid-dependent transcription 
factors and regulate a variety of pathways related to fatty acid metabolism49. The 
PPAR proteins like other fatty acid receptors transactivate as obligate 
heterodimers with the retinoid x receptors (RxR α/β/γ) through the binding of 
direct repeat sequences of five nucleotides with a single nucleotide spacer, known 
as PPAR response elements (PPRE)50. It is generally thought the PPAR proteins 
have a preference to interact with RxRα but recent in cell data showed that 
PPARγ was actually most often interacting with RxRβ51. The PPAR proteins 
regulate a number of pathways related to lipid metabolism and differ primarily in 
tissue distribution. Particularly PPARα and PPARδ appear to have very similar 
functions but differ in tissue distribution with PPARα being most heavily 
expressed in the liver52 and PPARδ having highest expression in skeletal 
10 
 
muscle53. Both these proteins are involved in signaling which leads to the 
metabolism of lipids as an energy source. Due to this there has been significant 
research on PPARα as a therapeutic target for dyslipidemia leading to the fibrate 
family of FDA approved drugs54. There has been significantly less research on 
PPARδ as a therapeutic target. Some experimental ligands have been created but 
none were suitable for human use55,56. 
PPARγ is expressed at low levels ubiquitously in almost all tissue types. 
There are two common isoforms which exist, PPARγ1 and PPARγ2, these 
isoforms differ only by the presence of an additional 28 residues on the N-
terminus of the protein in PPARγ2, in mice PPARγ2 contains an additional 30 
residues. For the purpose of clarity in the introduction all PPARγ residue numbers 
will be referred to in the form PPARγ1 #/ PPARγ2 # since both numbering 
systems are used extensively in literature. There are no currently known 
differences in the activity of the two isoforms of this protein. They do however 
differ significantly in tissue distribution. PPARγ1 is expressed at low levels in the 
majority of tissues while PPARγ2 is expressed almost completely in adipose 
tissue57. It has been shown that a high fat diet (HFD) in mice will lead to the 
expression of PPARγ2 in other tissues58,59. Depending on the tissue there appears 





Figure 3. Tissue specific expression of PPARγ in mice. The relative abundance of the PPARγ 
mRNA in a wide variety of tissue types shows highest expression in adipose tissue and the colon 
but some expression in almost all tissue types. Figure was adapted from Lee et al60. 
1.3.1 Function of PPARγ in adipose tissue 
The activity of PPARγ was first determined through its induction during 
adipogenesis61,62. The function of this protein is best understood through the roles 
it plays in adipogenesis and lipogenic pathways. As stated above the majority of 
PPARγ is expressed in adipose tissue. Adipose PPARγ has been shown to act as 
the master regulator of adipogenesis. This was first observed from PPARγ null 
mice which were completely unable to generate any adipose tissue63. Later 
experiments demonstrated that PPARγ knockout mouse embryonic fibroblasts 
were unable to be differentiated into adipocytes consistent with this protein 
playing an essential role in adipocyte differentiation64. Interestingly, it was also 
found through the selective ablation of PPARγ in mouse adipocytes that this 
protein is also required for maintenance as ablated cells died within a few days65. 
PPARγ was also identified as playing a role in the self-renewal of adipose 
tissue66. This was determined through the identification of a niche of adipocyte 
progenitor cells in the adipose vasculature which heavily expressed PPARγ and 
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could be differentiated into adipocytes by treatment with a PPARγ ligand unlike 
similar cells obtained from other tissues. Interestingly, adipose tissue is also the 
only location where PPARγ2 is expressed to significant levels in healthy animals. 
The specific role this isoform plays is not well understood as this tissue also 
heavily expresses PPARγ1. 
A function unique to PPARγ in adipose tissue is the “beiging” of white 
adipose tissue (WAT)67. This leads to a phenotypic shift which makes this tissue 
behave more similarly to brown adipose tissue (BAT). It had been thought that 
humans lack this tissue type, but recent research determined that there is a 
somewhat small reservoir of BAT in humans and like other adipose cells PPARγ 
was essential for its differentiation and maintenance68. This tissue unlike WAT is 
highly metabolically active and consumes lipids through uncoupled mitochondrial 
respiration to generate heat69. There has been significant research into this 
“beiging” phenomenon as due to the uncoupled oxidation of fatty acids this could 
be exploited for weight loss or the treatment of certain metabolic conditions. Thus 
far this “beiging” has only been observed following treatment with strong PPARγ 
activators and the exact mechanism is not fully clear70. The current hypothesized 
pathway is through stabilization of PRDM16, a transcription factor linked to BAT 
development. It has been found that the activation of PPARγ leads to an increased 
half-life for PRDM1671. This is supported by findings that deacetylation of 
PPARγ on two lysine residues, 240/268 and 265/293, leads to an association 
between PPARγ and PRDM1672. These findings have led to research to determine 
if this pathway is PPARγ transactivation independent and whether a ligand can be 
found which will preferentially increase this “beiging” without leading to 
canonical PPARγ signaling.  
1.3.2 Whole body signaling of PPARγ expressed in adipose tissue 
As well as regulating adipogenesis PPARγ also has important roles in 
adipose tissue which regulate glucose homeostasis. PPARγ activity increases the 
expression of the glucose transporter Glut473,74 and the c-cbl associated protein 
(CAP)75. Both of these proteins play important roles in insulin signaling. There is 
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also thought to be function in increasing insulin sensitization through the 
modulation of the release of cytokines and adipokines. It has been shown that 
PPARγ activation increases the release of adiponectin76. This adipokine is 
important in insulin signaling through signaling an increase in glucose uptake and 
a decrease in gluconeogenesis. Another important adipokine that is downregulated 
is leptin which is important in the regulation of the hunger response77,78. A 
significant amount of the PPARγ induced insulin sensitivity also comes from the 
reduction of pro-inflammatory molecules. For instance, high circulating glucose 
levels are highly inflammatory and have been linked to insulin resistance. As well 
PPARγ activation has been shown to reduce the expression of the pro-
inflammatory cytokine TNF-α79. This cytokine is also implicated in insulin 
resistance when at high levels and is frequently upregulated with type II diabetes 
mellitus (T2DM)80.  
Due to these strong effects in insulin sensitization PPARγ has been studied 
extensively as a medicinal target for T2DM. This has led to the development of 
multiple drugs which have been approved for human use by the FDA. 
Unfortunately, all of these drugs have been tied to severe negative side effects 
leading to the restriction or recall of some. Medicinally relevant ligands of PPARγ 
will be covered in more detail below in the section on synthetic ligands with the 
FDA approved ligands covered in the section on full agonists.  
1.3.3 Negative effects of PPARγ activation 
As stated earlier, PPARγ is expressed to low levels in the majority of 
tissue types. In many tissues this leads to beneficial effects such as are seen in 
adipose tissue. PPARγ activation in skeletal muscle81, the pancreas82,83 or the liver 
all leads to insulin sensitizing effects similar to those seen in adipocytes. Though, 
in the liver it is hypothesized that PPARγ activity leads to steatosis, a damaging 
accumulation of adipocytes84. However, literature also exists that suggests that 
PPARγ reduces liver steatosis85,86. So, the overall effect on liver health is unclear 
at this point.  There is also the observed effect of a pronounced decrease in 
inflammation in the brain. This has been of great interest in recent research 
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towards the treatment of neurodegenerative diseases. This will be covered in 
greater detail later in the section on anti-inflammatory effects. However, in some 
tissue types there are severe effects related to the activation of PPARγ which give 
rise to the negative side effects that have caused the recall or restriction of drugs 
targeting this protein.  
The best understood of these is a decrease in bone strength. This is caused 
by a decrease in osteoblastogenesis, the formation of bone tissue, and an increase 
in osteoclastogenesis, the resorption of bone cells. It has been found that the 
activation of PPARγ inhibits bone formation through a reduction in differentiation 
of osteoblasts87,88. To support this, it has also been shown that PPARγ-null 
embryonic stem cells will spontaneously differentiate to osteoblasts unlike normal 
embryonic stem cells89. As well, PPARγ-null hematopoietic mouse lineages are 
deficient in osteoclastogenesis90. This data indicates that the loss in bone integrity 
with PPARγ ligands occurs through the downregulation of osteoblastogenesis and 
upregulation in osteoclastogenesis. There is also evidence that PPARγ ligands can 
cause spontaneous differentiation of osteoblast precursors to adipocytes and lead 
to fat deposits forming in bone further decreasing bone integrity91. This was 
observed to lead to a large increase in hip fracture particularly in older women.  
Another common side effect seen with drugs targeting PPARγ is weight 
gain. This was originally thought to be due to the increase in adipogenesis caused 
by the activation of PPARγ. However, later work in two independent studies 
performed in mice implicated that this was actually due to the activation of 
PPARγ in the brain. This was determined in mice using both pharmacological and 
genetic methods92,93. Such findings were somewhat surprising as it was not 
thought that PPARγ ligands were capable of crossing the blood-brain barrier. 
These findings suggest that to understand the overall physiological ramifications 
of activating this protein it is not prudent to consider only the adipose tissue 
where these ligands have their most pronounced effect. 
There are other severe side effects with major ramifications regarding 
cardiac health. The first of these arises from PPARγ activity in the kidneys. It has 
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been shown that treatment with PPARγ agonists helps improve the pathogenesis 
of diabetic nephropathy (kidney damage)94, but this treatment also leads to edema. 
This arises due to an altered sodium and fluid reabsorption in the kidney. But, the 
exact mechanism is not totally clear as multiple studies on this topic have reported 
conflicting results95–97. Additionally, there are cardiac issues which occur from the 
activation of PPARγ in the heart98. In a healthy individual PPARγ is expressed to 
very low levels in the heart but with individuals who have metabolic disorders 
such as T2DM, heart PPARγ levels are greatly increased. Treatment with PPARγ 
ligands has been shown to increase the mass and fat content of the heart in mice99. 
As well, mice treated with PPARγ ligands have mitochondrial damage in the heart 
and develop cardiac myopathy100.  
1.3.4 Medical Ramifications 
Given the findings outlined above it is clear that PPARγ is a medicinal 
target of high value. This is particularly true for metabolic disorders such as 
T2DM and atherosclerosis. However, the current system of treatment does not 
appear to be optimal due to the negative side effects caused by increased activity 
of this protein. This has led research to shift to more selective modulators which 
activate the protein only fractionally but may give beneficial results through other 
signaling pathways. Unfortunately, the mechanisms which lead to such selective 
activation are incompletely or in some cases very poorly understood. This 
indicates that significantly more research is needed into specific mechanisms of 
PPARγ ligands which would allow for more intelligent drug design which could 





Figure 4: Effect of PPARγ activation in different tissues. The activation of PPARγ leads to 
beneficial effects (Green arrows) in certain tissues but also very negative effects in other tissue 
types. Figure was adapted from Ahmadian et al101. 
1.4 Endogenous ligands of PPARγ 
There is some debate as to the natural ligands of PPARγ. It is technically 
classified as an orphan receptor but several endogenous lipids which can bind to 
PPARγ have been identified. The concern with these natural ligands is that the 
identified fatty acids which bind PPARγ have very poor affinity, usually >10µM, 
this raises the concern that under physiological conditions these are never at a 
high enough concentration to bind. Additionally, they only function as partial 
agonists and it is thought that a more efficacious endogenous ligand should exist. 
The majority of these fatty acids which bind to PPARγ do so in a covalent manner 
to C285/313 on helix 3. Such a ligand would circumvent the low affinity. Only at 
the initial non-covalent binding step would concentration of the lipid have to be 
very high and then once the covalent bond is established there would be no risk of 
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ligand release due to low affinity. That has raised some concern as this would 
reduce the temporal control of signaling from this protein. This can be 
rationalized by the fact that many synthetic ligands likely have very low off rates 
due to their high affinity and would be bound for prolonged periods. Additionally, 
PPARγ has a relatively short half-life so the covalent binding of a ligand would 
not have too prolonged an effect102,103.  
All of the postulated endogenous ligands that have been identified thus far 
are polyunsaturated fatty acids (PUFA). The first ligand to be identified in 1995 is 
prostaglandin D2 with metabolites in the Prostaglandin J2 pathway having stronger 
effects. 15-deoxy-Δ12,14-Prostaglandin J2 (15d-PGJ2) showed the greatest effect 
by a fairly large margin, approximately 65% of the efficacy of the synthetic full 
agonist rosiglitazone104,105. This fatty acid requires the presence of C285/313 for 
function, though it will still bind at low affinity when this residue is mutated but 
ligand activity is abolished. Crystallography revealed this dependence on 
C285/313 to be due to the formation of a covalent bond between one of the sites 
of unsaturation and this cysteine residue in PPARγ106. The affinity is very poor 
with a transcriptional reporter assay failing to plateau at a concentration of 10µM. 
This may indicate that this lipid could activate the protein to a greater degree and 
the level seen is a function of only partial binding. However, when dealing with 
an endogenous ligand the likelihood of micromolar concentrations being present 
is very low. Particularly for a lipid such as this which can readily bind to a variety 
of proteins and will have very poor water solubility.  
Later work examined the effect of the binding of several other PUFA to 
PPARγ and was able to identify three new eicosanoid lipids which were able to 
activate PPARγ to some degree107. These were examined in both a hydroxy and 
an oxo state to determine if covalent attachment was necessary for function, since 
the hydroxy state is unable to form a covalent bond to cysteine. From this they 
observed that the covalent interaction was not actually necessary for the PUFA to 
act as an agonist but in the absence of a covalent bond significantly higher 
concentrations were required to observe the same response. Even with the 
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covalent PUFA micromolar quantities were still required to reach the EC50 in a 
transcriptional reporter assay, between 6-10µM. These concentrations seem 
physiologically unlikely indicating that these many not be relevant in a biological 
system. Another criticism is that the transcriptional reporter assay contained no 
reference ligand, so it is very difficult to say to what level these lipids actually 
increased transcription. Due to variability in the experimental system a reference 
synthetic ligand of well-characterized behavior is typically included to more 
accurately determine the effect of ligand binding. The most interesting finding in 
this is that with one of the PUFA, 13-S-HODE, the authors were able to obtain a 
crystal structure of PPARγ bound to two molecules of the lipid. This was one of 
the first reports of PPARγ binding two ligands simultaneously108. This 
phenomenon has recently been more thoroughly studied with synthetic ligands 
and it does appear that the co-binding of endogenous lipids with synthetic ligands 
may be a phenomenon which modulates the ligand behavior. The author in this 
work postulated that these PUFA may not be the endogenous ligand but that it 
may be a related lipid. They suggest that the more common metabolites of 
arachidonic acid, 5-oxo-EPA and 5-oxo-ETE could readily reach sufficient 
concentration in peripheral blood mononuclear cells for binding109. However, they 
do not make it clear if the concentrations they report, 10-150µM, are total 
concentration for these lipids which would suggest that a large percentage of this 
lipid would likely be bound in membranes and inaccessible for binding to PPARγ. 
It is worth noting that one of these postulated PUFA has been demonstrated to 
bind to PPARγ in cancerous cell lines and arrest the cell cycle thereby promoting 
apoptosis110.  
With these findings it is still unclear if PPARγ is an orphan receptor or if 
the endogenous ligand has been discovered. Given the low affinity seen in the 
postulated endogenous PUFA ligands it seems likely that none of these would be 
suitable ligands for signaling in a cellular environment. But to fully demonstrate 
this will require further research and it is possible that the exact endogenous 
ligand has not been identified but that the endogenous ligand may be closely 
structurally related to those which have been identified. It also should be noted 
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that the majority of research postulates that there is a single endogenous ligand. 
This is true for some nuclear receptors such as RxR and other vitamin receptors. 
However, PPARγ is lipid-dependent and expressed in a wide variety of tissues. 
Different tissues have markedly different lipid profiles, so it may well be that 
there is not a single endogenous ligand for this protein but several that are tissue 
dependent and may regulate pathways which are more relevant in that tissue. To 
provide insight as to their structure several lipids which have been identified as 
putative PPARγ ligands are shown in figure 7.  
1.5 Synthetic ligands of PPARγ 
Due to the medicinal importance of PPARγ a very large number of 
synthetic ligands have been made for this protein. Interestingly they are not very 
structurally conserved. There are some moieties which are relatively common in 
structures, such as a central indole, but the only thing which is completely in 
common is an amphipathic nature. These ligands must be somewhat amphipathic 
as the ligand binding pocket of PPARγ is intended to bind fatty acids and is 
therefore relatively hydrophobic. Due to the large size of the ligand binding 
pocket22, ~1500Å3, it can be difficult to exploit all potential interactions, but there 
are important residues which can be utilized to drive hydrogen bonding and 
therefore increase affinity and specificity111. A very common example of this is 
S342/370 in the β-sheet region. This residue forms hydrogen bonds either through 
the side chain or more commonly the backbone to a very large number of ligands 
which are structurally and functionally distinct. Due to this bonding event not 
being correlated with ligand function it is likely only significant as a potential 
target to increase selectivity and affinity. There are other residues which are 
frequently involved in hydrogen bonding that are distinct to the ligand class which 
will be discussed in more detail later.  
Another interesting characteristic of the binding of synthetic ligands to 
PPARγ is the so-called alternative binding site. This was discovered in 2015 
through the binding of two separate ligand molecules to a single protein112. This 
binding does not occupy the standard binding pocket but instead the ligand binds 
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in a region between the N-terminal region of helix 3 and the Ω-loop. It was 
originally thought that this binding only occurred as a result of a second ligand 
binding event and could explain some of the odd behavior seen with some partial 
agonists at high concentration. The second binding event is typically only 
observed with partial agonists and typically occurs at very low affinity, EC50 
values of approximately 10µM. However, since then there have been cases where 
ligands appear to preferentially occupy the alternative site. The partial agonists 
S35 and SR1664 (PDB 5DWL)  have both been crystallized bound only to the 
alternative site in the absence of other ligand molecules. It was suggested in the 
original paper on S35 that in solution this ligand had a preference to bind the 
alternative site almost exclusively113.  
A more in-depth discussion of synthetic ligands by their effect on the 
functional behavior of PPARγ will follow below. 
1.5.1 Ligand nomenclature used in nuclear receptors 
In the nuclear receptor field, ligand function is named based on their effect 
on transcriptional reporter assays. The most commonly performed of these is the 
GAL4-fusion transactivation assay. In this assay the LBD of the nuclear receptor 
of interest is fused to the DBD of the yeast protein GAL4. A vector with a GAL4-
UAS reporter, generally some form of luciferase, is also transfected to provide a 
readout. Based on the ligand binding state of the nuclear receptor LBD the 
endogenous coregulator proteins will be recruited to the reporter plasmid and 
regulate transcription of the reporter gene. This system has the advantage that the 
GAL4-DBD binds to DNA as a monomer so this circumvents the necessity of a 
dimer partner114.   However, this has the limitation that only the LBD of the 
nuclear receptor is being considered. Generally, ligand function is regulated 
primarily by the LBD but there are rare instances whereby the DBD or the 
unstructured AF-1 region will affect the activity of a ligand115. It appears likely 
that the relative scarcity of such reports is due to the almost exclusive use of the 
LBD of nuclear receptors for both in vitro and cell-based assays. The primary 
reason for this appears to be the simplicity of the system. This is particularly 
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troublesome for in vitro assays since full-length nuclear receptors are not very 
stable and will readily undergo proteolysis. This eventually leads to all protein 
degrading to the LBD state which adds uncertainty to the assay due to the 
presence of partially degraded protein which is functionally different than full-
length.  
 
Figure 5. Schematic diagram of a luciferase transcriptional reporter assays. Diagrams 
showing the mechanism of either a GAL4 transactivation assay (left) or a PXRE transactivation 
assay (right). The PXRE reporter is analogous to the PPRE reporters used with PPAR proteins. 
Figure was adapted from Luckert et al116. 
A variant of the above technique is the yeast two-hybrid assay117. This is a 
similar technique but instead of a fusion of the GAL4-DBD to the nuclear 
receptor LBD two expression plasmids are used. On the first is a fusion of the 
GAL4-DBD with an interacting protein of interest, usually the NR. The second 
contains a fusion of the coregulator of interest with the active domain of GAL4. 
Thereby when the two proteins bind transcription of a reporter gene is activated 
and through titration of a small molecule a ligand-dependent affinity can be 
determined. This has since been expanded into mammalian cell lines and is more 
commonly performed in this manner and referred to as a mammalian two-
hybrid118. The only major difference in the mammalian system is that the GAL4 
active domain is unsuitable in a mammalian cell line so the active domain of a 
viral protein, VP16, which is constitutively in an active state with high coactivator 
affinity is used instead. 
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As the DNA recognition of nuclear receptors began to become better 
understood a similar assay grew in popularity. This is commonly referred to as the 
PPRE transcriptional reporter. In this assay, instead of relying on a fusion of the 
LBD, full-length PPARγ is overexpressed and the reporter plasmid has PPRE 
enhancer sequences upstream of the promoter119.  
Both of these systems have the same drawbacks which are not 
straightforward to overcome. The first is that in these systems you do not know 
what coactivators or corepressors are being recruited. As stated before different 
coactivators control very different pathways in the cell and the ability to ascertain 
if a ligand could preferentially recruit specific coactivators, similar to the biased 
agonists seen in GPCR proteins121,122, would be of great value. Additionally, since 
the transcriptional machinery endogenous to the cell is not being overexpressed 
this sets a cap to the response that can be observed. Due to this limitation it is not 
currently clear if different full-agonists show different efficacy since any full 
agonist will eventually saturate the response.  
Based on transactivation assays described above, ligand function has been 
broken up into three primary groups. The first is the full agonists, which strongly 
drive transcription and have historically been the most studied ligands for 
medicinal purposes. The next are the non/partial agonists. These either do not 
drive transcription at all or show only a fraction of the response of the full 
agonists. With recent discoveries non/partial agonists have become one of the 
leading areas in PPARγ medical research but come with the caveat that they are 
structurally diverse, and their mechanism of action is poorly understood. The last 
group is the antagonists/inverse agonists. These two types of ligands are 
indistinguishable in transactivation assays but induce very different outcomes. 
The antagonist ligands function by having a portion of the ligand, often a bulky 
hydrophobic group such as a tert-butyl, that sticks directly out of the AF-2 surface 
and thereby disrupts the very specifically organized hydrophobic cleft required for 
any coregulator interaction. On the other hand, the inverse agonists are thought to 
specifically drive the recruitment of corepressor proteins while reducing affinity 
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for coactivator proteins. There is some thought that the inverse agonist behavior 
observed is not in fact due to a direct function of the ligand and instead occurs 
through a displacement of endogenous lipids bound to the protein. PPARγ is 
capable of binding a wide variety of fatty acids in the cell and even some as 
simple as nonanoic acid have been shown to have partial agonist character. 
Because of this, there is some argument whether or not inverse agonism is 
actually occurring in PPARγ, but recent data suggests that it is123.  
1.5.2 Alternate functional assays to determine ligand class 
There has been increasing use of in vitro assays to characterize ligands 
since the mid-2000s. Typically these assays utilize fluorescence-based techniques 
to look at coregulator binding to a purified NR protein as a function of the ligand 
bound. One flaw in these assays is the large size and unstable nature of most 
coregulators which are at least partially intrinsically disordered. As such, 
recombinant expression of the entire coregulator protein is usually not possible. 
Because of this most assays rely on a peptide containing only a single known 
LxxLL or CoRNR box. Some work has been done using the receptor interaction 
domain (RID) of coregulators such as SRC-2 but these are not as popular as these 
domains are still not trivial to purify to any significant yield124 and show only 
minor differences with assays utilizing the small peptides containing a single 
interaction motif. Another restriction is that at least one coregulator which binds 
with decent affinity must be known to perform these assays. Generally, for most 
nuclear receptors at least a portion of the coregulator interactome is known but 
specific affinity data is rare. Additionally, many coregulators contain multiple 
LxxLL125 or CoRNR126 boxes that bind different proteins with significantly 
different affinities which further complicates these studies since most of the 
interaction data was obtained from cells and the exact interacting motif is often 
ambiguous. There are two main forms of this assay which will be outlined below. 
The first form of this assay performed to any great extent was based on 
Fӧrster resonance energy transfer (FRET) often performed in a time-resolved 
(TR-FRET) fashion to reduce noise127–129. For simplicity, all FRET assays will be 
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referred to in this form, TR-FRET, for this work. In such an assay a fluorescently 
modified NR protein, most often through labeling with a fluorescently modified 
antibody, is pre-mixed with a fluorescently labeled coregulator peptide, often 
covalently modified with a fluorophore. To this mixture can then be titrated a 
solution of the ligand of interest and the change in FRET ratio can be fit to 
estimate binding of the coregulator to the NR. There are multiple downsides to 
this technique. The first is the very practical matter of cost, having to utilize 
multiple fluorophores and antibodies makes this a relatively expensive assay. The 
second more significant downside is that the data are somewhat challenging to 
interpret and relate to other data. Since the ligand is being titrated the EC50 value 
obtained from the fit is really only representative of the ligand’s affinity for the 
NR protein and not the affinity of the NR for the coregulator. To look at that 
relative affinity you instead have to examine the FRET window between 
unliganded and ligand bound and relate the fold-change in FRET ratio to estimate 
the affinity of the NR for the peptide. As well these assays are not exceedingly 
reproducible, relative effects seen in ligand behavior remain constant, but other 
properties such as FRET ratio or window are somewhat different between runs 
making in depth interpretation difficult. 
 
Figure 6. Fluorescence polarization binding assays. A schematic diagram of the fluorescence 
polarization assay. This technique is frequently used in NR through titrations to determine Kd 
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values of coregulator peptides. Figure was adapted from Fluorescence Polarization Assay to 
Quantify Protein-Protein Interactions in an HTS Format130. 
Once the technique became suitably adapted to a high-throughput assay  
the use of fluorescence polarization or anisotropy to look at binding events of NR 
with coregulators became popular, e.g. VDR131, THRb132, SRC1133. This system is 
much simpler as it requires only modifying either the protein or peptide with a 
fluorophore. This is typically done by the covalent addition of a fluorophore to the 
peptide. With the fluorescently modified component held at a fixed concentration 
the other protein can then be titrated in either pre-loaded with the ligand of 
interest or with a fixed ligand concentration in each well. The second method with 
a fixed ligand concentration is somewhat less common due to the low water 
solubility of nuclear receptor ligands. Given this poor solubility at low protein 
concentrations where the majority of the ligand is unbound there are concerns that 
the ligand will fall out of solution or aggregate and thereby have unforeseen 
effects. As the complex binds and the molecular mass increases the tumbling rate 
will lower increasing the polarization or anisotropy of the fluorophore. This 
increase can then be fit to determine a dissociation constant, Kd, for the 
coregulator and NR in each ligand bound state. This technique has become 
increasingly popular due to the low cost and relatively high throughput. It also 
allows for a more sensitive way to interpret the behavior of full agonists and 
inverse agonists than the cell-based assays.  
In 2009 a high throughput modification of the TR-FRET protocol was 
developed by Pamgene. In this protocol 53 peptides are immobilized on a chip 
and GST-fusion NR proteins can be titrated in with ligands bound36. A 
fluorescently modified anti-GST antibody is then added and the binding affinity 
can be determined from a non-linear regression. This technique is quite interesting 
but has not generated a lot of use in academic research most likely due to the cost. 
At this point only two papers can be located that utilize this first-generation 
technique. The first is the initial methods paper from the company and the other is 
looking at coregulator binding patters in estrogen receptor alpha (ERα) obtained 
from tumor cells134. The same group released a newer version of the technology in 
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a paper from February 2018 which reported an increase i the number of 
coregulator peptides to 154 and looked at changes in coregulator affinity with 
both the apo state and a reference full agonist ligand135. However, the results 
reported in this paper were not entirely consistent with results from their previous 
paper and with some of our own data, so there may be some issues in this newer 
technique. There are a couple of publications using this newer technology in the 
orphan receptor NR2E1 (TLX)136 or with ERα4 which showed robust results so 
the inconsistencies in this method may be more of an issue with PPARγ and not a 
problem for all NR. The previous generation of the Pamgene assay does seem 
robust and we have found good agreement with their results and our own 
coregulator recruitment data.  
1.5.3 Full agonist ligands of PPARγ 
Many full agonist ligands for PPARγ were developed as potential 
therapeutics of type II diabetes. A significant number of these ligands have gone 
into clinical or preclinical trials but relatively few have been found to be suitable 
for human use. This unsuitability is due to a wide variety of negative side effects. 
Some of these arise as an effect of canonical PPARγ activation which has been a 
concern in the development of therapeutic agents which target this protein. 
However, there are a number of other severe side effects that occur from full 
agonists of PPARγ where the mechanism is unclear. Despite this, full agonist 
ligands of PPARγ are still an active area of study, though more modern 
compounds have been designed to not activate the protein as significantly as prior 
drugs. Through this the impact of side effects has lessened but is still a very 
significant concern.  
Full agonism is the best understood mechanism of action in PPARγ. 
Almost all full agonists share the same core mechanism which consists of a direct 
hydrogen bond from the ligand to Y474/501 on helix 12137,138. This interaction 
stabilizes helix 12 in a conformation which is appropriate for interaction with the 
LxxLL motif on coactivators. These ligands also make other conserved hydrogen 
bonds within the protein to S289/317 on helix 3, H323/351 on helix 5 and 
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H449/477 on helix 11139. These aid in stabilizing other portions of the AF-2 
region in a suitable conformation to interact with coactivators. NMR studies have 
also shown that full agonists reduce the available conformational ensemble more 
so than the other ligand classes140. The significance of this is not understood but it 
is hypothesized that limiting the plasticity of the protein will lock the protein in a 
conformation suitable for coactivator recruitment and thereby help to lower the 
energetic penalty associated with coactivator binding, which will increase binding 
affinity. Our own data, which will be shown in chapter 3, support this hypothesis 
and also indicates that it is not only the overall stability of the protein which is 
important for full agonist function but that the stabilization of the β-sheets, the Ω-
loop and helix 5 in particular are important for the highest efficacy in agonism. 
Interactions in these regions are important in an optimal orientation of the AF-2 
residues for productive interactions with the coactivator peptide. Additionally, 
these data illustrate that the AF-2 surface is not defined solely by interactions on 
helix 3 and helix 12 but that there are important interactions, both selective and 
general, arising from residues in helices 3’ and 4.  
Two major classes of full agonist ligands for PPARγ exist. These are the 
glitazones which contain an thiazolidinedione (TZD)141 head group which 
mediates the important interactions with the AF-2 region and the glitazars which 
are derivatized from L-tyrosine142. Interactions are more complex with the glitazar 
ligands than with the glitazone ligands. This is due to the fact they are typically 
significantly more structurally complex than the glitazones and while the AF-2 
interactions do arise from the conserved carboxylate within the tyrosyl moiety this 
group is frequently located in the central region of the molecule. Such greater 
structural complexity allows the glitazar ligands the ability to interact more 
extensively in significant regions than the glitazones, particularly around the Ω-
loop and β-sheets. This greater degree of interactions appears to lead to higher 
affinity than is seen for the glitazones and in some cases greater agonist efficacy. 
It should be stated however, that higher efficacy is not a hallmark of the glitazar 
ligands as some including saroglitazar and aleglitazar only act as partial agonists 
for PPARγ. Unfortunately, the glitazar ligands have been strongly linked with 
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very negative side effects and only a single member, saroglitazar which is a pan-
PPARα/γ ligand, has been approved for human use and is only approved in 
India143. There has been greater success with ligands from the glitazone family. 
Of these three have been approved for human use by the FDA (troglitazone, 
rosiglitazone and pioglitazone) and an additional one is approved for human use 
in Canada and the European Union, edaglitazone.  
The first of the FDA approved full agonists was troglitazone (Rezulin). 
This drug was approved for human use in 1997 but within one year of use a 
severe side effect was observed. This side effect had not been apparent in either 
preclinical animal or human testing. It was found that in a small percentage of 
people taking this drug severe liver damage was occurring in some cases leading 
to liver failure. Due to this negative side effect the drug lost approval for human 
use in 2000. It is still not entirely clear what the cause of this side effect was but 
there is some evidence that, in mice with dysfunctional oxidative stress responses 
in the mitochondria of liver hepatocytes, liver damage is induced by troglitazone. 
This suggests that troglitazone may be causing liver damage through an increase 
in oxidative stress in hepatocyte mitochondria144,145. However, this damage is 
relatively mild which is inconsistent with the side effect observed in humans.  
Research continued into this ligand family and the next compound to be 
approved for human use was rosiglitazone (Avandia) in 1999. This ligand also 
induced severe side effects including edema, weight gain, increased bone fracture 
in women and cardiac issues. There were a number of reports of heart failure 
associated with this medication146–148 which led in 2007 to the addition of a black 
box warning which severely limited the availability in the U.S. Around the same 
time this medication was completely banned for human use by the European 
Medical Association (EMA). Since this time the black box warning has been 
lifted in the U.S. following a large randomized study by the manufacturer which 
showed the initial studies indicating heart failure were not reproducible, but this 
medication remains banned in Europe. Following this a similar medication, 
pioglitazone (Actos), was approved which carried much milder cardiac risks and 
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in some research has actually been shown to improve cardiac health in type 2 
diabetes patients149. This medication unfortunately has been linked to bladder 
cancer risk leading to its ban in portions of Europe150. Additionally, it carries the 
same side effects seen in rosiglitazone with the exception of the cardiac issues. 
These shared side effects (edema, bone fracture and weight gain) appear to occur 
as a consequence of PPARγ signaling and so may occur with any full agonist 
drug. 
Due to severe side effects, research has begun to shift away from these full 
agonists towards less efficacious partial agonists. Many of these compounds have 
gone into clinical or preclinical trials but as yet none have been approved for 





Figure 7. Chemical structures of representative ligands of PPARγ. A-D: The structure of four 
endogenous lipids which have been shown to bind PPARγ with an approximately 10μM affinity. 
All of these except 9-S-HODE bind covalently to C285/313. E-G: Structures of three inverse 
agonist ligands. T0070907 and GW9662 are both covalent and appear to act through a distinct 
mechanism to SR10221. H-K: The structure of 4 partial agonist ligands of PPARγ. These range in 
activity from no transactivation activity, SR1664, to fairly high activity, INT-131. I-O: Structures 
of four representative full agonist ligands. Troglitazone, Pioglitazone and Rosiglitazone are all 
TZD ligands which have been FDA approved for human use. GW1929 is a glitazar ligand which 




1.5.4 Inverse agonists and antagonists of PPARγ 
Comparatively few inverse agonists or antagonists have been explored in 
literature relative to the other ligand types. Typically, these are not thought to 
have a wide variety of medicinally useful effects, which limits research interest. 
There have been some reports of the covalent inverse agonists T0070907151,152 
and GW9662153,154 having an anticancer effect by arresting the replication of 
human cancer cell lines. The issue in this research is that both of these ligands 
have rather strong off target binding, GW9662 can bind PPARα with a Kd of 
approximately 20nM155 and T0070907 can do the same with a Kd of around 
1µM156, both of these concentrations are much lower than were used in these 
studies. The Kd values estimated for these two ligands are somewhat based on 
assumption since they are both covalent, they have no koff value and so the Kd 
reflects only a contribution from the kon. As well the mixed agonist/antagonist 
BADGE was able to promote apoptosis in cancer cells, but this was only at 
concentrations in excess of 50µM. This would suggest that the observed effects 
are almost certainly due to off target binding and not due to PPARγ signaling157. 
The mechanism of inverse agonism has been of some interest. A lot of this 
interest comes as a comparator to other NR where inverse agonists are of more 
value (e.g. ERα where the antagonist tamoxifen is the leading breast cancer 
medication). It is thought the mechanism of inverse agonism is shared among 
nuclear receptors so a greater understanding in one system should be of use in 
studies of a different NR. Typically, inverse agonists are thought to function 
through the displacement of helix 12 from the AF-2 surface158. This hypothesis is 
based on crystal structures of various other nuclear receptors bound to the 
corepressor SMRT in which helix 12 is never resolved and the helix 11- helix 12 
loop points into space159. This is further supported by a pair of dominant negative 
NR, Rev-Erb α and β which completely lack a helix 12. The lack of this helix is 
thought to be what makes these proteins dominant negative due to its importance 
in coactivator interactions. That would be consistent with the observation that the 
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CoRNR box has a larger footprint when bound to the nuclear receptor then the 
LxxLL box so some conformational change must occur to prevent a direct steric 
clash with helix 12. Such a clash can be observed when a corepressor peptide 
from a crystal structure is docked on an apo PPARγ structure. Unfortunately, no 
crystal structure of a corepressor bound to PPARγ has been published as of yet. 
There are a small number of inverse agonist or antagonist ligands that have been 
crystallized bound to PPARγ. Recent structures of the antagonists SR10171 and 
SR11023 indicate that helix 12 is being pulled away from the AF-2 surface and 
towards the N-terminus of helix 348. This conformational change would generate 
the additional space needed for the CoRNR box interaction but is surprising given 
that typically helix 12 appears to be pushed off the surface in other nuclear 
receptors not pulled to a different portion of the protein.  
Our own data, which will be presented in chapter 4 of this work, indicates 
that there are two distinct mechanisms of inverse agonism in PPARγ. The first is 
the displacement of helix 12 which occurs with bulky ligands that appear to 
directly make sterically unfavorable interactions with helix 12 and lead to 
displacement of this helix from the AF-2 surface. The second which is unique to 
the comparatively small covalent inverse agonists appears to be driven by a 
relocalization of helix 12 to a position lower relative to helices 3 and 4 than it is in 
a partial agonist or agonist bound state but oriented in the same fashion as it 
would be in an agonist bound state. Such a mechanism leads to helix 12 actually 
making productive binding interactions with corepressors. It appears likely that 
these productive interactions with helix 12 are what make T0070907, one of the 
covalent inverse agonists mentioned above, the most efficacious known ligand of 
its class. Some example structures of representative inverse agonists can be seen 
in figure 7.  
1.5.5 Partial agonist ligands of PPARγ 
Recently the partial and non-agonists have become the most heavily 
studied group of PPARγ ligands160. The difference between these two groups is 
not well defined and many works will refer to the same ligand as either a partial 
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or non-agonist. For the purpose of brevity in this work all ligands from these 
groups will be referred to as partial agonists. Partial agonists are synthetic ligands 
that activate PPARγ transcription to only a small fraction of the full agonist 
response. These responses range from very weak: SR1664161 or nTZDpa162 have 
almost no transcriptional effect, to somewhat marked effects: Int131 activates up 
to approximately 40% the level of a full agonist163. This group is the most 
structurally diverse and therefore it has been difficult to determine what 
interactions are significant for their effects. Additionally they make relatively few 
direct interactions with the protein which further complicates a mechanistic 
understanding at an atomic level.  
The mechanism of action for partial agonists is very poorly understood. It 
has been shown that they function in a manner independent of helix 12 
conformation which is unsurprising as they do not form direct hydrogen bonds to 
Y473/501 as the full agonists do164. Rather they make extensive contacts on helix 
3, some contacts to the Ω-loop and direct hydrogen bonds to S342/370 in the β-
sheet region165. Particularly during the second or alternative binding event they 
make no contacts at all on the AF-2 surface. Additionally, they do not stabilize the 
protein as is seen with the full agonists. In complexes bound to partial agonists, 
the protein appears to remain highly plastic with a similar amount of rigidity as is 
seen in the apo state, when assayed by 2-dimensional NMR techniques. This is 
consistent with our own observations that the binding of partial agonist ligands 
does not restrict the conformational ensemble of either helix 3 or helix 12 of the 
AF-2 region, these data are presented shown in chapters 2 and 3. Despite this, a 
large number of these ligands still drive coactivator recruitment in in vitro assays 
and are seen to drive transcription through either transactivation assays or qPCR. 
How exactly they have this agonist behavior is not understood at this point. 
While the mechanism remains elusive it has been seen that many partial 
agonists increase insulin sensitivity in cell-based assays or in model animals. 
They also carry far less side effects than seen with full agonists which often cause 
weight gain, edema or bone fracture. This reduction in side effect severity is 
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thought to be due to the lesser transactivation of PPARγ seen with this ligand 
family160. Some of these ligands, particularly SR1664166 and MRL24167, were 
observed to increase insulin sensitivity to almost the level seen with the full 
agonists. Due to this several of these ligands have gone into clinical or preclinical 
trials for type II diabetes treatment but as yet  none have been approved for 
human use.  
1.6 Other significant areas in drug design for PPARγ 
 
Figure 8. Post-translational modifications of PPARγ. A representation of PPARγ showing 
identified post-translational modification sites and their functional outcome. Figure was adapted 
from Ahmadian et al101. 
1.6.1 Post-translational modifications of PPARγ 
 Several post-translational modifications occur of PPARγ which have 
significant effects on the functional outcome. This includes a phosphorylation 
event on the AF-1 at S84/112 which has been well demonstrated to reduce the 
activity of PPARγ168,169. A sumoylation event on K79/107 has been shown to 
downregulate PPARγ activity. Interestingly an association with ubiquitin ligases, 
PIASxβ or Ubc9, at this site upregulates PPARγ activity in a manner independent 
of sumoylation170. As well, it was found that preventing this sumoylation event 
lead to insulin sensitizing effects in mice but no increase in adipogenesis171. This 
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may be a future avenue of drug discovery but this finding was only made this year 
so as yet no further research has been published. The deacetylation of PPARγ by 
SIRT1 has been determined to be important for the so-called “beiging” of adipose 
tissue which can be induced by PPARγ ligands. Acetylation of PPARγ was shown 
to directly inhibit association with PRDM16 which is essential for this observed 
behavior72. One of these modifications, sumoylation of K367/395, is suggested to 
be important for the anti-inflammatory effects seen with PPARγ172. However, 
there is debate as to whether this actually occurs with other literature directly 
stating that this residue is in fact not a target of sumoylation173. The most recently 
discovered post-translational modification is the phosphorylation of S245/273 
which will be covered in significant detail below due to the fact it is the leading 
area of active drug development research.  
1.6.2 Regulation of the phosphorylation of S245/273 
The mechanism of increased insulin sensitivity seen with partial agonists 
remained elusive until 2010 when a post translational modification was 
discovered in the work of Choi et al174. This modification is a phosphorylation of 
S245/273 in a unstructured loop proximal to the β-sheets. The phosphorylation of 
this residue was confirmed by an alanine mutation which increased the expression 
of several proteins dysregulated in obesity.  It was found that the phosphorylation 
of this residue almost completely abolished the insulin sensitizing effects seen 
with PPARγ ligands. This phosphorylation also seemed to lead to an overall 
downregulation of expression of PPARγ regulated genes. PPARγ contains a site 
which matches four of the five residues for a cyclin-dependent kinase 5 (CDK5) 
recognition motif175 in a loop between the first of the β-strands and helix 2’. As 
such this appeared to be the mediating kinase176. The role of this kinase was 
demonstrated by the addition of a specific inhibitor of CDK5 or RNAi of CDK5 
which strongly reduced the phosphorylation. Tracking levels of this kinase 
showed that mice fed a high fat diet (HFD), 60% fat, had greatly increased levels 
of CDK5 in adipose tissue. This suggests that the upregulation of this kinase and 
phosphorylation of PPARγ could be an important cause of dysregulation of many 
PPARγ controlled genes.  
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It was also found that the addition of PPARγ specific drugs significantly 
reduced this phosphorylation event. The addition of rosiglitazone to an in vitro  
kinase assay showed a 50% reduction in phosphorylation at 30nM, relatively 
close to the IC50 value for this ligand, though large doses of approximately 3µM 
were required to prevent phosphorylation. A much stronger effect was seen with 
the partial agonist MRL24 which was able to block most phosphorylation at a 
level of only 30nM. However, this ligand has a sub nanomolar IC50 value, so it is 
not clear if the difference is due to ligand behavior or merely an artifact of the 
fraction bound. Further examination of other partial agonist ligands which 
function well in insulin sensitization showed they also efficiently prevented this 
phosphorylation event. In fact the ligands most effective at preventing this 
phosphorylation were all partial agonists with the exception of a single full 
agonist, farglitazar. Other glitazars were not utilized in this study so it is not clear 
if other ligands of this class such as saroglitazar or GW1929 might also be very 
effective at blocking this post-translational modification. The authors postulate 
this reduction is due to a stabilization of this loop as evidenced by reduced 
hydrogen deuterium exchange of this loop and the neighboring β-sheet region. 
Later work by the same group suggests that thyroid receptor associated protein 3 
(THRAP3) is recruited to PPARγ through this phosphorylated residue and that 
this is the root cause of dysfunction in gene expression caused by CDK5177. 
Based on these findings research into PPARγ therapeutics has shifted 
towards partial agonist ligands which can effectively block phosphorylation. The 
performance of ligands in an in vitro phosphorylation assay has become 
somewhat of a gold standard in papers covering novel ligands and their potential 
value in insulin sensitization. One concern with this assay however is that it seems 
to only perform well in a western blot178. Western blotting gives rise to 
complications as to quantification. Typically, these must be quantified through 
pixel counting which is not the most precise measurement and can have a smaller 
dynamic range than other techniques. The development of fluorescent indicators 
or automated systems which utilize chemiluminescent signals have greatly 
improved the potential accuracy in quantifying a blot but are not as commonly 
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used as the traditional horseradish peroxidase (HRP) colorimetric indicator and 
pixel counting179. In a few papers an ADP-Glo assay is used to measure 
phosphorylation through the consumption of ATP but this is not used 
commonly180. A single methods paper exists which outlined a protocol to perform 
this assay through enzyme-linked immunosorbent assay (ELISA)181 which would 
improve the accuracy of quantification, but this method does not seem to have 
been adopted by the research community. Our own efforts to reproduce this assay 
have been unsuccessful.  
1.6.3 Anti-inflammatory effects in nervous system 
It has previously been observed that a number of PPARγ ligands have 
moderately strong anti-inflammatory effects. Interestingly these are observed to 
relatively similar levels in both full agonists such as rosiglitazone182 or 
pioglitazone183 as well as with partial agonists such as MRL24, UHC1178 and 
INT131. The exact mechanism of this behavior is currently not well understood. It 
has been shown that this effect is independent of PPARγ DNA binding184 and is 
therefore postulated to be due to a poorly understood transrepressive activity or 
possibly to occur through the S245/273 phosphorylation. The most common 
hypothesis for how these anti-inflammatory effects occur is through PPARγ 
binding to the NFκB subunit p65185. This interaction has been demonstrated to 
occur in cells via immunoprecipitation assays. The majority of anti-inflammatory 
effects observed with PPARγ ligands occur through the downregulation of NFκB 
signaling186–188. Due to this observation it is postulated that in a ligand dependent 
manner PPARγ associates with NFκB and prevents the transcriptional activity of 
this pro-inflammatory transcription factor. It is not clear if this is occurring in a 
manner similar to NFκBIB proteins which sequester NFκB and thereby 
downregulate activity or if possibly this effect may be due to PPARγ binding to 
NFκB which is bound to DNA in a repressive manner. Such transrepression has 
been reported with other nuclear receptors such as glucocorticoid receptor (GR)189 




Figure 9. PPARγ activation leads to a variety of anti-inflammatory effects. Activation of 
PPARγ by agonist ligand introduction leads to a pronounced anti-inflammatory effect through a 
largely unknown pathway. These effects manifest in a variety of cell types and have been found to 
be exploitable to reduce chronic inflammation in the nervous system. Figure was adapted from 
Ohshima et al190. 
Due to their anti-inflammatory effects, several PPARγ synthetic ligands 
have been shown to have potential therapeutic value in treatment of 
neurodegenerative disease183,191,192. These conditions all cause a chronic 
inflammatory state and these ligands are thought to have beneficial effect through 
this transrepressive pathway. Examples of these effects include a reduction in 
insoluble Aβ42 load in rat brains with pioglitazone treatment183. Pioglitazone has 
also been shown to have beneficial effects on animal models of Parkinson’s 
disease192,193. These effects are not explicitly due to full agonism. Multiple partial 
agonist ligands have been shown to be of benefit in therapy of neurodegenerative 
disease. In 2016 the partial agonist INT131, which has previously entered clinical 
trials as a type 2 diabetes therapeutic, began a new clinical trial as a potential 
therapeutic for multiple sclerosis. This has potentially opened a new pathway in 
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therapy for currently untreatable neurodegenerative diseases. However, as 
promising as some of the results observed may be there is still a large amount of 
work to be done before such a therapy would be suitable for human use.  
1.7 Objectives of this work 
The goal of this work is to gain a better understanding of the various 
mechanisms of PPARγ ligands at the molecular level. This information is 
incomplete for all PPARγ ligands and for certain ligand classes such as partial 
agonists almost nothing is known of their mechanism of action. Mechanistic 
information gained would be of great use in more intelligent drug design which 
could lead to the creation of therapeutics which retain beneficial effects while 
reducing negative side effects. The future goal would be to gain enough of an 
understanding of differential coregulator recruitment, coregulators are a highly 
diverse group which often lead to very different functional consequences, to 
develop so-called “biased ligands” which would preferentially recruit specific 
coregulator proteins. Biased ligands were first designed for the GPCR proteins 
and function through a preferential signaling of a single pathway instead of all 
outcomes of activation. Thus far they have shown great promise in providing 
similar therapeutic benefits as existing therapies but with significantly reduced 
side effects. To add to understanding of the conformational mechanisms of 
PPARγ ligands three projects were completed. 
In the first project, which will be covered in chapter 2, the conformational 
effects of ligand binding on the C-terminal helix, helix 12, were examined. This 
helix is the most functionally significant portion of the AF-2 region in terms of 
overall coregulator affinity. So, a better understanding of how this region changes 
with the binding of a wide group of structurally and functionally distinct ligands 
is important to the understanding of how the protein is primed for coregulator 
binding. This study also allowed for better determination of the role of this helix 
in coregulator recruitment. For a long-time helix 12 has been the primary portion 
of the protein to be studied but it is clear that it is not the only significant region 
of the protein for activity. 
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The second project, described in chapter 3, had two goals. The first and 
most important was to identify a region of the protein that conveys the extreme 
selectivity seen in nuclear receptor and coactivator interactions. This is 
fundamental in the idea of creating a biased ligand since such bias would require 
the preferential recruitment of specific coactivators. As well the mechanism by 
which full agonists have differential efficacy was examined. The purpose of 
examining full agonism was not as much to understand full agonism, as this does 
not appear to be the optimal therapeutic pathway due to side effects. Rather the 
goal was to identify other regions of the protein where a particularly efficacious 
agonist might interact besides the direct helix 12 interaction. This could 
potentially allow the design of therapeutics that induce a more modest response in 
terms of protein activation and thereby have less deleterious side effects 
The third project, described in chapter 4, examines one of the mechanisms 
of inverse agonism in PPARγ. To this point only a single mechanism is thought to 
occur leading to inverse agonism in nuclear receptors which involves the 
displacement of helix 12 from the AF-2 surface. This work identifies a novel 
mechanism which actually conveys greater inverse agonist efficacy, higher 
corepressor affinity, than the ligands which operate through the more standard 
pathway. Currently inverse agonists have not been studied much for their 
therapeutic value but there is some evidence they may be useful as cancer 
therapeutics through the arrest of the cell cycle. While these data may not be 
immediately useful for PPARγ research there may be value due to the high 
structural similarities among NRs. Which makes it quite possible that these 
mechanisms are conserved. This knowledge could be then utilized with other NR 
where inverse agonists are of great medical significance. If this is the case than it 
could lead to an entirely new route in drug design for these proteins. 
   Through the completion of this work and other work which can build on 
findings established herein it is hoped that a more fundamental understanding of 
this medicinally significant protein can be gained. This would allow for the design 
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of better therapeutic strategies for the treatment of the metabolic and 
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The nuclear receptor ligand-binding domain (LBD) is a highly dynamic 
entity. Crystal structures have defined multiple low-energy LBD structural 
conformations of the activation function-2 (AF-2) coregulator binding surface yet 
it remains unclear how ligand binding influences the number and population of 
conformations within the AF-2 structural ensemble. Here, we present a nuclear 
receptor coregulator binding surface structural ensemble in solution, viewed 
through the lens of fluorine-19 (19F) nuclear magnetic resonance (NMR) and 
molecular simulations, and the response of this ensemble to ligands, coregulator 
peptides and heterodimerization. We correlate the composition of this ensemble 
with function in peroxisome proliferator-activated receptor gamma (PPARγ) 
utilizing ligands of diverse efficacy in coregulator recruitment. While the 
coregulator surface of apo and partial agonist bound PPARγ is characterized by 
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multiple thermodynamically accessible conformations, the full and inverse 
agonist bound PPARγ coregulator surface is restricted to a few conformations 
which favor coactivator or corepressor binding, respectively.  
2.2 Introduction 
Nuclear receptors are ligand-regulated transcription factors that mediate 
the transcriptional actions of lipophilic endogenous ligands, including steroid 
hormones and lipids194, and are the target of ~13% of US FDA approved drugs195. 
The binding of these natural ligands, as well as synthetic ligands and FDA-
approved drugs, to the nuclear receptor ligand-binding domain (LBD) affects the 
recruitment of transcriptional coregulator proteins to target gene promoters, which 
influences chromatin remodeling and gene transcription196. Crystal structures of 
nuclear receptor LBDs have revealed in exquisite detail the molecular contacts 
created between the receptor and ligand, as well as low energy “active” and 
“inactive” conformations of helix 12197–200. Helix 12 is a critical regulatory 
structural element in the activation function-2 (AF-2) coregulator interaction 
surface of many nuclear receptors201. Over 100 crystal structures have been solved 
of the peroxisome proliferator-activated receptor gamma (PPARγ) LBD bound to 
ligands of various scaffolds and pharmacological activities202. Surprisingly, the 
backbone conformations of these structures, in particular the conformation of 
helix 12, are all very similar despite the fact that PPARγ is bound to ligands that 
produce a diverse range of functional outputs. Thus, it is difficult to understand 
the structural mechanism of action by which the binding of ligands with diverse 
activities affect helix 12 conformation from crystallography data alone. One 
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hypothesis is that helix 12 consists of a dynamic ensemble of conformations, and 
not one single or “static” conformation in the presence or absence of a bound 
ligand138,203. However experimental evidence describing this ensemble is lacking 
and it remains poorly understood how binding of pharmacologically distinct 
ligands affects the ensemble of coregulator binding surface and helix 12 
conformations.  
 Solution structural methods indicate prevalent, ligand dependent helix 12 
movement. Hydrogen deuterium exchange mass spectrometry (HDX-MS) 
demonstrates a relationship between helix 12 stability and agonist binding for 
nuclear receptors161,204–206. NMR studies implicate movement on the 
microsecond-millisecond (µs-ms) time scale between two or more conformations 
over a large portion of the apo and partial agonist bound PPARγ LBD. These 
movements result in very broad or unobserved NMR resonances that prohibit 
structural analyses. Full agonists robustly diminish these dynamics140,207–209. 
Furthermore crystal structures, HDX-MS, and protein NMR have provided 
complementary information revealing a relationship between structure and 
function for PPARγ (e.g. the presence or absence of critical hydrogen bonds 
between ligand and helix 1222) however a direct observation of the ligand 
dependent ensemble implied by these data is lacking. This raises the question: are 
there multiple long-lived conformations that correlate with functional efficacy 
(e.g. coregulator affinity) in nuclear receptors?  
It remains challenging to quantify the number, relative population and 
kinetics of exchange between the conformations that compose this putative 
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ensemble and how the ensemble is influenced by binding small molecules and 
coregulators. 19F (fluorine-19) NMR spectroscopy is exceptionally sensitive to 
structural and environmental changes, can reveal structural information from 
regions of a protein that are unobserved via 2D/3D NMR210, and can be used to 
probe how ligands affect the conformational ensemble of proteins211–215. Here, 
using 19F NMR combined with biochemical coregulator interaction analysis and 
molecular simulations, we define the ligand dependent conformational ensemble 
of the coregulator interaction surface, including helix 12, which controls the 
transcriptional activity of PPARγ. The data presented here indicate that helix 12 
and the coregulator binding surface of apo and partial agonist bound PPARγ is 
found in a broad energy well with multiple local minima of similar potential 
energy separated by relatively small kinetic barriers, allowing exchange on the μs 
to ms time scale. In contrast, when PPARγ is bound to a full agonist or inverse 
agonist, helix 12 and the coregulator binding surface occupies narrow energy 
wells with fewer thermodynamically accessible conformations. In addition, 
simulations define some of the probable structures that compose these ensembles. 
These data better elucidate how ligands induce functional effects via nuclear 
receptors. 
2.3 Results 
2.3.1 Diverse activities of synthetic PPARγ ligands 
We assembled a set of 16 pharmacologically distinct PPARγ ligands that 
we and others developed or previously characterized in cellular and structure-
function studies (Supplementary Fig. 16). The set of ligands includes full and 
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partial agonists that robustly or mildly enhance transcriptional activation; 
antagonists/non-agonists that block activation or maintain constitutive basal 
cellular transcriptional activity; and inverse agonists that repress transcription 
compared to the basal receptor activity. In a time-resolved fluorescence resonance 
energy transfer (TR-FRET) coregulator interaction assay, full agonists such as 
GW1929 and rosiglitazone that induce robust PPARγ transcription142,216, increase 
binding of a peptide derived from Mediator of RNA polymerase II transcription 
subunit 1 (MED1) coactivator (Figure 1a), and decrease binding of a peptide 
derived from the nuclear receptor corepressor 1 (NCoR1) referred to herein as 
NCoR (Figure 1b). In contrast, ligands that function as inverse agonists such as 
T0070907 and SR10221 lower PPARγ transcriptional responses relative to basal 
cellular activity156,161,217, increase binding of NCoR (Figure 1b), and decrease 
binding of MED1 (Figure 1a). Crystal structures of ligand-bound PPARγ LBD 
typically show a non-crystallographic dimer configuration containing two chains, 
A and B (Supplementary Fig. 2a). The main difference between the two chain A 
and chain B protein molecules involves helix 12, which adopts distinct 
conformations commonly referred to as “active” and “inactive”. The “active” 
conformation is assumed to be the conformation in solution when bound to a full 
agonist that induces increased transcription. Notably, these “active” and 
“inactive” helix 12 conformations are both influenced by crystal contacts 




Figure 1. Differences in nuclear receptor coregulator interaction differentiates 
pharmacologically distinct synthetic PPARγ ligands. TR-FRET biochemical assay shows the 
effect of the compounds on the interaction between PPARγ LBD and peptides derived from the (a) 
MED1 coactivator and (b) NCoR corepressor, plotted as TR-FRET ratio (665 nm/620 nm) vs. 
ligand concentration (n=2, standard deviation). The data shown represents technical replicates 
from a single experiment and the experiment was repeated four times with similar results. The 
window of efficacy in these data is representative of ligand induced changes in coregulator affinity 
for PPARγ. An increase in TR-FRET ratio indicates a strengthening of affinity for MED1/NCoR 
compared to apo while a decrease indicates a ligand induced weakening of affinity for the 
coregulator. The effect of vehicle (DMSO) is negligible (Supplementary Fig. 5), furthermore the 
DMSO concentration is constant across the titration both in this figure and all other TR-FRET data 
presented. 
 
2.3.2 NMR-detected coregulator binding surface structural ensemble 
To facilitate 19F NMR studies of the coregulator binding surface, which is 
composed of portions of helix 3, 4 and 12, we introduced a cysteine residue on the 
C-terminus of helix 12 at several locations (K502C, Y505C and Q498C) and on 
helix 3 (Q322C) of the PPARγ ligand binding domain (LBD) to allow covalent 
linkage of 3-Bromo-1,1,1-trifluoroacetone (BTFA), a small molecule containing a 
48 
 
trifluoromethyl (–CF3) group. Q498C caused protein instability, whereas BTFA 
attached to Y505C did not show pronounced ligand induced changes to the 19F 
NMR spectra of the PPARγ LBD, presumably due to its position at the 
unstructured C-terminus of helix 12 (Supplementary Fig. 1). However, Q322C 
and K502C yielded well-functioning protein with pronounced ligand inducible 
changes; we used these mutants to probe the conformational ensemble of the 
PPARγ coregulator binding surface (i.e. the AF-2 surface).  
Molecular simulations indicate that K502 (wild-type residue) and K502C-
BTFA (modified residue) are both solvent exposed in the “active” helix 12 
conformation and are not likely to sterically hinder coregulator binding in this 
“active” conformation (Figure 2, Supplementary Fig. 3). Control experiments 
indicate that the introduced cysteine on helix 12 (C502) is preferentially labeled 
over the only native cysteine (C313), which could be because C313 points into the 
ligand binding pocket (Supplementary Fig. 4). We refer hereafter to BTFA 
labeled PPARγ K502C protein as PPARγK502C-BTFA, we also use PPARγK502C-
BTFA with a C313A mutation (referred to as PPARγC313A,K502C-BTFA) for 
comparison, as this protein can only be labeled on helix 12. 19F NMR signals in 
these labeled proteins could conceivably arise from BTFA labeled co-purified 
protein impurities, however, the spectrum of PPARγC313A, which lacks all 
cysteines, reveals no detectable signal from impurities (Supplementary Fig. 5).  
Next, we determined the effects of mutations and labeling on the function 
of the PPARγ LBD. First, we measured ligand Ki values using a competitive 
ligand displacement assay to determine if the mutations and BTFA label affects 
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ligand affinity. Compared to wild-type, the PPARγK502C-BTFA and 
PPARγC313A,K502C-BTFA proteins exhibit a 5- and 11-fold median reduction in 
ligand affinity respectively (Supplementary Table 1) however, only four ligands 
(GQ-16, BVT.13, ciglitazone and troglitazone) are predicted to be at less than 
93% occupancy in our samples under the conditions used for the NMR 
experiments reported here (Supplementary Table 2). Second, we measured 
coregulator recruitment efficacy and EC50 using TR-FRET. As expected from the 
calculated Ki values, PPARγK502C-BTFA has a 2- and 5-fold median reduction in 
EC50 and PPARγC313A,K502C-BTFA has a 1- and 9-fold median reduction in EC50 in 
recruiting MED1 and NCoR respectively compared to wild-type PPARγ 
(Supplementary Table 3). Importantly, ligand induced coregulator recruitment 
efficacy is highly correlated for PPARγK502C-BTFA and WT indicating that 
PPARγK502C-BTFA is functionally similar to wild type PPARγ LBD (R2=0.8 for 
NCOR and R2=0.98 for MED1; Supplementary Fig. 6d and 6f). In contrast, the 
relative NCOR recruitment efficacy differs between PPARγC313A,K502C-BTFA and 
WT, while the relative MED1 recruitment efficacy is comparable to WT in this 
labeled mutant (R2=0.11 for NCOR and R2=0.8 for MED1; Supplementary Fig. 
6d and 6f). We also found that the mutations and labeling had little effect on 
recruitment efficacy and EC50 of a coactivator peptide derived from CREB-
binding protein (CBP) for both labeled forms of PPARγ (Supplementary Fig. 6b 
and 6e and Supplementary Table 4). 
 In addition, we compared mutant and WT PPARγ affinity for fluorescein 
isothiocyanate (FITC) labeled NCoR, MED1 and a peptide from the silencing 
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mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor 
utilizing fluorescence polarization (FP). Labeling did not significantly affect 
affinity of NCoR or MED1 for the four tested PPARγ-ligand complexes 
(Supplementary Fig. 7) and consistent with the TR-FRET data, PPARγK502C-
BTFA affinity for NCOR and MED1 correlated most closely with WT PPARγ. 
Both labeled PPARγs affect SMRT peptide affinity, although PPARγK502C-BTFA 
does so to a lesser extent, indicating that the label may directly interfere with 
SMRT binding (Supplementary Fig. 7). In general, these data indicate that the 
relative coregulator affinities are consistent between WT and especially 
PPARγK502C-BTFA. Given these data we focused on PPARγK502C-BTFA to 
correlate structure with function and utilize PPARγC313A,K502C-BTFA to confirm 
specific labeling of PPARγK502C-BTFA and in cases where increased signal to 
noise is required. PPARγK502C-BTFA is incompletely labeled (Supplementary 
Fig. 4d) to avoid labeling C313 (Supplementary Fig. 4a-c), which decreases the 
NMR signal. In addition, PPARγK502C that is not labeled with BTFA is not TR-
FRET active (Supplementary Fig. 4e) but has the same affinity for coregulators 
as PPARγK502C-BTFA (Supplementary Fig. 7b), therefore any unlabeled portion 




Figure 2 | 19F NMR analysis of PPARγK502C-BTFA bound to 16 pharmacologically distinct 
ligands. (a) Location of covalently attached BTFA tag. (b-s) 19F NMR spectra (medium grey 
lines) of PPARγK502C-BTFA (b-q) bound to ligand and ordered according to mean weighted 
19F chemical shift or (r) delipidated and (s) non-delipidated apo-protein. Fitted peaks are colored 
according to fitted 19F chemical shifts; deconvoluted spectra and residuals are shown in black and 
light grey lines, respectively. Some of these spectra have been replicated (Supplementary Fig. 
10) (t) Plot of the full width half max (FWHM) of the major fitted peaks (only peaks that comprise 
>5% of the spectrum area are included) versus fitted chemical shifts. Clusters were detected by 
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bivariate kernel density estimation (purple contours) with weighted mean 19F chemical shift values 
annotated on top of the plot. Computational simulations were run of labeled PPARγ (PPARγK502C-
BTFA) bound to one of these 16 ligands (GW1929) that demonstrate that the tag stays on or near 
the surface of the protein (Supplementary Fig. 3) 
 
We collected 19F NMR spectra of PPARγK502C-BTFA bound individually 
to each of the 16 synthetic ligands (Figure 2b–q), as well as spectra of apo-
protein with and without delipidation (Figure 2r,s). Bacterially expressed PPARγ 
often contains fatty acids, which can have functional effects218 and therefore we 
remove these lipids, additional data regarding the effects of delipidation on 
structure and function are presented below. 19F NMR provides a time-averaged 
view of the conformational ensemble of helix 12, thus long-lived major 
conformations (>ms lifetime) show up as distinct peaks, while conformations with 
lifetimes on the µs-ms timescale show up as a broad single peak. A single 
conformation (i.e. fast exchange among minor conformational variants) produces 
a single narrow peak. We used an objective deconvolution219 method to determine 
the number of peaks and corresponding peak line widths that compose the 
recorded spectra. The line widths of the peaks obtained from the objective 
deconvolution are consistent with measured NMR lifetimes of the 19F (T2) that we 
obtained for several liganded states (Supplementary Table 5). Bivariate kernel 
density estimation of all the deconvoluted spectra revealed two primary clusters 
of peaks, or conformations and a third lowly populated cluster (Figure 2t). In 
general, ligands known to be efficacious or strong agonists (e.g. GW1929, 
rosiglitazone, pioglitazone, and troglitazone) populate the most upfield (right) 
group of the narrowest peaks in cluster 1. Ligands of other pharmacological types, 
including partial agonists and inverse agonists are found in cluster 2, which is 
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composed of wider peaks, indicative of ensembles composed of multiple 
conformations. A third lowly populated cluster of downfield chemical shifts and 
relatively narrow peak widths, cluster 3, occurs for T0070907 and GW9662 
ligands that covalently bind to C313 in the canonical ligand-binding pocket and 
function as inverse agonists in cell-based assays156,217. These covalent ligands do 
not attach to the introduced cysteine on helix 12 (C502; Supplementary Fig. 5a-
b). PPARγC313A,K502C-BTFA loaded with or without the same 16 ligands show 
very similar 19F NMR spectra to PPARγK502C-BTFA, except for ligands which 
covalently bind to C313, which as expected look similar to ligand-free/apo-
protein because PPARγC313A,K502C-BTFA lacks C313 (Supplementary Fig. 8). 
Overall these data indicate a diverse ligand dependent helix 12 conformational 
ensemble. 
 
A contribution to the ligand-dependent differences in 19F NMR chemical 
shift values could be the relative solvent exposure of the BTFA probe –CF3 group, 
which can be determined by collecting 19F NMR spectra as a function of D2O 
concentration. When increasing amounts of D2O are added to the sample, a large 
upfield shift (i.e., to the right) of the 19F NMR peak indicates high solvent 
exposure of the BTFA probe while a smaller shift indicates low solvent 
exposure215, for example a solvent exposed 5-fluorotryptophan shifted 0.217 ppm 
upfield in 90% D2O buffer220. The chemical shift of free BTFA, which has high 
solvent exposure, has nearly the largest chemical shift change of any measured 
here (0.115 ppm upfield), whereas the solvent protected MRL24 ligand CF3 
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group, which is buried deep in the ligand binding pocket, moves in the opposite 
direction with increasing D2O concentrations (Figure 3 and Supplementary Fig. 
13). Given the solvent protected position of MRL24 CF3 in the ligand binding 
pocket221, the movement in the opposite direction of the MRL24 ligand CF3 group 
likely indicates interaction between the ligand CF3 group and the protein that is 
perturbed upon addition of D2O32. GW1929 bound PPARγC313A,K502C-BTFA has 
the largest upfield chemical shift (0.116 ppm; Figure 3), which is consistent with 
molecular simulations that show that K502 and C502 both have considerable 
solvent exposure in the “active” conformation (Supplementary Fig. 3). These 
data indicate full agonists primarily populate the “active” crystalized 
conformation in solution, while apo, partial agonists and inverse agonists are 




Figure 3 | Helix 12 solvent exposure is distinct for the “active” helix 12 conformation, apo-
protein and inverse agonist-bound conformations. (a) 19F NMR spectra of delipidated apo-
PPARγC313A,K502C-BTFA bound to 0.2 molar equivalent of GW1929 (left); and T0070907-bound 
PPARγK502C-BTFA with excess free BTFA; at the indicated concentrations of D2O. Due to the 
high binding affinity of GW1929 (4 nM), all three expected peaks (two apo-protein peaks and one 
GW1929 peak) are present in slow exchange on the NMR time scale, allowing analysis of the 
three conformations simultaneously. (b) D2O solvent isotope-induced changes, plotted as % D2O 
versus change 19F NMR chemical shift values for various peaks; a dotted grey line is shown to 
highlight no D2O-induced change in 19F NMR chemical shift. These experiments were performed 
once.  
PPARγ protein expressed in bacteria can pull down medium chain fatty 
acids, which function as weak partial agonists218. In agreement, non-delipidated 
(native) apo-protein that is partially bound to endogenous E. coli lipids (Figure 
2s) afforded 19F NMR spectra with two peaks of similar chemical shift to 
delipidated apo-protein (Figure 2r) along with several other lowly populated 
peaks. Comparison of 2D NMR spectra of delipidated and non-delipidated 
PPARγ LBD and PPARγC313A,K502C-BTFA in apo form or bound to ligands 
indicate that E. coli lipids have relatively minor effects on helix 12 and backbone 
structure (Supplementary Fig. 9a-b). In addition, TR-FRET data collected using 
non-delipidated or delipidated PPARγ-LBD shows essentially the same ligand 
dependent coregulator recruitment potency and efficacy (Supplementary Fig. 9c 
and 9d). In separate protein preparations we did observe some variation in 
T0070907 bound spectra (Supplementary Fig. 10c) which could be due to 
variable amounts of residual co-bound lipids remaining after delipidation as 
PPARγ has a very large ligand binding pocket that can accommodate more than 
one bound ligand208. Overall, these data indicate that some inverse agonists do 
more than simply displace activating lipids, but instead induce a distinct PPARγ 
LBD state with higher affinity for corepressors than delipidated apo protein.  
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We probed ligand induced changes in another region of the PPARγ 
coregulator binding surface using a Q322C mutation, which is located in helix 3, 
generating PPARγC313A,Q322C-BTFA. The fluorine probe in this variant is solvent 
exposed in the “active” conformation and maintains wild type like recruitment of 
coregulators (Figure 4 and Supplementary Fig. 11). The chemical shift 
difference induced by ligands is relatively small; however, just as with the helix 
12 probe, ligands decrease the conformational diversity of this region with the 
strongest agonists (rosiglitazone and GW1929) yielding the narrowest peaks 
indicative of a single main conformational ensemble. Similar to apo PPARγK502C-
BTFA (Figure 2r), apo PPARγC313A,Q322C-BTFA produces a spectrum with two 
main wide peaks, indicative of two sub ensembles composed of multiple 
conformations with slow exchange between the sub ensembles (Figure 4). These 
data indicate that the ligand free coregulator binding surface is composed of two 
main structurally diverse (i.e. wide NMR peak) ensembles in slow exchange. 
Alternatively, one of the peaks could be PPARγ bound to residual E.coli lipids, 
however this unlikely given that the spectra is stable over time (Supplementary 
Fig. 11) whereas E.coli lipid bound PPARγK502C-BTFA spectra change with time 
(Supplementary Fig. 10a). The exchange rate between these two apo NMR 




Figure 4 | A helix 3 probe on the coregulator binding surface confirms agonist induced 
reduction in conformational complexity of the coregulator binding surface. a) Fluorine NMR 
spectra of PPARγC313A,Q322C-BTFA bound to the indicated ligands. The small sharp left shifted 
peak in all the spectra is free BTFA. b) Trajectory frame from a simulation of PPARγC313A,Q322C-
BTFA bound to a coactivator peptide (MED1; green) with 322C-BTFA shown in orange as 
spheres (fluorine atoms are turquoise). These experiments were performed once.  
 
2.3.3 Slow exchange between ensemble structures 
A single well populated 19F NMR peak is observed for BTFA probes 
placed in two areas of the coregulator binding surface (helix 3 and 12) when 
PPARγ-BTFA is bound to a strong agonist such as GW1929 or rosiglitazone. 
However, for less efficacious ligands, multiple-well populated 19F NMR peaks are 
observed in slow exchange on the NMR time scale indicating that the peaks 
represent distinct coregulator binding surface conformations with lifetimes on the 
order of milliseconds or longer.  
To confirm the apparent slow exchange between different conformations, 
we performed 19F chemical exchange saturation transfer (CEST) NMR 
experiments on PPARγ where multiple peaks, or conformations, are present 
(Figure 5a and Supplementary Fig. 12). Of the five ligands and apo protein 
studied, four ligands and apo protein show obvious slow chemical exchange 
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between a well-populated minor resonance and the most abundant resonance. In 
the case of T0070907, exchange was difficult to detect, likely because exchange 
rates less than ~0.4 s-1 are too slow to be effectively detected using this method 
under our experimental conditions (Supplementary Fig. 12a and 12b).  
 We next quantified the exchange rate between peaks. PPARγK502C-BTFA 
bound to GW9662 and troglitazone each showed very slow exchange between 
peaks, making precise measurement difficult (0.3 and 0.4 s-1; Supplementary Fig. 
12d). However, for pioglitazone and ciglitazone, the exchange between the two 
prominent peaks is 1.2 and 1.4 s-1 (95% CI 1.1 to 1.3 s-1 for pioglitazone and 1.3 
to 1.5 s-1 for ciglitazone; Figure 5b). In addition, we found exchange of 1.0 s-1 
(95% CI 0.9 to 1.1 s-1) between the two resolved apo peaks of PPARγC313A,Q322C-
BTFA (Supplementary Fig. 12c). These slow exchange rates are consistent with 
the notion that the detected conformations originate from larger scale movements 
involving many atoms223, indicating helix 12 and the coregulator binding surface 
exchanges between two or more distinct conformations. Almost all of the signal 
in the ligand bound spectra do not overlap with the apo spectrum, thus implying 
that exchange between conformations is occurring while bound to ligand. These 
data raise the possibility that these ligands are found in at least two functionally 
distinct main conformations exchanging on the seconds time scale. This idea is 
consistent with the fact that the PPARγ non-agonist/antagonist SR1664 has been 




Figure 5 | Chemical exchange saturation transfer indicates slow exchange between liganded 
states with multiple helix 12 conformations. (a) A selective Gaussian pulse was used to saturate 
the 19F spectra bound to the indicated ligands at locations indicated by pink circles. The height of 
the pink circles indicates the height of the peak indicated by the black arrow when the selective 
pulse was carried out at the chemical shift of the pink circle. If exchange is occurring between the 
two peaks the pink dots should mirror the spectrum. (b) A selective Gaussian pulse was used to 
saturate the spectrum at an on resonance (a; orange box arrow) and off resonance (a; blue box 
arrow) location, the peak height of the most abundant resonance (a; black arrow) was monitored as 
a function of the duration of the saturation pulse, and the resulting peak intensities were fit to 
extract the exchange rate. 95% confidence intervals for the fit of the calculated exchange rates are 
shown in parentheses. PPARγK502C-BTFA was used for these data except for ciglitazone which 
used PPARγC313A,K502C-BTFA for increased signal to noise. These experiments were performed 
once. 
 
2.3.4 Connecting the helix 12 structural ensemble to function 
To test whether the 19F NMR detected helix 12 conformations correlate to 
function within our set of 16 ligands, we compared the weighted mean 19F NMR 
chemical shift values to ligand efficacy for recruitment of MED1 (coactivator), 
NCoR (corepressor) and for a subset of these ligands, CBP (coactivator) in the 
TR-FRET coregulator interaction assay. For PPARγK502C-BTFA there is a 
correlation between mean ligand induced 19F NMR chemical shift and ligand 
induced MED1, CBP and NCoR recruitment efficacy (Figure 6a). There are 
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similar correlations for PPARγC313A,K502C-BTFA (Supplementary Fig. 14) but not 
for PPARγC313A,Q322C-BTFA. In addition, we used fluorescence polarization (FP) 
to measure the affinity of a subset of PPARγ-ligand complexes for coregulators 
(MED1, NCoR, and SMRT) and compared these to labeled and wt PPARγ and 
found that ligand specific affinity correlates with NMR chemical shift (Figure 6b 
and Supplementary Fig. 14). The most efficacious agonist for MED1 and CBP 
binding in our ligand set (GW1929) induces the most upfield mean chemical shift 
of the PPARγK502C-BTFA probe. Similar trends are observed for other agonists, 
including the right shifted peaks of thiazolidinedione (TZD/glitazones) ligands. In 
contrast, downfield mean chemical shifts are prevalent in apo-protein and inverse-
agonist (T0070907) bound PPARγK502C-BTFA, which show the highest efficacy 
and affinity for NCoR and SMRT binding (Figure 6). These data indicate that the 




Figure 6 | Ligand-directed helix 12 ensemble dictates PPARγ-coregulator interaction. (a) Plot 
of mean 19F NMR chemical shift values (PPARγK502C-BTFA) versus TR-FRET endpoint data for 
the recruitment of MED1, NCoR and CBP peptides to PPARγK502C-BTFA (top panels) and wt 
PPARγ LBD (bottom panels) for the set of 16 pharmacologically distinct synthetic PPARγ ligands 
and apo-protein (select ligands for CBP). Error bars are relatively small for end point TR-FRET 
values (Figure 1 and Supplementary Figure 6) and excluded for clarity b) Plot of mean 19F NMR 
chemical shift values (PPARγK502C-BTFA) versus MED1, NCoR and SMRT peptide dissociation 
constant (Kd) for PPARγK502C-BTFA (top panels) and wt PPARγ LBD (bottom panels) as 
measured by fluorescence polarization for a subset of the ligands in panel a. Linear regression fit 
is shown as a solid line and the correlation coefficient (R2) for the fitted line is indicated. The 
ligands with the highest efficacy for MED1 and NCoR recruitment for PPARγK502C-BTFA are 
highlighted. Error bars represent standard deviation of two (K502C-BTFA Kd and wt SMRT Kd) 
or three (wt MED1 and NCoR Kd) independent experiments. 
 
2.3.5 Coregulators shift the conformational ensemble 
The data above demonstrate that ligands of different pharmacological 
activities can stabilize functionally distinct coregulator binding surface 
62 
 
conformations. To determine how coregulator binding influences these ligand 
dependent conformational ensembles in solution, we performed 19F NMR with 
and without coactivator (MED1 and CBP) and corepressor (SMRT and NCoR) 
peptides; and in the absence or presence of the most efficacious agonist 
(GW1929) or inverse agonist (T0070907) and a less efficacious inverse 
agonist/antagonist (GW9662) (Figure 7a). Similar to strong agonists, addition of 
coactivators to apo-protein induces an upfield (right) shifting of the spectra. In 
contrast, similar to inverse agonists, addition of corepressors to apo-protein 
induces a downfield (left) shifting of the spectrum. Notably, corepressor co-
binding to T0070907/PPARγK502C-BTFA results in smaller perturbations to the 
fluorine spectra than coactivator co-binding. The opposite is observed for 
coregulator co-binding to GW1929/ PPARγK502C-BTFA. Apo-protein and 
GW9662 bound PPARγK502C-BTFA are almost equally changed by addition of 
coactivators or corepressors (Figure 7c). These data suggest that the 
GW1929/PPARγ and T0070907/PPARγ coregulator binding surface structural 
ensembles are near ideal for MED1/CBP and NCoR//SMRT binding, 
respectively. In contrast, the apo-protein and GW9662 structural ensembles are 




Figure 7 | Coregulator binding shifts the helix 12 conformational ensemble in a manner 
predicted by ligand induced shifts to the ensemble. (a) Deconvoluted 19F NMR spectra of apo-
PPARγC313A,K502C-BTFA and PPARγK502C-BTFA bound to GW1929 or T0070907 in the absence 
and presence of MED1 coactivator or NCoR corepressor peptides. The percent of total signal area 
found in the left sharp peak is shown for T0070907 and GW9662 spectra. The small sharp peak at 
~-83.3 ppm is free BTFA. (b) Mean weighted chemical shift values from the plots in (a). (c) 
Fraction of the total peak areas in the four colored boxed regions in (a), which roughly correspond 
to the clustered spectral regions from Figure 2; with the two middle regions corresponding to the 
two peaks observed for apo-protein. Agonist bound PPARγ is changed little by MED1 binding, 
whereas NCoR binding changes the spectrum drastically and vice versa for inverse agonist 
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(T0070907) bound PPARγ. *SMRT induced mean chemical shift in GW1929 bound PPARγK502C-
BTFA is the same as NCoR. These experiments were performed once. 
 
2.3.6 RXRα heterodimerization shifts the inverse agonist ensemble 
PPARγ binds enhancer regions on DNA and affects gene expression 
primarily as a heterodimer with RXRα225. We therefore performed experiments to 
determine the effect of RXRα heterodimerization on the conformational ensemble 
and on coregulator recruitment. Other than the expected broadening and 
consequently decreased signal from the larger molecular weight complex, RXRα 
heterodimerization has a relatively small effect on the 19F spectra of 
PPARγC313A,K502C-BTFA when co-bound to GW1929 (agonist), MRL24 (less 
efficacious partial agonist) and apo. RXRα binding to PPARγK502C-BTFA co-
bound to T0070907 (inverse agonist) induces a large change in the spectrum, 
decreasing the relative population found in the left shifted peak (Figure 8a), 
which is expected to disfavor NCoR binding. Consistent with the change in 19F 
NMR spectrum, NCoR binding is decreased and MED1 recruitment is increased 




Figure 8. | Heterodimerization of PPARγ LBD with RXRα LBD favors MED1 binding, 
disfavors NCOR binding. (a) 19F NMR of PPARγK502C-BTFA bound to T0070907 and 
PPARγC313A,502C-BTFA bound to MRL24 or GW1929 or with no ligand bound was performed in 
the presence (orange) or absence (black) of RXRα LBD. These experiments were performed once. 
(d) The 19F NMR signal from the MRL24 ligand. Broadening and consequent reduction in signal 
intensity is expected as a consequence of the increased rotational correlation time of the 
heterodimer complex. (b-c) TR-FRET was used to measure interaction between wt PPARγ LBD 
and MED1 or NCOR in the presence or absence of equimolar concentrations of RXRα. Error bars 
represent standard deviation of two technical replicates within a single experiment. The 
experiment was repeated twice and gave similar results each time. (e) Heterodimerization favors 
MED1 binding (p=0.0017) and disfavors NCOR binding (p=0.0076) to apo PPARγ. In addition, 
visual and statistical comparison of NCOR and MED1 recruitment to PPARγ LBD saturated with 
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ligand (4 highest concentrations of ligands) indicates that RXRα affects coregulator recruitment to 
T0070907 bound PPARγ (NCOR p=0.0042; MED1 p=0.0027) more than GW1929 (NCOR 
p=0.44; MED1 p=0.34) or MRL24 (NCOR p=0.0141; MED1 p=0.061). All p values are derived 
from a two-tailed t test.  
 
2.3.7 Simulations suggest a diverse ligand dependent ensemble.  
The extreme broadening observed in apo PPARγ alone or bound to NCoR 
peptide originate from multiple conformations exchanging every μs to ms. We 
reasoned that we could sample some of these conformations in independent long-
time scale simulations of apo alone or apo bound to NCoR. We also simulated 
inverse agonist (T0070907) bound PPARγ LBD with and without co-bound 
NCoR to gain additional insight into how this ligand changes the coregulator 
binding surface conformational ensemble. We built simulation models using 
crystal structures with helix 12 in an “inactive” chain B conformation 
(Supplementary Fig. 2d) to avoid steric clash with bound NCoR peptide. We ran 
simulations at 37°C (NMR was run at 25°C) and with the TIP3P water model 
(TIP3P is much less viscous than actual water226), to speed relaxation to a local or 
global energy minimum (i.e. stable conformation) given that this chain B 
“inactive” conformation may be in a higher energy conformation. These 
simulations were allowed to run until reaching a structure that remained 
reasonably stable for at least 5 μs as judged by consistent helix 12 RMSD relative 
to the starting structure (Supplementary Fig. 15). These stable conformations are 
representative of a local or global free energy minima. Three of four independent 
simulations of PPARγ LBD alone (apo) relaxed to a cluster of distinct but similar 
conformations that are somewhat similar to the starting chain B crystal structure, 
while the fourth does not appear to stabilize to the same degree and goes to a 
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distinct conformation. These results are consistent with the broad ligand free (apo) 
PPARγ 19F peaks observed which indicate exchange between two or more 
conformations (Figure 9a) and are also consistent with previous free energy 
calculations that indicated the “inactive” chain B crystal structure is very similar 
to low energy apo structures227. Addition of NCoR to apo PPARγ LBD results in 
up to 12 μs of relative instability (Supplementary Fig. 15b) before finally 
relaxing to several different stable conformations that are consistent with the idea 
that NCoR pushes helix 12 away from the coregulator binding surface, yielding a 
diverse collection of conformations that are consistent with the observed broad 
helix 12 19F NMR peaks observed for this complex (Figure 9b). All three 
simulations of T0070907 bound to PPARγ LBD relax to very distinct 
conformations (Figure 9c). Addition of NCoR to T0070907 bound PPARγ 
provides a path to one dominant energy minima as all three simulations in this 
complex reach conformations similar to an “active” conformation but with helix 
12 shifted to accommodate the longer LXX I/H IXXX I/L helix of corepressors 
compared to the LXXLL motif of coactivators42. These data are consistent with 
our 19F NMR data that demonstrate that NCoR binding to the T0070907 PPARγ 
LBD complex induces a shift towards one particular conformation from several 




Figure 9 | Microsecond timescale molecular simulations point to a diverse ligand dependent 
ensemble and a possible NCoR bound structure. (a-d) Root mean square deviation (RMSD) of 
helix 12 relative to an “inactive” (1PRG chain B) structure and an “active” conformation (1PRG 
chain A) for helix 12 in four different simulated complexes. Helix 12 from these “inactive” and 
“active” structures is shown in all panels (grey pipe). SMRT bound to PPARα (PDB code: 1KKQ) 
was aligned to 1PRG chain A and the SMRT helix is shown in panels b and d (grey pipe). 
Fourteen independent simulations of (a) apo PPARγ LBD, (b) apo + NCoR corepressor, (c) 
inverse agonist (T0070907) bound PPARγ LBD, and (d) PPARγ LBD co-bound to T0070907 and 
NCoR corepressor were carried out for 10 to 30 μs and the last 5 μs were analyzed (4 each for apo 
simulations and 3 each for T0070907 simulations). Colors on the RMSD plots indicate relative 
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number of frames; red indicates the most prevalent and blue the least. Representative structures 
from the centroid of the major clusters are shown with helix 12 highlighted in color (4 apo, 4 apo 
+ NCOR, 3 T0070907 and 3 T0070907 + NCoR). Helix 12 disassociates from the LBD in one apo 
+ NCoR simulation. The cluster for this simulation (centered at 21.3Å (x) and 23.8Å (y)) is not 
shown, however a representative structure is shown in light blue. Corresponding 19F NMR data 
from Figure 7 are shown in each panel. (e) A model for helix 12 conformational diversity based 
on simulation and experiment. Apo or partial agonist bound PPARγ helix 12 is found in many 
similar conformations of varying helical structure producing broad NMR peaks and rapid 
hydrogen deuterium exchange, while full agonist is found in a tighter cluster of conformations. 
Co-binding of the inverse agonist T0070907 and the corepressor NCoR produces one main 
conformation similar to an “active” conformation, but with helix 12 shifted. Fuzziness implies 
intermediate exchange (μs to ms) between the conformations. 
 
2.4 Discussion 
The data presented here for the first time explicitly reveal the 
conformational ensemble of the coregulator binding surface, including helix 12, 
of a nuclear receptor and the effects of ligands on that ensemble. A model of 
nuclear receptor activation arises from these data and previously published work, 
which indicates that nuclear receptors and other proteins are found in ensembles 
of structures and not a single structure207,211–213,228,229. The structural variance 
around this primary structure varies from protein to protein, however for nuclear 
receptors this variance appears to be considerable140,207,230. The data presented 
here indicate that the coregulator binding surface, including helix 12, exchanges 
relatively quickly (i.e. μs to ms lifetimes) between many conformations of similar 
free energy in a broad rough energy well for apo PPARγ, partial agonist bound 
PPARγ, and apo PPARγ bound to NCoR. Furthermore, agonist and inverse 
agonist binding reduces the complexity of the apo ensemble and forms distinct, 
narrow energy well(s) increasing the population found in structurally distinct 
“active” or “inactive” state(s) which favor coactivator or corepressor binding 
respectively (Figure 7 and 9e). Very slow exchange (seconds) across high kinetic 
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barriers is observed for some agonists and inverse agonists, indicating that these 
ligands hold helix 12 in narrow and deep energy wells with rare exchange 
occurring between sub-ensembles (Figure 5). Consistent with these data, free 
energy calculations indicate that helix 12 in apo-PPARγ is found in two broad 
energy wells with conformations similar to both “active” and “inactive” apo-
PPARγ helix 12 crystal conformations, whereas helix 12 in rosiglitazone-bound 
PPARγ is found in one deep narrow well with a conformation similar to the 
“active” chain A conformation227. Importantly, these data reveal a correlation 
between ligand efficacy and the prevalence of at least three distinct structural 
ensembles using a diverse set of 16 pharmacologically distinct PPARγ ligands. 
 The long time-scale simulations presented here are qualitatively consistent 
with the experimental results. Simulations started from an “inactive” chain B 
structure PPARγ relax to multiple different structures depending on the ligand and 
coregulator that are bound to PPARγ (Figure 9). Apo PPARγ LBD relaxes to 
conformations similar to the starting “inactive” chain B structure, while addition 
of NCoR binding pushes helix 12 into various different structures, consistent with 
the idea that NCoR does not interact productively with helix 12 in apo PPARγ. In 
contrast, simulations of NCOR and T0070907 co-bound to PPARγ relax to two 
very similar structural clusters, which are consistent the idea that helix 12 
interacts productively with NCoR in this complex. In addition, simulations of 
GW1929 bound to PPARγ starting with helix 12 in an “active” chain A 
conformation remain in a similar helix 12 conformation throughout the simulation 
(Supplementary Fig. 3), indicating that as expected this is the dominant 
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conformation for agonist bound PPARγ in solution. In addition to movement of 
helix 12 between different positions relative to the rest of the LBD these 
simulations indicate that the length and helicity of helix 12 can weaken in some 
conformations (Figure 9), which could contribute to broad 19F NMR peaks and 
increased exchange rates in HDX-MS161. Overall it is encouraging that these non-
converged simulations qualitatively agree with 19F NMR and provide a glimpse of 
possible conformations that comprise a portion of the observed 19F NMR spectra, 
however quantitative comparison between the 19F NMR spectra and converged 
simulations remains a future challenge. 
This view of the coregulator binding surface, including the number and 
relative populations of conformations and sub-ensembles that comprise the 
ensemble is made possible by using a single fluorine probe which provides high 
sensitivity, a single signal which obviates the need to transfer spin between 
residues, and a total lack of background signal. 19F NMR requires mutation and 
labeling of PPARγ which perturbs corepressor affinity (especially SMRT) but has 
less effect on NCoR interaction and little effect on coactivator affinity as 
measured by TR-FRET peptide recruitment and FP affinities for corepressor 
(NCOR and SMRT) and coactivator (MED1 and CBP) peptides (Supplementary 
Fig. 7). Based on these observed functional effects, we propose that any effect 
from the mutations would likely shift inverse agonist bound mean NMR chemical 
shifts toward the center decreasing the population found in the inverse agonist 
conformational state (cluster 3). Depending on the chemical shift difference and 
rate of exchange between the conformations this will result in movement of a 
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peaks chemical shift and/or a decrease in population of the cluster 3 (left cluster). 
For example, a left shifted narrow peak at a chemical shift typical of inverse 
agonism (cluster 3) and a broad peak at a chemical shifts typical of 
antagonist/partial agonist (cluster 2) are observed  for PPARγK502C-BTFA bound 
to the inverse agonist T0070907156,217 and less efficacious inverse 
agonist/antagonist GW9662 (Figure 2 and 7). Addition of NCOR or SMRT shifts 
the population from cluster 2 to cluster 3, while the mutations and labeling may 
shift the equilibrium population in the opposite direction toward the 
antagonist/partial agonist cluster (cluster 2). Thus, it may be that helix 12 of WT 
PPARγ LBD bound to T0070907 is found in a conformation represented by the 
“inverse agonist” cluster (cluster 3; left shifted narrower peak) to a larger degree, 
than detected by PPARγK502C-BTFA. 
This work adds detail to how ligands in general control the activity of 
nuclear receptors. Our data not only confirm that helix 12 and the coregulator 
binding surface exists as a ligand specific dynamic structural ensemble, but also 
indicate the relative populations of sub-ensembles that comprise the overall 
structural ensemble and correlate function with this ensemble. Further definition 
of the conformational ensemble of the entire protein and the kinetics and 
thermodynamics of exchange between the members of the ensemble will build an 
accurate model of how ligands produce functional outputs via nuclear receptors 




 2.5.1 Protein purification 
A pET-46 plasmid carrying the genes for ampicillin resistance and N-
terminally 6xHis tagged PPARγ containing a tobacco etch virus nuclear inclusion 
protease (TEV) recognition site between the His tag and protein of interest was 
transformed into chemically competent E. coli BL21(DE3) Gold cells. Cells were 
grown in either ZYP-5052 autoinduction media or terrific broth (TB). Cells grown 
in TB at 37 °C were induced at an OD600 of approximately 0.8 by the addition of 
0.5mM IPTG and the temperature lowered to 22 °C. Induction proceeded for 
16 hours prior to harvesting. Harvested cells were homogenized into 50 mM 
Phosphate (pH 8.0), 300 mM KCl, 1 mM TCEP and lysed using a C-5 Emulsiflex 
high-pressure homogenizer (Avestin). Lysates were then clarified and passed 
through two Histrap FF 5 ml columns in series (GE Healthcare). Protein was 
eluted using a gradient from 15-500 µM imidazole. Fast protein liquid 
chromatography (FPLC) was performed on either an NGC Scout system (Biorad) 
or an ÄKTA Start (GE Healthcare). Eight mg of recombinant 6xHis tagged TEV 
was added to eluted protein followed by dialysis into 50 mM Tris (pH 8.0), 
200 mM NaCl, 1 mM TCEP, and 4 mM EDTA. The protein was again passed 
through HisTrap FF columns in order to separate cleaved protein from TEV as 
well as the cleaved 6xHis tag. The cleavage step was only performed on protein 
which would be used for NMR or fluorescence polarization, protein used for TR-
FRET did not have the 6xHis tag removed. The protein was then further purified 
by gel filtration using a HiLoad 16/600 Superdex 200 PG (GE Healthcare). Size 
exclusion was performed in 25 mM MOPS (pH 8.0), 300 mM KCl, 1 mM TCEP, 
and 1 mM EDTA buffer. Protein was then dialyzed into 25 mM MOPS (pH 7.4), 
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25 mM KCl, and 1 mM EDTA buffer. Protein purity in excess of 95% was 
determined by gradient 4-20% SDS-PAGE analysis (NuSep). Protein 
concentration was determined using ε280 = 12,045 M-1cm-1. 
15N labeled protein was grown in M9 minimal media containing 99% 
15NH4Cl (Cambridge Isotope Laboratories) as the sole nitrogen source. For this 
growth cells were grown at 37°C and 180 rpm until an OD600 of approximately 
1.0 was reached. At this point the temperature was dropped to 22°C for 1 hour. 
Following cool down period protein expression was induced by the addition of 
500 µM IPTG during induction cells remained at 22°C. Protein expression and 
purification was then accomplished utilizing the same protocol as outlined above. 
2.5.2 Delipidation of PPARγ 
To delipidate PPARγ LBD, purified protein was diluted to 0.8 mg/ml and 
batched with Lipidex 1000 (Perkin Elmer) at an equal volume. This mixture was 
batched for 1 hr at 37 °C and 100 rpm. Immediately following this treatment, 
protein was pulled through a gravity column by syringe. To increase yield, it was 
found that speed of elution was important; protein could not remain on the resin at 
room temperature in excess of 3 min. Two more column volumes of pre-warmed 
25 mM MOPS, 25 mM KCl, and 1 mM EDTA were also pulled through in the 
same manner. Quality of delipidation was then estimated by 19F NMR, loss of 
lipid can be most easily detected by a reduction in the peak at -84.1 ppm. When 





Mutations in PPARγ LBD were generated using the Quikchange 
Lightning site-directed mutagenesis kit (Agilent). To generate each mutation the 
following primers were used: K502C Forward 5’-
aggttaattattagtacaagtcgcagtagatctcctgcaggagcgg-3’, Reverse 5’-
ccgctcctgcaggagatctactgcgacttgtactaataattaacct-3’; C313A Forward 5’-
ccacggagcgaaactgagcgccctgaaagatgcgg-3’, Reverse 5’-
ccgcatctttcagggcgctcagtttcgctccgtgg-3’, Q322C Forward 5’-
catactctgtgatctcgcacacagcctccacggagc-3’, Reverse 5’-
gctccgtggaggctgtgtgcgagatcacagagtatgc-3’. The presence of expected mutations 
and absence of spurious mutations was confirmed by Sanger sequencing 
(Eurofins).  
2.5.4 Preparation of NMR samples 
NMR samples were prepared to a final concentration of 150 µM protein in 
470 µL volume containing 10% D2O. Addition of ligand was done in two separate 
injections of compound to reduce precipitation. Injections were spaced 30-60 min 
apart to allow time for binding. All ligands were dissolved in D6-
dimethylsulfoxide (DMSO) with the exception of GQ-16 which was dissolved in 
D7-dimethylformamide (DMF). Deuterated solvents were obtained from 
Cambridge Isotope Laboratories Inc. and were at least 99% isotopically pure. 
Final concentrations of ligand for samples of PPARγK502C-BTFA were 1.25x 
ligand to protein (187.5 µM) with the exception of troglitazone, pioglitazone, and 
ciglitazone, which were loaded to 2.0x (300 µM) due to poor binding affinity. In 
samples of PPARγC313A,K502C-BTFA, ligand concentration was 1.1x to protein 
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(165 µM) with the exception of troglitazone, pioglitazone, and ciglitazone, which 
were loaded to 1.5x (225 μM). To decrease the likelihood of labeling the single 
native cysteine (C313) in PPARγK502C-BTFA, we first loaded ligands into the 
protein and then labeled with BTFA since bound ligands would restrict access to 
C313 for all experiments involving PPARγK502C-BTFA. In both cases, the ligand 
concentration in DMSO was controlled to maintain a constant volume of DMSO 
or DMF addition to the sample (8.80 µL for PPARγK502C-BTFA and 7.76 µL for 
PPARγC313A,K502C-BTFA) including for apo and E. coli lipid samples. For peptide 
studies, 1 mM peptide in identical buffer to protein was added at a 2:1 molar ratio 
(final concentration 300 μM peptide and 150 μM protein). For non-covalent 
ligands, samples were labeled with 2.0x BTFA after addition of ligand. For 
covalent ligands, samples were labeled with 10x BTFA following preincubation 
of T0070907 or GW9662; and addition of 1.5 and 2 ligand molar ratios yielded 
very similar spectra, indicating complete covalent modification of C313 and 
likely no bonding to K502C (Supplementary Fig. 5). After addition of BTFA, 
protein was incubated for 30-60 minutes and then buffer exchanged at least 100x 
using 10kDa Amicon Ultra-15 concentrators (Merck Millipore) to remove excess 
unbound BTFA. Following this buffered D2O was added. 
Variable D2O NMR samples were prepared by buffer exchanging protein 
samples greater than 100x into 25mM MOPS 25mM KCl 1mM EDTA pD 7.4 
buffer prepared in either 50% or 100% D2O using Amicon Ultra-4 10kDa 
centrifugal filters (EMD Millipore). 100% D2O buffer was adjusted to read pD 7.4 
(pH 7.0231), and then mixed with appropriate amounts of H2O buffer that had been 
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adjusted to read pH 7.4. Following this, ligands were added to the appropriate 
concentration as usual. The samples which contained only 10% D2O were 
prepared as usual with the standard addition of 10% buffered D2O to the final 
sample. Samples of PPARγK502C-BTFA were already loaded with ligand and 
labeled appropriately with BTFA prior to exchange into deuterated buffers. 
2.5.5 Fluorescence Polarization (FP) assay 
Fluorescence Polarization peptide binding assays were performed by 
plating a mixture of 50 nM peptide with an N-terminal fluorescein (FITC) tag, 12-
point serial dilutions of PPARγ-LBD (wild-type, PPARγK502C-BTFA, 
PPARγK502C, or PPARγC313A,K502C-BTFA), and PPARγ ligands from 50μM to 
24nM. PPARγ-LBD and PPARγ ligands were added at a 1:1 ratio. This mixture 
was added to wells of low-volume 384-well black plates (Grenier Bio-one, 
catalogue number 784076) to a final volume of 16 μL. Peptides were synthesized 
by Lifetein LLC (Somerset, NJ) for the for Mediator Complex Subunit 1 (MED1) 
peptide, sequence: NTKNHPMLMNLLKDNPAQD; and the Nuclear Receptor 
Corepressor 1 (NCoR) peptide, sequence: GHSFADPASNLGLEDIIRKALMG 
(2251-2273). Other peptides were purchased from ThermoFisher (Waltham, MA) 
for Mediator Complex Subunit 1 (MED1) peptide, sequence: 
NTKNHPMLMNLLKDNPAQD (catalogue number PV4549); CREB-Binding 
Protein (CBP) peptide, sequence: AASKHKQLSELLRGGSGSS (catalogue 
number PV4596); and Silencing Mediator for Retinoid and Thyroid Hormone 
Receptors (SMRT), sequence: HASTNMGLEAIIRKALMGKYDQW (catalogue 
number PV4424). All dilutions were made in 25 mM MOPS (pH 7.4), 25 mM 
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KCl, 1 mM EDTA, 0.01% fatty-acid free Bovine Serum Albumen (BSA) (EMD 
Millipore, catalogue number 126575), 0.01% Tween, and 5 mM TCEP. Assay 
titrations were performed in duplicate. Plates were incubated in the dark at room 
temperature for 2 hr before being read on a Synergy H1 microplate reader 
(BioTek). Fluorescence polarization was measured by excitation at 485nm/20nm 
and emission at 528nm/20nm for FITC. Data was fit using nonlinear regression 
(agonist vs response – variable slope 4 parameters) in Prism 7.0b. For FP, TR-
FRET and Fluormone competitive binding assays we did two technical replicates 
and repeated these experiments independently in the lab for once (Fluormone) or 
2 or more times FP and TR-FRET. We chose these number of technical replicates 
and independent experiment replicates based on our experience with the limited 
variability inherent in these biochemical assays  
 
2.5.6 Time-resolved Förster resonance energy transfer (TR-FRET) assay 
TR-FRET peptide recruitment assays were performed by plating a mixture 
of 8 nM 6xHis-PPARγ-LBD (wild-type, PPARγK502C-BTFA or PPARγC313A,K502C-
BTFA), 0.9 nM LanthaScreen Elite Tb-anti-His Antibody (LifeTechnologies 
catalogue number PV5863), 200 nM peptide (N-terminally biotinylated and C-
terminally amidated), 400 nM streptavidin-d2 (Cisbio, catalogue number 
610SADLB), and 12-point serial dilutions of PPARγ ligands from 50 μM to 
1 pM. This mixture was added to wells of low-volume 384-well black plates 
(Grenier Bio-one, catalogue number 784076) to a final volume of 20 μL. Peptides 
were synthesized by Lifetein LLC (Somerset, NJ) for Mediator Complex Subunit 
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1 (MED1) peptide; sequence: VSSMAGNTKNHPMLMNLLKDNPAQ; and 
Nuclear Receptor Corepressor 1 (NCoR) peptide, sequence: 
GHSFADPASNLGLEDIIRKALMG (2251-2273). All dilutions were made in 
25 mM MOPS (pH 7.4), 25 mM KCl, 1 mM EDTA, 0.01% fatty-acid free Bovine 
Serum Albumen (BSA) (EMD Millipore, catalogue number 126575), 0.01% 
Tween, and 5 mM TCEP. Assay titrations were performed in duplicate. Plates 
were incubated in the dark at room temperature for 2 hr before being read on a 
Synergy H1 microplate reader (BioTek). TR-FRET was measured by excitation at 
330nm/80nm and emission at 620nm/10nm for terbium and 665nm/8nm for d2. 
Change in TR-FRET was calculated by 665nm/620nm ratio.  
Data was fit using nonlinear regression (agonist vs response – variable 
slope 4 parameters) in Prism 7.0b. Outliers were automatically detected using 
Prism 7.0b’s implementation of the ROUT method232 and excluded from the 
curve fitting (20 out of 2260 total data points were flagged as outliers). However, 
all data points, including detected outliers were included in figure graphs. In cases 
where curve fitting failed the TR-FRET value nearest the calculated free ligand 
concentration in the NMR experiment was used, otherwise the TR-FRET value at 
the calculated free NMR ligand concentration was calculated using the fitted 
curve. These TR-FRET ratio values were used to correlate with NMR chemical 
shift values. One ligand, nTZDpa, showed a biphasic TR-FRET curve. This could 
be due to several factors including ligand aggregation233, absorption interference 
in the TR-FRET assay (nTZDpa contains an indole group that could in principle 
cause interference), or alternate site binding effects208; we therefore utilized the 
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value of the TR-FRET ratio for nTZDpa based on a fit that did not include the last 
two concentrations (10 and 50 μM), so as to exclude most effects of the second 
transition. In addition, the 50 μM SR2088 point was not run because we did not 
have sufficient ligand. All error bars are standard deviation. 
2.5.7 Fluormone competitive binding assays 
PPARγ ligand inhibition constants (Ki) were measured using a protocol 
adapted from LanthaScreen TR-FRET PPARγ Competitive Binding Assay 
(Invitrogen, catalogue number PV4894). Assay was performed by plating a 
mixture of 8 nM 6xHis-PPARγ-LBD, 2.5 nM LanthaScreen Elite Tb-anti-His 
Antibody, 5 nM LanthaScreen Fluormone Pan-PPAR Green (Invitrogen, 
catalogue number PV4896), and 12-point serial dilutions of PPARγ ligands from 
50 μM to 140 fM. This mixture was added to wells of low-volume 384-well black 
plates (Grenier Bio-one) to a final volume of 16 μL. All dilutions were made in 
25 mM MOPS (pH 7.4), 25 mM KCl, 1 mM EDTA, 0.01% fatty-acid free BSA 
(EMD Millipore), 0.01% Tween, and 5 mM TCEP. Assay titrations were 
performed in duplicate. Plates were incubated in the dark for 2 hr at room 
temperature before being read on a Synergy H1 microplate reader (BioTek). TR-
FRET was measured by excitation at 330nm/80nm and emission at 495nm/10nm 
for terbium and 520nm/25nm for Fluormone. Change in TR-FRET was calculated 
by 520nm/495nm ratio. Nonlinear curve fitting was performed using Prism 7.0b 
(Graphpad Software, Inc.) as described above for the TR-FRET data, including 
manual exclusion of highest two concentrations for nTZDpa. 30 of the 1224 total 
81 
 
data points for all three proteins (WT, PPARγK502C-BTFA and PPARγC313A,K502C-
BTFA) were automatically excluded by Prism in the fits. 
2.5.8 Ki calculation 
The inhibition constant for each PPARγ ligand was calculated by applying 
a corrected Cheng-Prusoff (Kenakin, TP 1993 in Pharmacologic analysis of 
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where IC50 is the concentration of the ligand that produces 50% displacement of 
the Fluormone tracer, Lo is the concentration of Fluormone in the assay (5 nM), 
and KD is the binding constant of Fluormone to wild-type or the two BTFA 
labeled mutants, Ro is the total receptor concentration and Lb is the concentration 
of bound Fluormone in the assay with no addition of test ligand. The affinity of 
Fluormone for the two BTFA labeled mutant proteins was determined via TR-
FRET by titration of fluormone into each mutant bound to Elite Tb-anti-His 
Antibody. Dissociation constants of fluormone for wild-type was measured as 
PPARγ LBD is 7.9 ±0.2 the variants were measured as 26 ±3 nM for PPARγK502C-
BTFA and 44 ±4 nM for PPARγC313A,K502C-BTFA and PPARγC313A 12 ±1 nM. 
2.5.9 NMR spectroscopy 
Acquisition of spectra was performed using a Bruker 700 MHz NMR 
system equipped with a QCI-F cryoprobe. Chemical shifts were calibrated using 
an internal separated KF reference in 20 mM KPO4 (pH 7.4) and 50 mM KCl 
contained in a coaxial tube inserted into the NMR sample tube. KF was set to 
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be -119.522 ppm, which is the shift of the KF signal with respect to the 19F basic 
transmitter frequency for the instrument (658.8462650 MHz) at 298.2K, the 
temperature at which samples were run. Routine 1D fluorine spectra were 
acquired utilizing the zgfhigqn.2 pulse program (Bruker Topspin 3.5), which 
consists of a 90° pulse followed by acquisition with proton decoupling 
(acquisition=0.7 s). Settings were D1=1.2 s, AQ= 0.82 s. Approximately 500 to 
4000 transients were collected. Saturation transfer experiments were carried out 
using the stddiff pulse program. Settings were D1=1.6 s, AQ=0.6 s. For some 
experiments the total duration of the saturating pulse (Gaus1.1000, 54.52 dB, 
50ms) was 1.6 s (D2O) and the location of the saturating pulse was varied. In 
other experiments, the duration of the saturating pulse was varied, with the 
saturating pulse location held constant and the rate of exchange was fit using 
equation 50 found in a previous publication234. An off resonance selective 
saturating pulse was used to determine the peak intensity at time t=0 and R1 was 
determined experimentally (Table 2). Fits of the saturation transfer data were 
accomplished with a single free parameter using these experimentally determined 
values for initial intensity and R1 (2.7s-1 used for all fits except GW9662 which 
used 2.4s-1). Transverse and longitudinal relaxation lifetimes (T1 and T2) were 
determined by fitting data acquired using an inversion recovery experiment 
(Bruker pulse program t1ir) and cpmg pulse sequence (Bruker cpmg) in Prism 
7.0b (Graphpad Software, Inc.) using standard formulas. Spectra were 
deconvoluted in an objective manner with models chosen statistically by a fitting 
program219. All fits were carried out in the same manner with the same settings in 
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the fitting program, except where noted. Relative phase of fitted peaks was 
allowed to vary slightly (π/50 radians) to accommodate imperfect phasing of these 
broad signals. The fitting algorithm219 assumes Lorentzian lineshapes of similar 
phase. Intermediate exchange effects and field inhomogeneity are likely present in 
some of these spectra, which will result in inaccuracies in the fitted models; 
however, notwithstanding these limitations, the deconvolution method provides 
an objective view of the possible underlying spectral structure and populations. 
Two-dimensional [1H,15N]-TROSY-HSQC NMR data were obtained using the 
trosyf3gpphsi19.2 pulse program. Select NMR spectra were replicated in two 
different ways. 1) Some NMR samples were measured via NMR initially and then 
days to weeks later to determine if certain parts of the spectrum changed. Cs 
would indicate that non-reversible processes contribute to that part of the signal, 
such as unfolding or degradation of the protein. 2) Some spectra were run twice 
utilizing protein from the same batch as utilized for the first spectra or from an 
entirely different protein preparation. 
2.5.10 Molecular dynamics simulations 
 Residues in our physical protein constructs used in NMR that were 
missing in crystal structures (except the N-terminal glycine, which is an unnatural 
vestige of the cleaved His tag) were added using the modeller235 extension within 
Chimera236 and a PDB file was saved. This PDB file was then submitted to the 
h++ server237 (http://biophysics.cs.vt.edu/H++) to determine the state of titratable 
protons at pH 7.4, along with more realistic rotamers for some residues. This h++ 
PDB file was then given AMBER names for the various protonation states of 
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histidine determined by h++ using pdb4amber (AmberTools14238). PDB files of 
Cysteine-BTFA residue was created through modification of a cysteine residue in 
Chimera. This PDB file was then submitted to the RED server239 for RESP240 
charge derivation and geometry optimization. RESP values for the cysteine 
backbone of these modified residues were constrained to match AMBER cysteine 
residue values as part of the input to the RED server. In a manner similar to that 
outlined in sections 2-3 in tutorial 5 on the ambermd.org site 
(http://ambermd.org/tutorials/basic/tutorial5/), the output mol2 file was then used 
to prepare an ac file and then a prepin file containing the same RESP derived 
charges (Supplementary Methods) and two force modification files. The 
AMBER parameter database derived frcmod file (Supplementary Methods) was 
loaded after the GAFF241 parameter database derived frcmod file 
(Supplementary Methods) within Tleap in order to use AMBER parameters 
where possible for the Cysteine-BTFA residue. Tleap was then used to generate 
parameter and coordinate files using both ff14SB242 and GAFF values. A 
truncated octahedron solvation cell with boundaries at least 10 Angstroms from 
any protein atom was built with TIP3P243 water. The system was neutralized with 
Na+ ions and K+ and Cl- atoms were added to 50 mM. Joung and Cheatham ion 
parameters244 were used. Minimization (imin=1) and equilibration was carried out 
in nine steps with non-bonded cutoff (cut) set to 8 angstroms and with the 
equilibrations carried out at 310 Kelvin. First, steepest descent minimization 
(ntmin = 2) with strong restraints (restraint_WT = 5 kcal/mol Å2) on protein 
heavy atoms for 2000 steps was used followed by NTV MD with shake, the same 
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restraints and 1 fs steps for 15 ps. Next, two rounds of 2000 steps of steepest 
descent minimization with progressively relaxed restraints (restraint_WT = 2 and 
0.1 kcal/mol Å2) followed by a round without restraints. This was followed by 
three rounds of NTP MD with shake (5ps, 10ps and 10ps in duration), and protein 
heavy atom restraints of 1, 0.5 and 0.5 kcal/mol Å2. A final unrestrained NTP MD 
simulation was then run for 200 ps with 2 fs steps. The final restart file from this 
process was used along with a hydrogen mass repartitioned parameter file 
(modified using parmed) to run new simulations with new randomized atomic 
velocities using 4 fs steps at 310 Kelvin. Analysis was carried out using 
CPPTRAJ245. All production simulations were carried out using pmemd.cuda or 
pmemd.cuda.MPI. 
The S enantiomer of GW1929, which was used in NMR and TR-FRET, 
was built using Maestro (Schrödinger, LLC). The pyridine ring nitrogen of 
GW1929 was the only atom with a predicted pKa near 7.4 (calculated 7.56 +/- 
1.12) using the EPIK module (Schrödinger, LLC). We chose to model this 
nitrogen as deprotonated. There is no crystal structure for GW1929 bound to 
PPARγ, however there is for GI262570, which is bound to PPARγ LBD in the 
1FM9 crystal structure. GI262570 is identical to GW1929 for about 2/3 of the 
molecule. GW1929 was docked into the 1FM9 crystal structure with GI262570 
removed using AutoDock Vina246. The best scoring docked binding mode 
overlaid well with GI262570. In this docked model in the helix 12 interacting 
region the two ligands themselves are identical. RESP charges for GW1929 were 
derived using the RED server and force modification files generated using GAFF 
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parameters. 1FM9 was modified (or not) to incorporate cysteine-BTFA 
(parameterized as described above) in place of K502 and docked with GW1929 in 
a similar way to that described above to build PPARγK502C-BTFA and PPARγ  
bound to GW1929.  
1PRG chain B was used to create the build for apo and 3BOR chain B was 
used to build T0070907 bound PPARγ LBD. 3BOR contains GW9662 which 
differs from T0070907 by one atom. T0070907 has a nitrogen in place of a carbon 
atom in one of the ligand rings. This change was made in Chimera and the ligand 
parameterized and incorporated into the structure as described above for BTFA. 
NCoR (same sequence as used in NMR and TR-FRET including N-terminal 
acetylation and C-terminal amidation) was added to these builds utilizing Chimera 
using the following procedure. The core helix structure from NCoR (from 2OVM) 
was aligned to SMRT on a PPARα SMRT structure (1KKQ), apo PPARγ chain B 
(1PRG) was then aligned to PPARα and the PPARα/SMRT structure deleted 
leaving the aligned NCoR on apo PPARγ chain B. A similar procedure was used 
with the 3BOR structure to create T0070907 co-bound with NCoR on PPARγ. 
These PDBs were then used to create the final solvated, minimized and 
equilibrated structure in a manner similar to that described above. 
 All simulations were run with settings shown in Supplementary Methods 
including utilization of SHAKE247, with variability in the frequency of writing 
various files to disk. K-means clustering was performed and representative 




2.5.11 Data availability 
Data files for TR-FRET, Fluormone competitive binding assays, and FP 
are publicly available at https://osf.io/rqdpz/. Any other datasets generated during 
and/or analyzed during the current study are available from the corresponding 
author on reasonable request. 
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Nuclear receptors are a diverse superfamily of transcription factors which 
are the target of 13% of FDA approved drugs. These proteins function through the 
recruitment of coregulator complexes which modulate transcription. These 
coregulator interactions are exceptionally specific and regulate very different 
pathways. The mechanism by which this selectivity arises is poorly understood. In 
this work a helix 4 motif on the LBD of nuclear receptors is identified. Through 
this motif specific interactions are made with coactivators which convey a large 
degree of specificity. We find that the frequency of interaction between these 
residues and coactivators is proportional to coactivator affinity in the nuclear 
receptor peroxisome proliferator-activated receptor γ (PPARγ). The significance 
of this motif is also verified via molecular dynamics simulations in the nuclear 
receptor estrogen receptor α (ERα). Additionally, the mechanism by which full 
agonists display differential efficacy in PPARγ is presented. 
3.2 Introduction 
The nuclear receptor (NR) superfamily of transcription factors regulates a 
variety of important pathways in metabolism and development. This superfamily 
is made up of 48 proteins in the human genome which makes up the largest group 
of transcription factors1,2,248. Dysfunction in these transcription factors is linked to 
a variety of disease states including cancers153,249–251, metabolic 
syndromes46,49,53,146,252,253 and developmental disorders254–256. Thus far 20 of these 
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proteins when modified at the genetic level have been linked directly to disease 
states257–260. Due to this the NR family has been a focus of drug development with 
approximately 13% of all FDA approved drugs targeting members of this 
family261,262. 
The activity of NR is controlled through the recruitment of coregulator 
proteins. These coregulators are classified into either coactivators which through 
their interaction promote transcription of regulated genes or corepressors which 
reduce the expression of regulated genes263,264. The interaction of NR and 
coregulators is highly specific often to the degree of interacting only with a single 
motif inside a coregulator. These interaction motifs are the well characterized 
LxxLL motif, NR box (referred to as LxxLL box in this work), seen in 
coactivators16,265,266 or the less well understood motif in corepressors which 
contain either (L/I)xxI(/V)I or Lxxx(I/L)xxx(I/L), referred to as the CoRNR 
box17,267,268. These LxxLL or CoRNR boxes appear to be necessary and sufficient 
for the interaction and in many cases only a single motif is needed for high 
affinity binding to the LBD of an NR269,270.  
NR-coregulator interactions can occur in one of two regions of the NR, 
either the unstructured and very poorly conserved activation factor 1 (AF-1) 
region of the protein29,271, or more often through the LBD of the NR via the 
activation factor 2 (AF-2) region272,273. Current knowledge of the mechanism of 
binding focuses on two major interactions. The first is a hydrophobic cleft present 
in the NR LBD which allows for interaction with the conserved regions of either 
the LxxLL or CoRNR box14,20,274. The second which is most significant for the 
interaction of coactivators is the so-called charge clamp. This consists of a 
conserved lysine at the C-terminal of helix 3 and a conserved glutamate on helix 
1223,275. These two residues serve to anchor the coactivator through interactions 
with the peptide backbone of the LxxLL motif in the mousetrap model of 
coactivator binding138. However, neither of these interactions are specific to the 
coactivator being bound as they interact with conserved motifs.  
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In this work we identify a highly conserved motif on helix 4 of the NR 
ligand binding domain (LBD) which makes direct coregulator interactions in the 
large majority of NR-coregulator crystal structures. This eight-residue motif 
makes highly selective coregulator interactions through the side chains of the first 
and last residues in the motif. We propose that this motif leads to a large degree of 
the observed selectivity in NR coregulator interactions. This hypothesis is verified 
experimentally in the NR, peroxisome proliferator-activated receptor gamma 
(PPARγ). From this we observe that the degree of helix 4-coactivator interactions 
are directly related to the affinity of the complex. Additionally, we identify a 
structural mechanism which gives rise to differential efficacy among full agonists 
of this protein. Molecular dynamics driven analysis of NR-coactivator interactions 
in both PPARγ and estrogen receptor alpha (ERα) indicate that this structural 
mechanism of coregulator selectivity appears to be conserved among this 
superfamily of proteins. This provides valuable insight into the currently 
unknown mechanism by which NR selectively recruit specific coregulators and 
better defines the functionally important AF-2 region of the NR LBD.  
3.3 Results 
3.3.1 Coregulator helix 4 interactions in NRs 
A query of the protein data bank revealed that of the 48 NR in the human 
genome 42 had crystal structures of the LBD. Of these, 27 had structures that 
were solved bound to a coregulator peptide. From these structures we were able to 
find 23 NR-coregulator complexes that resolved direct interactions between helix 
4 residues on the NR and side chains of the coregulator peptide. Almost all of 
these interactions arose from two residues on helix 4 spaced eight residues apart. 
Examining the residues in this region we were able to identify a conserved motif. 
Three of the residues in this motif were almost 100% conserved across all NR. 
These are an aspartate at position two, a glutamine at position three and a leucine 
in position six. A consensus logo of this motif is shown in Figure 1, other 
consensus logos can be found in Figure S1. Additional interactions were seen in 
some NR-coactivator structures originating from the residue immediately prior to 
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this conserved motif (seen with FXR, LXRβ and all ROR proteins), as well as two 
with interactions from an arginine located five prior to this motif in helix 3’ (in 
structures of AR, CAR and GR). However, due to the scarcity of these 
interactions it is not realistic to make inferences about their role, but they likely 
are significant in selectivity of coactivator recruitment.  
 
Figure 1. Conservation of the helix 4 motif sequence. A: Consensus logo of the primary 
sequence for all nuclear receptors for the helix 4 motif. This omits three proteins (DAX1, GCNF 
and TR2) of the 48 human nuclear receptors. This motif is degenerate and cannot be identified in 
GCNF and TR2. In DAX1 this motif has expanded to nine residues and cannot be aligned due to 
this. B: Example crystal structure of HNFα bound to SRC1 (PDB 1PZL) which shows direct 
hydrogen bonding from the side chain of both helix 4 residues, D205 and R212. The consensus 
logo was generated using WebLogo276. 
 
Next, the 15 remaining NR with crystal structures were examined. Among 
these this motif could be identified in all but one, Testicular receptor 4 (TR4). In 
this case there is a similar sequence but among the three conserved residues in this 
motif only the position 6 leucine is present. Further examination of the remaining 
NRs based purely on primary sequence was performed. This identified a further 
two proteins, testicular receptor 2 (TR2) and germ cell nuclear factor (GCNF), 
which do not contain this motif. However, literature on these proteins indicate that 
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such a lack may not be surprising as they are not known to bind coregulator 
proteins on the AF-2 surface. For the purposes of examining this motif these three 
proteins will not be considered due to the lack of consensus. The presence of this 
motif gives insight into a mechanism through which NR LBDs preferentially bind 
certain coactivators. Currently this is not well understood as the characterized 
interactions, the hydrophobic cleft which interacts with the LxxLL box and the 
charge clamp are conserved among NR.  
Examining these sequences, we were able to determine several 
characteristics of this eight-residue motif, this motif is shown for all 46 NR in 
which it could be identified in Figure S2. The first residue is not heavily 
conserved but is most frequently an acidic residue, 19 out of 39 cases, and is a 
residue capable of hydrogen bonding in 79.5% of NR. When this residue is 
capable of hydrogen bonding it is frequently observed to make interactions with 
side chains of the coregulator peptide, 14 of 22 proteins crystallized in the 
presence of a coregulator. The second residue is the fully conserved aspartate. It is 
not clear what the purpose of this residue is as it is not properly aligned to interact 
with a coregulator, but it may serve a structural role in the conserved fold seen 
with NRs. The next residue is the fully conserved glutamine in position three. 
This residue appears to predominantly make water mediated hydrogen bonds to 
the carbonyl of one of the leucine residues in the LxxLL motif. It can however 
hydrogen bond directly to the side chain of a residue in the peptide, but this is less 
common. The fourth residue is poorly conserved but is a non-aromatic 
hydrophobic residue (isoleucine, methionine or valine) in 89% percent of the 
considered cases. Two proteins where this residue is changed are the NR0B 
family (DAX1 and SHP) which function more like coregulator proteins than as 
NRs. The other proteins where this residue has changed are the NR4A family 
(Nur77, Nurr1 and Nor1) which have been shown to lack a normal coregulator 
binding surface29,271 and have been found to bind corepressor proteins in a cleft 
between helix 11 and helix 12, which is the opposite side of H12 from the normal 
coregulator binding surface30. The fifth residue is very poorly conserved, but this 
is unsurprising as it is oriented directly away from the peptide and does not appear 
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to have any role in peptide recognition or binding. The sixth residue seems to play 
no role in peptide binding but makes a large amount of hydrophobic contacts 
which connect helices 4, 8 and 9. This suggests the conservation of this residue 
has nothing to do with peptide binding and instead is important for proper folding 
of NRs. The seventh residue is almost exclusively a leucine, in three cases is an 
isoleucine (AR, MR and PGR) and appears to make non-specific hydrophobic 
interactions to the leucine repeat in the LxxLL motif of the coactivator peptide. 
The final residue again seems to make specific hydrogen bonds or salt bridge 
interactions to the side chains of the peptide. This residue is not very conserved 
but by majority is a basic residue, 68%, but can also be a glutamine, 18%, or a 
glutamate, 15%.  
Separating out these proteins by family reveals patterns relevant to 
coregulator specificity profiles within subfamilies. The final residue seems to be 
heavily conserved within NR families. In NR1 the motif exclusively ends with a 
lysine while in NR2 all proteins have a motif ending in arginine with the 
exception of PNR and TLX. However, both PNR and TLX are not well 
understood proteins so this may indicate that these proteins share their coregulator 
recruitment pattern more with the NR3 family than with the NR2 family. In the 
NR3 family the final residue of this motif is less conserved and is just as likely to 
be a glutamine or a glutamate. This may indicate that in these subfamilies there 
are differences in preferential recruitment of coactivators. Also interesting is that 
in the NR1 family the motif sequence is 100% conserved within subfamilies, with 
the exception of NR1I where the vitamin D receptor (VDR) differs from the 
consensus sequence of the other two. This is not seen in either NR2 or NR3 and 
may indicate a greater similarity in coactivator recruitment for proteins from the 
NR1 family. We further examined the conservation of this motif across several 
nuclear receptors and species. From this it appears that this motif is 100% 
conserved in mammals and begins to deviate slightly when more distantly related 
species are examined. However, this deviation was only found in those nuclear 
receptors which have a somewhat degenerate motif, TR4 and Nurr1 (Figure S3). 
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3.3.2 Experimental confirmation of coactivator selectivity 
There are relatively few NR proteins where the relative affinity of many 
different coregulator peptides are known. However, there are three, PPARγ36, 
TLX136 and ERα134, wherein the binding of a wide variety of coregulator peptides 
have been examined using the PAMGENE system. As well there are some data 
for relative coregulator affinities for VDR131 and THRβ132 but significantly fewer 
coregulator interactions were examined.  Due to a robust pool of synthetic ligands 
and experience in this system we examined the significance of this motif in 
PPARγ, which will serve to experimentally verify the importance of these helix 4 
interactions and to determine if they are involved in the selective recruitment of 
coactivator LxxLL boxes to the receptor. There are no published crystal structures 
of PPARγ which show both helix 4 interactions expected from this motif, (i.e. 
involving N312 and K319). However, both interactions can be seen 
independently, the N312 interaction is seen in crystal structures with PPARγ-
coactivator 1 alpha (PGC1α) and the K319 interaction can be seen in crystal 
structures with either steroid receptor coactivator 1 or 2 (SRC1 or SRC2). We 
hypothesized that co-crystallization of PPARγ with the most efficacious available 
full agonist and a high affinity coactivator peptide would reveal both these 
interactions.  
3.3.3 Agonist efficacy in PPARγ 
There exist many full agonists for PPARγ including two which are 
currently FDA approved for human use, rosiglitazone and pioglitazone, as well as 
several experimental ligands of the glitazar or glitazone classes. However, it is not 
clear which of these is the most efficacious in coactivator recruitment. Based on 
in cell transcriptional reporter assays it is frequently assumed that these ligands 
promote the same level of coactivator recruitment and the main differences 
observed are due to ligand affinity or bioavailability277,278. However, this is 
inconsistent with biophysical data obtained from fluorescence polarization (FP) 
assays. As such we wished to look at a variety of structurally and functionally 
diverse ligands, including inverse agonists, partial/non-agonists and full agonists, 
to determine if there are reproducible differences. This was performed with three 
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distinct biologically relevant high affinity peptides, PGC1α, CREB-binding 
protein box 1 (CBP-1) and MED1-2 as well as a corepressor peptide of nuclear 
receptor corepressor 1 box 2 (NCoR1-2). This will determine if differences in full 
agonist efficacy could exist and if differences in coregulator peptide affinity are 
reproducible. These assays were performed by means of FP whereby protein pre-
loaded with ligand is titrated into a fixed concentration of fluorescently labeled 
peptide, the increase in polarization upon binding can be fit to a non-linear 
regression to determine a Kd of interaction. To simplify interpretation data are 
represented as a heatmap representing the fold change in affinity with ligand 
relative to the apo state (Figure 2a and b). Actual Kd values are shown in table 





Figure 2. Identification of the most efficacious full agonist of PPARγ.  A-B: Fluorescence 
polarization of either the heterodimer of the PPARγ-RxRα LBD or the full-length complex of 
PPARγ2-RxRα-SULT2A1 PPRE. Data are shown as fold-change relative to the apo state. All data 
shown represents two technical replicates from a single experiment. The experiment was 
replicated independently a second time and those results are shown in figure S4. Curve fits for 
these data are shown in figure S4. C: The crystal structure of the PPARγ LBD complexed with 
GW1929 and the MED1-2 peptide. D: Crystal structure of the PPARγ LBD complexed with 
GW1929. For both structures the direct protein-ligand interactions are shown in the inset. Protein 
ligand interactions were determined using the Protein Ligand Interaction Profiler279. E-F: Blowup 
of the ligand binding pocket for the crystal structures in C and D showing the large system of 
highly ordered water molecules which form water-mediated hydrogen bonds between the ligand 
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and the protein. The bonds originating from the ligand are shown in green while the fully water 
mediated are in purple.  
 
This assay was performed both in a heterodimer of the PPARγ-LBD and 
the RxRα-LBD as well as the more biologically relevant form of the full-length 
PPARγ2 and full-length RxRα bound to a PPAR response element from the 
SULT2A1 gene. In both cases the same pattern was seen wherein the full agonist 
GW1929 binding led to higher affinity for all studied coactivators than did the 
other ligands. This demonstrates that full agonists of PPARγ do have different 
levels of efficacy in coactivator recruitment contrary to the relative affinities 
implied from in cell transcriptional assays. It is not completely clear why this is, 
but we hypothesize that in transcriptional assays such as GAL4 the endogenous 
transcriptional machinery is limiting, preventing differentiation of full agonist 
behavior. This idea is supported by the phenomenon of squelching wherein 
coregulator recruitment to reporter plasmids decreases expression from other 
genes due to limiting supplies of endogenous coregulators such as components of 
the mediator complex. 
3.3.4 Crystallization of PPARγ 
We selected mediator of RNA polymerase II transcription subunit 1 
LxxLL box 2 (MED1-2) to attempt crystallization of a PPARγ structure where 
both putative selective helix 4 interactions could be resolved as MED1-2 has not 
previously been crystallized with PPARγ and has high affinity for PPARγ. This is 
significant as existing structures of PPARγ include SRC1-1, SRC1-2, SRC2-2 and 
PGC1α which do not have high affinity for PPARγ. Since GW1929 has not 
previously been crystallized bound to PPARγ and induces the highest affinity for 
MED1-2 of any tested ligand we set up trials to co-crystallize the PPARγ-LBD 
with GW1929 as well as with GW1929 and the MED1-2 peptide, Figure 2c-f. 
Both yielded high-quality crystals which diffracted to 1.9Å, crystallographic data 
is tabulated in table S3. Initial analysis of the GW1929 bound PPARγ-LBD did 
not reveal anything significantly different than seen previously in other full 
99 
 
agonist bound PPARγ crystal structures. The ligand makes the same four 
hydrogen bonds to the protein that are seen in many full agonist bound structures. 
Hydrogen bonds are observed between GW1929 and protein residues S289, 
H323, H449 and Y473280,281. Hydrophobic contacts are also similar to those seen 
with farglitazar, a closely structurally related ligand, barring only two novel 
contacts to helices 11 and 12281. This indicates the difference in efficacy with 
GW1929 and other full agonists is likely not due to direct ligand-protein 
interactions.  
What is unique in this crystal is that even in the absence of coregulator 
peptide it is monomeric which is uncommon for PPARγ structures; only three 
other WT PPARγ structures are monomeric (3BC5, 3R5N and 4XLD). 
Additionally, there are no gaps of electron density in the polypeptide chain, 
including a fully resolved Ω-loop which is also somewhat unusual for a structure 
of PPARγ. Previous literature suggests that stabilization of the  Ω-loop is 
important for agonism107, which would be consistent with observations here. The 
most striking characteristic is the presence of a large system of water-mediated 
hydrogen bonds which originate from the ligand. These bonds appear to anchor 
together helices 3, 5 and the β-sheet region. Previously it has been shown that 
rigidification of PPARγ is related to agonism140, so this large stabilizing network 
may contribute to the increase in ligand efficacy seen with GW1929.  
Examining the structure bound with MED1-2 almost no structural change 
is observed with peptide binding, Figure 3a. The ligand still makes the same 
interactions to the protein and the water-mediated hydrogen bond network is still 
present, although the network of water-mediated hydrogen bonds has changed 
slightly, contacting the Ω-loop in a stabilizing manner. The Ω-loop undergoes 
aconformational change upon peptide binding. This may be because the structure 
without peptide helix 3 contains one additional turn. No crystal contacts were 
seen in the unit cell to the Ω-loop indicating that the stabilization observed here is 
an effect of the ligand and not a crystallographic artifact. The one other region of 
the protein where significant change relative to the peptide free structure is seen is 
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the phosphorylation loop, residues 238-246, but this region does appear to have 
significant contacts in the unit cell suggesting these differences may be due to 
crystal packing forces. As hypothesized both singularly observed helix 4 
hydrogen bonds, involving residues N312 and K319, were observed in the 
GW1929 bound MED1-2 structure simultaneously. This is consistent with the 
idea that these interactions are important in high affinity binding interactions and 
are more likely to be observed in crystals representing such structures.  
Due to the lack of observed conformational change in the PPARγ-
GW1929 complex upon MED1-2 binding, it was of interest to compare it to 
previously published structures of rosiglitazone with and without coactivator 
peptide, Figure 3b. We attempted to co-crystallize PPARγ with rosiglitazone and 
MED1-2 for a more useful comparison but were unsuccessful. For this 
comparison the monomeric crystal structure of PPARγ bound to rosiglitazone, 
PDB ID:4XLD, and a structure bound to rosiglitazone and a peptide of the 
reasonably high affinity coactivator PGC1α were selected, PDB ID:3CS8. 
Pairwise alignment and superposition of the peptide bound and free structures of 
GW1929 and rosiglitazone reveal that the lack of conformational change observed 
with GW1929 appears to be unique. In the rosiglitazone bound structures change 
is observed in helices 3 and 4 with significant changes seen in helix 11. In 
addition, the Ω-loop is not fully resolved in either structure, however the resolved 
portion indicates different conformations in this region. We hypothesized that the 
similarity of the GW1929 and GW1929+MED1 structures and the dissimilarity of 
the rosiglitazone structures indicates that GW1929 binding restricts the protein to 
a conformational state that is nearly identical to the coactivator bound state and 
thereby would reduce any energetic penalties arising from conformational change 







Figure 3. GW1929 stabilizes PPARγ in a state similar to the coactivator bound state. A:  
Right, crystal overlays of the GW1929 bound PPARγ-LBD in the presence (blue) and absence of 
MED1-2 (tan). Left, crystal overlays of the rosiglitazone bound PPARγ-LBD in the presence (tan, 
4XLD) and absence of PGC1α (blue, 3CS8). B: TROSY-HSQC of the PPARγ-LBD. Left, overlay 
of the GW1929 and rosiglitazone bound states. Center, overlay of the GW1929-MED1 and the 
GW1929 bound state. Right, overlay of the rosiglitazone-PGC1α and the rosiglitazone bound 
states. C: 19F NMR of PPARγK474C-BTFA. D:19F NMR of PPARγQ294C-BTFA with 13 structurally 
and functionally distinct ligands. An * denotes labeling of the native cysteine, C285. All NMR 
samples were run once. Labels above indicate the synthetic ligand present in the NMR sample.  In 




3.3.5 15N HSQC of PPARγ in the presence of coactivators 
Because a crystal structure represents only a single low energy state of a 
protein and we have previously observed PPARγ to be highly plastic we wished 
to confirm these observations by NMR. Towards this end, we analyzed 15N 
labeled PPARγ bound to either rosiglitazone or GW1929 in the presence and 
absence of MED1-2 using TROSY-HSQC NMR, Figure 3c. This allows for the 
observation of significant changes in the backbone conformation of PPARγ upon 
peptide binding. Comparison of the peptide free rosiglitazone and GW1929 bound 
states showed only minor differences. A few more resonances are observed in the 
GW1929 bound state consistent with greater structural rigidity. While the 
GW1929 bound state spectrum remains virtually unchanged upon MED-1 
addition the rosiglitazone bound spectrum changes. Several new resonances are 
observed upon MED1-2 addition which indicates that the protein is rigidifying. 
Additionally, almost all peaks have an upfield shift in the 1H dimension. Taken 
together this indicates that rosiglitazone does not induce or select a conformation 
as conducive to coactivator binding as GW1929 does. MED1-2 binding to the 
rosiglitazone PPARγ complex requires significant conformational 
change/selection which requires energy and lowers affinity.  
3.3.6 Probing the PPARγ AF2 conformational ensemble by 19F NMR 
Using 19F NMR we focused on specific AF2 regions that contain the 
charge clamps, which are crucial to coactivator recruitment to determine any 
structural differences in these regions between full agonists. To accomplish this 
PPARγ-LBD was irreversibly modified with a trifluoro group (3-bromo-1,1,1-
trifluoroacetone; BTFA), via an introduced cysteine as we have done 
previously282. In this work we will utilize the helix 12 probe, PPARγ-BTFAK474C, 
and a helix 3 probe near the helix 3 charge clamp, PPARγ-BTFAQ294C. The 
PPARγ-LBD contains only a single native cysteine C285 which points into the 
ligand binding domain and is largely blocked when ligands are bound to the 
orthosteric site282, thus we BTFA label ligand bound PPARγ to avoid labeling the 
native cysteine. In addition, we confirm all spectra seen in the PPARγ-BTFAQ294C 
variant with a double mutant which removes the native cysteine, PPARγ-
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BTFAC285A,Q294C. Both the single PPARγ-BTFAQ294C and PPARγ-BTFAC285A,Q294C 
were tested for protein function by FP assays and found to have minimal effects 
on peptide affinity (Table S4). Both labeled mutants had similar affinity for 
coregulator peptides as wt PPARγ and appropriate ligand induced changes in 
affinity for coregulator peptides (Table S4).  
The helix 12 probe (PPARγ-BTFAK474C) produces nearly identical spectra 
when bound to GW1929 or rosiglitazone (Figure 3d). Upon addition of MED1-2 
both spectra shift upfield, although rosiglitazone shifts more. Thus, the 
differential affinity for coactivators induced by these ligands may not arise 
primarily due to helix 12 conformation. This is perhaps not surprising as both 
ligands make direct hydrogen bonds to Y473 on helix 12 based on crystal 
structures. Additionally, both ligands induce a similar loss in affinity for NCoR1-
2,  whose affinity is highly sensitive to the conformation of helix 12282.  
Previously it was shown by hydrogen deuterium exchange mass 
spectrometry (HDX-MS) that all analyzed PPARγ ligands stabilized helix 3 to 
some extent, however the C-terminus of helix 3, which contains the charge clamp, 
was not resolved164. More recently it was found that rosiglitazone did not 
significantly stabilize the charge clamp region, however this was performed in the 
PPARγ/RxRα heterodimer124. We performed fluorine NMR of PPARγ-
BTFAQ294C, which contains a probe near the helix 3 charge clamp (K301), bound 
to a wide variety of 11 apo or ligand-bound states ranging from inverse agonists 
to full agonists to determine any correlation between spectra and ligand activity 
(Figure 3e). All strong agonists induced a single narrow peak, indicating that they 
are reducing the conformational flexibility in this region. Less efficacious 
agonists and non-agonists produced broader or multiple peaks and apo state 
produced three peaks. Chemical exchange saturation transfer (CEST) NMR and 
apo WT PPARγ-BTFA spectra confirmed that the middle apo peak arises from 
labeling of the native cysteine (Figure S6). Interestingly, all the highly 
efficacious agonist ligands (rosiglitazone and pioglitazone) except GW1929 
produced the same shift and peak structure. The GW1929 bound state of PPARγ-
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BTFAQ294C also had a single narrow peak but a unique shift. These data suggest 
that some of the difference in efficacy arises from a unique conformation of helix 
3 when bound to GW1929. NMR with all ligands was replicated in PPARγ-
BTFAC285A,Q294C which produced nearly identical spectra with some differences 
observed for lower affinity ligands. These differences likely arise from labeling of 
the native cysteine in the single mutant, which may be more accessible in low 
affinity ligand PPARγ complexes (Figure S7).  
3.3.7 Mutagenic analysis of PPARγ 
Since the interactions from this motif seem to be related to high affinity 
interactions and specificity of coactivator recruitment, we decided to test this 
through mutagenesis. A series of mutations in PPARγ-LBD were made including 
K301A, N312A, K319A and E499L which are the two charge clamp residues and 
the two residues on helix 4 which interact with coactivators. We determined the 
dissociation constant of MED1-2, CBP-1 and PGC1α derived peptides for WT 
PPARγ-LBD and the point mutants with the full agonists rosiglitazone and 
GW1929 using FP. These peptides vary in affinity for the PPARγ full agonist 
complex. Due to anticipated low affinity due to mutation only full agonist ligands 
were examined. CBP-1 has the highest affinity, MED1-2 has high affinity, while 
PGC1α has moderate affinity. We attempted to measure affinity for SRC1-2 using 
FP, however the affinity for WT PPARγ-LBD was too low to allow for 





Figure 4. The effect of removing helix 4 residues on coactivator affinity is proportional to the 
affinity of the peptide. A: Fold change in peptide affinity relative to WT for either the GW1929 
or rosiglitazone bound PPARγ LBD point mutants relative to WT. Boxes denoted with an * 
indicate that the affinity is too low to be accurately determined, >50,000nM, while those marked 
with NBD, no binding detected, indicates that there was no indication of binding at any 
concentration used. Data shown is the average of two independent experimental replicates. The 
PPARγ WT LBD affinity is shown for each complex in the leftmost column in nanomolar. Curve 
fits and exact Kd values are shown in figure S8 and table S4 respectively. B: TR-FRET of WT and 
point mutant PPARγ LBD with the MED1-2 peptide. C: TR-FRET of WT and point mutant 
PPARγ LBD with the SRC1-2 peptide. Data shown in B and C represents four technical replicates 
run in a single experiment. An experimental replicate is shown in figure S9 for each peptide as 
well as results with other ligands for the MED1-2 data. 
 
As expected, mutation of the charge clamp significantly effects all peptide 
binding. Removal of the helix 3 charge clamp residue induces at least a 20-fold 
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loss in affinity for all coactivators while the removal of the helix 12 charge clamp 
almost completely ablates coactivator binding (Figure 4a). The effect of 
mutations on helix 4 are more interesting. In the case of CBP-1 we see 
approximately a 10-fold loss in affinity with the K319 mutation and over a 60-
fold loss in affinity with the N312 mutation. This indicates that for the very high 
affinity peptide both these residues are highly important for binding. With the 
somewhat lower affinity MED1-2 there is approximately a 10-fold loss in affinity 
with either helix 4 mutation (Figure 4a). This indicates that both these residues 
are still significant for this interaction but that the N312 interaction is less 
important than for CBP-1. When examining the moderate affinity PGC1α either 
helix 4 mutation has only a 2-fold loss in affinity despite all crystal structures of 
PPARγ-LBD with this coactivator showing interaction with N312.  
Since it was not feasible to examine SRC1-2 binding through FP we 
utilized time resolved (TR)-FRET based binding assays to examine mutational 
effects on the binding of this low affinity peptide. In this assay the FRET ratio, 
which reflects the amount of SRC1-2 bound to PPARγ, was used as a proxy for 
relative affinity. This assay was run at various SRC1-2 concentrations to ensure 
reproducibility. Ligand induced changes in TR-FRET were measured for MED1-2 
to determine if the results correlate with dissociation constants obtained using FP 
(Figure 4b and c). TR-FRET data for MED1-2 with additional ligands and 
experimental replicates are shown in Figure S9. 
The MED1-2 results were consistent with the FP results for the E499L 
mutation, which  completely abolished binding for all complexes. Both helix 4 
mutations reduced binding significantly. The PPARγK319A mutant had more of an 
effect on FRET than PPARγN312A (Figure 4b), consistent with FP (Figure 4a). 
The E499L mutation completely abolished binding of SRC1-2 similar to the other 
coactivators tested using FP. In contrast, the helix 4 mutations had smaller or even 
opposite effects on SRC1-2 binding when compared to the higher affinity 
coactivators. The PPARγN312A mutant did not affect SRC1-2 binding and the 
PPARγK319A mutant had increased binding of SRC1-2 compared to WT. This 
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supports our hypothesis that these helix 4 interactions are important for high 
affinity binding between nuclear receptors and coactivators and consequently for 
coactivator specificity, that is they determine the coactivator binding profile for a 
given nuclear receptor.  
3.3.8 Molecular dynamics indicates this mechanism in shared in nuclear 
receptors 
After confirming the role the helix 4 residues plays in the selective 
recruitment of coactivators to PPARγ, we questioned whether this mechanism is 
shared across nuclear receptors. Towards this end molecular dynamics 
simulations were employed in another NR with known relative coregulator 
binding affinities, ERα134. Simulations were performed from crystal structures 
deposited to the PDB, 3UUD and 5DX3, which were bound with low affinity 
coactivator peptides, SRC1-2 and SRC2-2 respectively. Unfortunately, no crystal 
structures existed which were bound to a high affinity peptide so the relatively 
high affinity peptide SRC1-3 was docked in silico using existing SRC1 containing 
structures. These simulations were performed in both the point mutant utilized in 
crystallography, Y537S, as well as a WT protein where the mutation was 
reversed. The Y537S mutant and WT ERα showed significantly different 
behavior. It is not immediately clear why this is, but this mutation is proximal to 
helix 12 and likely exerts a significant effect on the helix 12 conformational 
ensemble. Thus we focus here on the results using WT ERα.  Protein stability and 
proper binding modes of the peptide were confirmed for through whole protein 
RMSD and analysis of hydrogen bonding between the charge clamp residues and 





Figure 5. Molecular dynamics indicate the significance of this motif in ERα. A: Significantly 
greater interaction is seen between the terminal residues of the helix 4 motif and a high affinity 
coactivator, SRC1-3, peptide with ERα than is seen with two lower affinity coactivator peptides, 
SRC1-2 and SRC2-2. Each point represents the fraction of hydrogen bonding or salt bridge 
interactions between the indicated residue and coactivator peptide from a single monomer within 
the homodimer of ERα. For each simulation the two data points along with the mean are shown.  
 
These simulations showed higher prevalence of hydrogen bonding 
between residues 1 and 8 of the helix 4 motif and the peptide for the high affinity 
peptide (SRC1-3) than for the low affinity peptides (SRC1-2 and SRC2-2; Figure 
5). The non-selective central residue in the helix 4 motif, which makes primarily 
non-specific backbone interactions, had similar prevalence of protein-peptide 
interactions for all complexes. These results support the idea that these helix 4 
residues control coactivator specificity for the 40 nuclear receptors which contain 
this conserved motif.  
3.4 Conclusions 
The data presented herein identifies a mechanism for the selective nature 
of NR-coregulator interactions, wherein a specific LxxLL or CoRNR box of a 
coregulator makes discriminating interactions with conserved helix 4 residues, 
controlling relative affinity. The charge clamp residues exert the greatest effect on 
binding energy, but do not discriminate between coactivators, as they bond to the 
backbone of the peptide. The hydrophobic interactions of the leucines, isoleucines 
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and other hydrophobic residues in the LxxLL motifs also impart affinity but do 
not discriminate between the known coactivators, many of which have been 
identified by their possession of this hydrophobic motif15,283. We found that the 
degree to which helix 4 residues interact with an LxxLL box is proportional to the 
affinity of the coactivator complex for both ERα and PPARγ. 
We determined that different full agonists induce distinct affinities for 
coactivators, in contrast to cell-based transactivation assays, which may suffer 
from transcriptional machinery squelching. The most efficacious ligand identified 
was the tyrosine derivative GW1929142. In addition, we found that the difference 
between GW1929 and another highly efficacious full agonist, rosiglitazone, is 
independent of helix 12. Rather, it appears that this ligand better stabilizes the 
whole of the LBD of PPARγ in a conformation which is almost identical to that 
seen when bound with coactivator. This removes the requirement of major 
rearrangement of the protein to allow for coactivator binding thereby increasing 
the net binding energy. This effect appears to arise primarily through a large 
system of ordered water molecules which allow the ligand to stabilize a much 
larger area of the protein than would be expected through water-mediated 
hydrogen bonds.  
This work reveals the physical mechanism by which NR preferentially 
bind certain coregulator proteins and better defines the AF-2 region of NR 
proteins. These data indicates that the AF-2 is made up of two distinct regions 
which serve different purposes in coactivator binding events. The first comprised 
of the C-terminal of helix 3 and helix 12 provides the majority of the binding 
energy but none of the selectivity. While the second region, helix 3’ and helix 4, 
makes highly specific interactions which determine coactivator specificity. This 
could lead to design of drugs which alter the conformation of the second region 
specifically and drive the preferential recruitment of desired coactivators to lead 




3.5.1 Materials Used 
Isopropy-beta-D-thiogalactopyranoside (IPTG) was obtained from 
Goldbio (I2481C50). Tris-(2-carboxyethyl)phosphine hydrochloride (TCEP) was 
obtained from Biosynth (C-1818). Trizma base (T1503), MOPS (RDD003), 
Potassium Chloride (746436), Ethylenediaminetetraacetic acid (EDTA, 798681), 
Monobasic potassium phosphate (795488), Dibasic potassium phosphate 
(795496), 3-bromo 1,1,1-trifluoroacetone (BTFA, 374059), and Tween 20 
(P1379) were obtained from Sigma Aldrich. Sodium Chloride (0241) was 
obtained from Amresco. Fatty acid free bovine serum albumin (126575) was 
obtained from EMD Millipore. Pierce protease inhibitors (88265) were obtained 
from Fisher Scientific. 
3.5.2 Protein Purification 
A pET-45b plasmid carrying the genes for ampicillin resistance and N-
terminally 6xHis tagged PPARγ LBD or containing a tobacco etch virus nuclear 
inclusion protease (TEV) recognition site between the His tag and protein of 
interest was transformed into chemically competent E. coli BL21(DE3) Gold 
cells. Cells were grown in terrific broth (TB). Cells grown in TB were induced at 
an OD600 of approximately 0.8 by the addition of 0.5mM IPTG. Induction 
proceeded for 16 hours prior to harvesting. Harvested cells were homogenized 
into 50mM Phosphate, 300mM KCl, 1mM TCEP pH 8.0 and lysed using a C-5 
Emulsiflex high-pressure homogenizer (Avestin). Lysates were then clarified and 
passed through two Histrap FF 5ml columns in series (GE Healthcare). Protein 
was eluted using a gradient from 15-500µM imidazole. Fast protein liquid 
chromatography (FPLC) was performed on either an NGC Scout system (Biorad) 
or an ÄKTA Start (GE Healthcare). To eluted protein 2-8mg of recombinant 
6xHis tagged TEV was added, approximately 1:40 w/w TEV to PPARγ, followed 
by dialysis into 50mM Tris, 200mM NaCl, 1mM TCEP and 1mM EDTA pH 8.0. 
To separate cleaved protein from TEV as well as cleaved 6xHis tag the protein 
was again passed through HisTrap FF columns. The cleavage step was only 
performed on protein which would be used for NMR or FP, protein used for TR-
FRET did not have the 6xHis tag removed. The protein was then further purified 
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by gel filtration using a HiLoad 16/600 Superdex 200 PG or HiLoad 16/600 
Superdex 75 PG (GE Healthcare). Size exclusion was performed in 25mM 
MOPS, 300mM KCl, 1mM TCEP, 1mM EDTA buffer pH 8.0. Protein was then 
dialyzed into 25mM MOPS, 25mM KCl, 1mM EDTA buffer pH 7.4. RxRα-LBD 
was purified by the same protocol as PPARγ-LBD with the only difference being 
that in all buffers for RxRα purification the TCEP concentration was increased to 
5mM to reduce tetramerization. FL PPARγ2 or RxRα was purified in the same 
manner with the caveat that the 6xHis tag was not cleaved for this protein as the 
cleavage negatively affected protein activity. Protein purity in excess of 95% was 
determined by gradient 4-20% SDS-PAGE analysis (NuSep) for the PPARγ-LBD 
or the RxRα-LBD. In the case of the FL PPARγ2 or RxRα the presence of 
degradation products made assessing purity more difficult.  
3.5.3 Expression of 15N-labeled PPARγ LBD 
To express 15N-labeled PPARγ LBD E. coli BL21(DE3) gold cells 
carrying the same pET-45b vector as above were grown in modified M9 media 
containing 15NH4Cl as the sole nitrogen source were grown to an OD of 
approximately 1.0 at 37°C and 180 rpm. M9 media was made following the 
protocol of Justine M. Hill and amended to include a vitamin extraction. This 
vitamin extraction was made by dissolving a centrum for men vitamin tablet in 
20ml of 18MΩ water as much as possible. This solution was then centrifuged at 
4,000g for 20 minutes and the supernatant was removed. 1.0ml of this supernatant 
was added to each liter of M9 medium. Following this the temperature was 
dropped to 22°C for one hour prior to induction. Cells were induced with 1mM 
IPTG and induction proceeded for 16 hours. PPARγ LBD was then purified as 
described above. 
3.5.4 Delipidation of PPARγ 
To delipidate PPARγ LBD purified protein was diluted to 0.8mg/ml and 
batched with Lipidex 1000 (Perkin Elmer) at an equal volume. This mixture was 
batched for 1 hour at 37°C and 100 rpm in an incubator. Immediately following 
this treatment, protein was pulled through a gravity column by syringe. To 
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increase yield, it was found that speed of elution was important, protein could not 
remain on the resin at room temperature in excess of 3 minutes. Two more 
column volumes of pre-warmed 25mM MOPS, 25mM KCl and 1mM EDTA were 
also pulled through in the same manner.  
3.5.5 Site-Directed Mutagenesis 
Mutations in PPARγ LBD were generated using the Quikchange 
Lightning site-directed mutagenesis kit (Agilent). To generate each mutation the 
following primers were used: K474C Forward 5’-
aggttaattattagtacaagtcgcagtagatctcctgcaggagcgg-3’, Reverse 5’-
ccgctcctgcaggagatctactgcgacttgtactaataattaacct-3’, C285A Forward 5’-
ccacggagcgaaactgagcgccctgaaagatgcgg-3’, Reverse 5’-
ccgcatctttcagggcgctcagtttcgctccgtgg-3’., Q294C Forward 5’- 
gcatactctgtgatctcgcacacagcctccacggagc -3’, Reverse 5’- 
gctccgtggaggctgtgtgcgagatcacagagtatgc -3’The presence of expected mutations 
and absence of spurious mutations was confirmed by Sanger sequencing 
(Eurofins).  
3.5.6 Preparation of NMR Samples 
NMR samples were prepared to a final concentration of 150µM protein in 
470µL volume containing 10% D2O. Addition of drug was done in two separate 
injections of compound to reduce precipitation. Injections were spaced 20-30 
minutes apart to allow time for binding. All drugs were dissolved in D6-
dimethylsulfoxide (DMSO). Deuterated solvents were obtained from Cambridge 
Isotope Laboratories Inc. and were at least 99% isotopically pure. Final 
concentrations of drug for samples of PPARγ-BTFA were 1.25x drug to protein, 
187.5µM, with the exception of Troglitazone, Pioglitazone, and BVT.13 which 
were loaded to 2.0x, 300µM, due to poor binding affinity. In both cases the 
concentration of the drug was controlled to maintain a constant volume of DMSO, 
8.80µL for PPARγ-BTFA. Peptide addition to NMR samples was done to 2.0x 
peptide to protein, 300µM, of peptide dissolved to 1-1.5mM in buffer.  
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Following drug addition to PPARγ-BTFA, samples were labeled with 1.0x 
molar equivalents BTFA for non-covalent drugs, the covalent drugs, T0070907 
and GW9662, were labeled with 10x BTFA. After labeling the protein was 
incubated overnight and then buffer exchanged approximately 100x using 10kDa 
Amicon Ultra-15 concentrators (Merck Millipore) to remove excess unbound 
BTFA. Following this buffered D2O was added. 
3.5.7 Fluorine-19 (19F) NMR spectroscopy 
Acquisition of spectra was done on a 700 Mhz Bruker magnet with a QCI-
F cryoprobe. Various pulse programs were used. Chemical shift was calibrated 
using an internal separated KF reference (in 20 mM KPO4 pH 7.4 50 mM KCl) 
contained in a coaxial tube inserted into the NMR sample tube. KF was set to be -
119.522 ppm, which is the shift of the KF signal with respect to the fluorine basic 
transmitter frequency for the instrument (658.8462650 MHz) at 298.2K, the 
temperature at which samples were run. Routine 1D fluorine spectra were 
acquired utilizing the zgfhigqn.2 pulse program (topspin 3.5), which consists of a 
90-degree pulse followed by acquisition with proton decoupling (acquisition=0.7 
s). Settings were D1=1.2 s, AQ= 0.82 s. Approximately 500 to 4000 transients 
were collected. Saturation transfer experiments were carried out using the stddiff 
pulse program. Settings were D1=1.6 s, AQ=0.6 s. For some experiments the total 
duration of the saturating pulse (Gaus1.1000, 54.52 dB, 50ms) was 1.6 s (D20) 
and the location of the saturating pulse was varied. In other experiments D20 was 
varied, the saturating pulse was constant and the rate of exchange was fit using 
equation 50 found here234. An off resonance selective saturating pulse was used to 
determine the peak intensity at time t=0 and R1 was determined experimentally. 
Fits of the saturation transfer data were accomplished with a single free parameter 
using these experimentally determined values for initial intensity and R1. 2D 
TROSY amide proton nitrogen correlation data was obtained using the 
trosyf3gpphsi19.2 pulse program. Transverse and longitudinal relaxation lifetimes 
(T1 and T2) were determined by fitting data acquired using the cpmg and t1ir 
pulse programs in Prism 7.0b (Graphpad Software, Inc.) using standard formulas.  
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We deconvoluted the spectra in an objective manner with models chosen 
statistically by a fitting program. All fits were carried out in the same manner with 
the same settings in the fitting program, except where noted. Relative phase of 
fitted peaks was allowed to vary slightly (π/50 radians) to accommodate imperfect 
phasing of these broad signals. The fitting algorithm219 assumes Lorentzian 
lineshapes of similar phase. Intermediate exchange effects and field 
inhomogeneity are likely present in some of these spectra, which will result in 
inaccuracies in the fitted models; however, notwithstanding these limitations, the 
deconvolution method provides an objective view of the possible underlying 
spectral structure and populations.  
 
3.5.8 Crystallization of PPARγ-LBD 
Crystals of PPARγ-LBD bound to GW1929 were grown by sitting drop 
with a 1:1 mix of protein to 200mM tri-lithium citrate, 20% w/v PEG 3350 (pH 
not fixed). Protein concentration was 10mg/ml (318µM) premixed with a 1.05x 
molar excess of GW1929 in D6-DMSO (334µM). Large rock/needle crystals grew 
from the mother liquor at 4°C in 3 days. Crystals of PPARγ-LBD complexed with 
both MED1-2 and GW1929 were grown by sitting drop with a 1:1 mix of protein 
to 100mM HEPES, 25% w/v PEG 2000 MME, pH 7.5. Protein concentration was 
10mg/ml premixed with a 1.05x molar excess of both MED1-2 and GW1929. 
Large plate crystals grew from the mother liquor at 4°C in three days. The MED1-
2 peptide used in crystallography was comprised of residues 631-655, primary 
sequence is Ac-VSSMAGNTKNHPMLMNLLKDNPAQ-NH2, the binding 
LxxLL motif is in bold. This peptide was synthesized by Lifetein LLC.  
3.5.9 Crystallographic analysis 
The PPARγ crystal co-crystallized GW1929 or GW1929 with MED1-2 
peptide crystals were cryoprotected by transferred into reservoir solution 
containing 15-20% (v/v) glycerol and flash-frozen in a 100K nitrogen gas stream. 
Diffraction data were collected at 100K and a wavelength of 0.979 Å at 
the Advanced Photon System SBC-CAT 19-BM beamlines equipped with an 
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ADSC Q210r CCD detector. Each crystal was collected with an oscillation range 
(0.2-0.5o per image) for a total 180-360o per dataset Images were indexed, 
integrated, and scaled using HKL2000284.The initial phasing map were 
determined by molecular replacement method with Phaser program, integrated in 
PHENIX software suite285 using coordinates of the previous published PPARγ 
structure (PDB code: 5TTO) as a searching model, against 10-2.5Å experimental 
data. The initial models were placed into a likelihood-weighted 2mFo-DFc map 
with COOT286  and first subjected to one cycle of rigid-body refinement using 
PHENIX. Subsequently, the models were further refined by iterative model 
rebuilding with COOT and refinement of atomic positions, real space, occupancy, 
and isotropic B-factor parameters with PHENIX using a small set of reflections 
(<10%) for calculation of Rfree. Ligand in each structure was located in a SIGMA-
A weighted mFo-DFc difference omit map287  computed with phases from the 
refined model. The models were further refined multiple rounds until Rfree 
converged. For Gw1929/MED1-2-bound PPARγ structure, additional TLS 
refinement was included in the final round of refinement. The final refined 
coordinates and structure factors for GW1929 and Gw1929/MED1-2-bound 
PPARγ protein have been deposited in Protein Data Bank (PDB) under ID code of 
6D8X and 6D94, respectively. Data collection and refinement statistics of a final 
model are shown in Table 1. 
 
3.5.10 Fluorescence polarization 
Fluorescence polarization was performed in 25mM MOPS, 25mM KCl, 
1mM EDTA, 5mM TCEP, 0.1mg/ml fraction V BSA, 0.01% Tween 20, pH 7.4. 
In this assay into 50nM of N-terminally FITC labeled peptide PPARγ loaded 
stoichiometrically with ligand was titrated over 12 points covering a range of 
24nM-50µM in a 384-well plate. Solutions were incubated for two hours in the 
dark at room temperature and then the fluorescence polarization at 528nm was 
measured using a Synergy H1 plate reader (Biotek). Fluorescence polarization 
data was plotted in GraphPad Prism 7.0 (GraphPad software) and the dissociation 
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constant, Kd, was determined by a non-linear regression. All assay conditions 
were run in duplicate.  
 Peptides used in fluorescence polarization assays are as follows, CBP-1, 
residues 62-81, primary sequence is AASKHKQLSELLRGGSGSS, MED1-2, 
residues 638-656, primary sequence is NTKNHPMLMNLLKPAQD, PGC1α, 
residues 136-155, primary sequence is EAEEPSLLKKLLLAPANTQ, NCoR1-2, 
residues 2251-2273, primary sequence is GHSFADPASNLGLEDIIRKALMG. 
FITC conjugated peptides of CBP-1 and PGC1α were purchased from Thermo 
Fisher, FITC conjugated peptides of MED1-2 and NCoR1-2 were synthesized by 
Lifetein LLC. 
 
3.5.11Time-Resolved Fӧrster Resonance Energy Transfer  
TR-FRET was performed in the same buffer and plate conditions as 
fluorescence polarization. In this assay 8nM of 6xHis tagged PPARγ-LBD and 
0.9nM of LanthaScreen Elite Tb Anti His antibody (LifeTechnologies catalogue 
number PV5863) was added to either 200nM of FITC-MED1-2 or 1,000nM of 
FITC-SRC1-2 in the presence or absence of 1µM ligand. Following addition of all 
components plates were incubated in the dark at room temperature  for two hours. 
TR-FRET was measured with excitation at 330/80nm and emission at 495/10nm 
for terbium cryptate and emission of 520/20nm for FITC. Change in TR-FRET 




Chapter 4: Inverse agonists induce drug specific structure 
and function via distinct molecular mechanisms in the 
nuclear receptor PPARγ. 
Zahra Heidari, Ian M. Chrisman, Scott Novick, Michelle Nemetchek, Theodore 
Kamenecka, Patrick Griffin, and Travis Hughes 
Data in this chapter is in preparation for publication 
4.1 Abstract 
The off state of PPARγ in particular and nuclear receptors in general is not well 
defined. While there are several published structures of PPARγ in an active/on state 
(i.e. bound to a coactivator) to date there is no published structure of PPARγ in an 
inactive/off state (i.e. bound to a corepressor). Furthermore, most antagonist and 
agonist bound PPARγ structures are very similar to the apo structure. In this study, 
we use NMR, hydrogen deuterium exchange mass spectrometry, and extensive 
accelerated molecular dynamics simulations of PPARγ alone or bound to several 
inverse agonists and antagonists as well as these complexes cobound to a nuclear 
receptor corepressor 1 (NCoR1) peptide to demonstrate that PPARγ can adopt 
distinct inverse agonist structural states.  We demonstrate that the helix 3 
conformational ensemble is ligand and inverse agonist dependent, including the 
helix 3 charge clamp. One inverse agonist (T0070907) appears to select/induce just 
two primary helix 3 and helix 12 structures, while the other (SR10221) 
selects/induces a more conformationally diverse ensemble.  One mechanism of 
inverse agonism involves disruption of a tripartite salt-bridge which destabilizes 
the active conformation via disruption of interactions between the helix 2-3 loop 
and helix 3 which aids formation of non-active helix 12 states with high affinity for 
corepressors. Finally, we show that these two distinct inverse agonist states induce 
differential corepressor peptide affinity. 
4.2 Introduction 
Peroxisome Proliferator-Activated Receptor γ (PPARγ) is a member of the 
nuclear receptor (NR) superfamily of ligand-dependent transcription factors which 
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control transcription of a myriad of genes which are implicated in many 
physiological processes including lipid homeostasis288,289. Drugs affect the 
transcriptional activity of nuclear receptors via recruitment of other proteins, 
termed co-regulators, which affect transcription through histone modification, post-
translational modification of the receptor, or through bridging to promoter 
associated transcriptional machinery290,291. The vast majority of nuclear receptor 
drugs bind deep in a ligand binding pocket within the ligand binding domain (LBD) 
allosterically changing the nuclear receptor surface. These changes include changes 
to the surface that interacts with most coregulators, the coregulator binding surface 
or activation function-2 (AF-2) surface which includes portions of helices 3, 4 and 
12. In this way drugs can modify transcription of genes regulated by a given nuclear 
receptor282,292. Surprisingly, the AF-2 surface looks very similar in many nuclear 
receptor crystal structures bound to antagonists and agonists. Some structures do 
show very distinct coregulator binding surfaces, although the influence of crystal 
contacts makes interpretation difficult293. Almost 200 crystal structures of PPARγ 
bound to various drugs and three different coactivators have been published 
indicating that full agonists stabilize helix 12 in a particular on/active 
conformation294. However, there is no structure of PPARγ bound to any corepressor 
or corepressor peptide (i.e. PPARγ in the transcriptionally off state) and relatively 
few studies have investigated the structural mechanism of PPARγ mediated 
transcriptional repression161,295,296. In fact, the idea that nuclear receptor inverse 
agonists are more than antagonists that displace activating endogenous ligands is 
not widely accepted. However, our recently published biophysical work indicates 
that bona fide inverse agonists of PPARγ exist282,296. Despite the lack of PPARγ – 
corepressor crystal structures important insight regarding the off structural state of 
PPARγ can be inferred from structures of other nuclear receptors bound to 
corepressors. These structures reveal diversity in the binding modes and structures 
of both well characterized corepressors such as silencing mediator of retinoic acid 
and thyroid hormone receptor (SMRT) and nuclear receptor corepressor 1 
(NCoR)20,200 and less characterized corepressors that do not bind to the traditional 
AF2 coregulator binding surface297. Similar to coactivators, each corepressor 
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contains several amino acid core motifs, or nuclear receptor boxes (NR boxes), of 
about nine residues that mediate binding to nuclear receptors20.  SMRT contains 
two such motifs while NCoR contains three298. Most of these core corepressor 
motifs have been crystalized with various nuclear receptors revealing 
characteristically longer alpha helices for corepressors than coactivators. This 
increased helix length20 requires a different AF2 structure for optimal binding of 
corepressors that often involves displacement of helix 12, such as in PPARα200, 
progesterone receptor299 and estrogen related receptor-γ274. In contrast several 
nuclear receptor-corepressor crystal structures display helix 12 in a position similar 
to the canonical active structure with coactivator bound, positioned roughly 
orthogonal to and making some contact with the corepressor helix n-terminus, but 
with a shifted helix 12 to accommodate the longer corepressor helix. For example, 
the crystal structure of the tetrameric form of the RXRα LBD shows interaction 
between helix 12 of a tetrameric partner and bound SMRT300 and glucocorticoid 
receptor (GR) bound to an antagonist shows an interaction between helix 12 and 
NCoR301.  
We detected active-like corepressor bound helix 12 conformations for 
PPARγ bound to NCoR using long conventional molecular dynamics simulations 
(cMD)282. Simulations of apo PPARγ show that H12 is pushed away from the 
coregulatory binding surface. Displacement of helix 12 from the coregulator 
binding surface has also been observed in numerous structures of nuclear receptors 
bound to corepressor core motifs20,200,298,302. In contrast, simulations of inverse 
agonist (T0070907156,282) bound PPARγ show helix 12 aligned orthogonal to the 
NCoR peptide with a potentially productive interaction between helix 12 and 
NCoR282. The physiological importance of these conformations is unknown as we 
observed very slow (μs to second) exchange between different conformations for 
many of these complexes, including the PPARγ-T0070907 NCoR complex282. It is 
therefore unlikely that these cMD simulations sampled all physiologically relevant 
conformations. The sampled structures could instead represent structures from a 
local minimum potential energy well that contributes little to the overall 
physiologic structural ensemble. We recently presented evidence that two distinct 
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inverse agonists (T0070907 and SR10221) induce ligand specific helix 12 
structural states that are different from the ligand free state. We also found that one 
or a few T0070907 helix 12 states in relatively fast exchange imparts high affinity 
for NCoR282,296. However, the structure(s) that compose this high corepressor 
affinity structural ensemble remains unknown. In addition, it is not known whether 
the structural state of other areas of the PPARγ coregulator binding surface 
contribute to the high affinity of this structural state for NCoR.  
Here, we develop and experimentally test simulation derived structural 
models for these off states of PPARγ utilizing extensive cMD and accelerated MD 
(aMD) simulations of PPARγ bound to the covalent PPARγ inverse agonist 
T0070907, SR10221 and co-bound to NCoR. Experimental data and the 
reconstructed physiological structural ensemble from these more extensive 
simulations supports the hypotheses that T0070907, SR10221 and apo have distinct 
structural ensembles that bind corepressors differently. It also supports the idea that 
T0070907 andSR10221 induce these structural states through different 
mechanisms. The molecular mechanism by which the inverse agonist T0070907 
induces/selects a conformational ensemble with high affinity for corepressor 
binding is explored using simulations, mutagenesis and NMR. The simulations 
reveal an n-terminal extension of helix 3 for T0070907 bound PPARγ and 
disruption of an ionic bond network involving the n-terminus of helix 3. Together 
these changes prevent interaction of the helix 2-3 loop (i.e. the omega loop) with 
helix 3 and change the interaction of the helix 11 to 12 loop and helix 12 with the 
rest of the molecule. Both the salt bridge network and the omega loop helix 3 
interaction have been shown to be important for transcriptional agonism107,303 and 
disruption of these interactions would be expected to enhance corepressor affinity. 
In line with this expectation, mutation of a key residue involved in this salt bridge 
bond network increases NCoR affinity and decreases affinity for a coactivator 
peptide across many ligands except for T0070907, which independently disrupts 
this salt bridge network. Previous research indicated interaction between SR10221 
and helix 3 that destabilizes helix 3. Here we find evidence of that SR10221 directly 
interacts with helix 12 to disrupt the active conformation. Thus, we present 
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evidence for two separate atomically detailed structural mechanisms of inverse 
agonism in PPARγ. Finally, we demonstrate that the distinct structural ensembles 
yield distinct functional effects by showing that T0070907 increases affinity for 
receptor interaction peptides from both NCoR and SMRT as compared to apo while 
SR10221 selectively increases affinity for SMRT peptide relative to apo. 
4.3 Results 
4.3.1 Accelerated molecular dynamics reveals a diverse apo PPARγ structural 
ensemble. 
Previously reported adaptive biasing-force simulations of ligand free (apo) 
and rosiglitazone bound PPARγ ligand binding domain (LBD) explored the helix 
12 energy landscape along defined reaction coordinates and found multiple distinct 
low energy conformations for apo PPARγ but just one for rosiglitazone bound 
PPARγ304. We refer here to the PPARγ LBD as PPARγ. Other forms of PPARγ will 
be referred to explicitly. In contrast to adaptive biasing-force simulations, 
accelerated MD simulations (aMD) do not use defined reaction coordinates but 
instead smooth the native potential energy landscape making sampling more 
efficient without restricting the conformational space that can be explored305. Given 
sufficient conformational sampling and a force field that reproduces protein 
structure accurately, the deepest wells in the aMD generated potential energy 
landscape contain the most prevalent structures found in the physiologic structural 
ensemble. Ligand free PPARγ and PPARγ bound to many distinct ligands have 
crystalized as a homodimer with each monomer in a distinct conformation, 
differentiated principally by the position of helix 12. One helix 12 conformation is 
considered active, while the other is considered inactive and of uncertain 
physiologic relevance. However, there are apparent contacts between helix 12 and 
other crystallographic unit cell members in both conformations in most 
structures282. We ran extensive (Supplementary Table 1) aMD simulations of apo 
and agonist (rosiglitazone) bound PPARγ starting with helix 12 in the active 
position. Similar to the adaptive biasing-force simulations, the agonist bound 
simulation produces one relatively narrow energy well, while the apo PPARγ 
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energy landscape has several energy minima that would be significantly populated 
at physiologic temperature (Figure 1a). Alternatively, we started very extensive 
aMD simulations (~57 μs) from the inactive apo structure. These simulations 
sample some of the same structures as the active apo simulation and reveal some 
similarity in overall energy landscapes, but do not converge completely (Figure 
1a). Both apo simulations share one low energy well/conformation, which is found 
in the third (1.06 kcal mol-1) and second (0.07 kcal mol-1) lowest energy well in the 
inactive and active simulations respectively (Figure 1c and Supplementary 
Figure 1). Overall these simulations indicate that the physiologic structural 
ensemble of apo PPARγ is very diverse, which is consistent with NMR and 
hydrogen deuterium exchange mass spectrometry (HDX-MS) 
data140,161,166,207,208,221,306. We observe four major classes of helix 12 conformations 
in this diverse ensemble, the active conformation, conformations roughly similar to 
the active conformation, but with a shifted helix 12 that enlarges the coregulator 
binding surface, conformations where helix 12 appears to bind the coregulator 
binding surface in a similar manner to a corepressor (which would block all binding 
to the coregulator binding surface) and finally conformations where helix 12 lies 
parallel to helix 3 (Supplementary Figure 1a and b). Interestingly, in the 
corepressor like conformation helix 10/11 is disrupted at 484/456 and 477/449 
respectively, bending significantly and allowing LXXLLXXXY residues of helix 
12 to bind to the coregulator binding surface. These helix 12 residues are oriented 
similarly to the L/IXXIIXXXF/Y/L motif20 of corepressors when aligned to a 
PPARα/SMRT structure (Figure 1e). In addition, similar corepressor like binding 
of helix 12 to the coregulator binding surface have been observed in rat ERβ307 and 
between PPARγ unit crystallographic cell members48,282 (Supplementary Figure 
9). Together, these helix 12 conformations appear to be a mix of those favorable 
for coactivator or corepressor binding and some that would favor binding of neither. 
In addition, both helix 3 and helix 11 show significant structural diversity. In the 
lowest and fourth lowest energy wells of inactive apo helix landscape to bind to 
some or all of the coregulator binding surface (Figure 1e). Helix 3 is 
conformationally diverse and in some cases, helicity is absent in the range of 
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residues 316/288 to 320/29 and in general helix 3 is bent at various angles in this 
region which leads to diverse positioning of the n-terminus of helix 3 (Figure 1d). 
This is consistent with our previously observed slow exchange (1.0 s-1) between 
two conformations of a 19F NMR of a probe placed near the location of the bend in 
helix 3 (Q322/294) in apo PPARγ282, although this pattern could also be explained 
by a population of apo PPARγ with helix 12 bound like a corepressor. Finally, there 
is an n-terminal extension of helix 3 observed in some apo structures 
(Supplementary Figure 1a and b). 
4.3.2 The active helix 12 conformation is not the primary component of the 
physiologic apo ensemble. 
 Simulations started from the active apo structure predict that almost all of 
the helix 12 conformations in the physiologic ensemble are similar to the active 
structure, whereas the inactive simulation suggests that only ~20% of the 
physiologic ensemble has an active-like helix 12 conformation. Bonding between 
K347/319 on helix 4 and helix 12 is characteristic of the active helix 12 
conformation but not the inactive conformation in PPARγ crystal structures 
(Figure 2a). In order to estimate values characteristic of the physiologic structural 
ensemble we clustered the structures found near the bottom of the deepest wells in 
the aMD generated landscape and started 1 μs cMD simulations from multiple 
representative structures for each well. Population weighted average values for 
various structural characteristics, including prevalence of the helix 4-12 salt bridge, 
were then calculated for each well from these cMD simulations and then these 
individual well values combined into one value representative of the putative 
physiologic structural ensemble using Boltzmann weighting (see methods). We 
refer to these values as Boltzmann averages. Simulations predict high prevalence 
(i.e. high Boltzmann average) for bonding between K347/319 and helix 12 in an 
active conformation in the PPARγ-rosiglitazone complex. Simulations predict that 
apo has either high or low prevalence of this interaction depending on whether the 
apo simulation was started in the active or inactive helix 12 conformation (Figure 
2b). Simulations indicate that in the absence of helix 12 bonding K347/319 interacts 
mainly with solvent (Supplementary Figure 2c). Therefore, a K347A mutation 
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should have minimal impact on structure unless there is K347/319 to helix 12 
bonding. We compared 2-dimensional protein NMR of wt and K347A mutant 
bound to various ligands to determine which PPARγ-ligand complexes have helix 
12 in the active conformation. Consistent with the inactive apo and the rosiglitazone 
simulations, these NMR data indicate that helix 12 in apo PPARγ does not interact 
with K347 while helix 12 of rosiglitazone bound PPARγ does. The K347A 
mutation induces many changes to the PPARγ-rosiglitazone structure including 
disappearance of helix 12 residue L496/469 and a shift in a residue near the 
coregulator binding surface (L429/401) (Figure 2b). In contrast, there are few 
changes to the apo PPARγ structure. This indicates that an active-like helix 12 
conformation is not a major component of the apo physiologic ensemble. However, 
an active-like conformation likely contributes some to the overall ensemble as 
demonstrated by the inactive apo simulations and changes in a few amide chemical 




Figure 1. Extensive aMD simulations indicate a diverse PPARγ structural ensemble. Multiple 
independent simulations were run for the indicated PPARγ ligand binding domain complexes (see 
Supplementary Table 1). a and f) The RMSD of helix 12 was calculated compared to a published 
apo PPARγ structure (PDB code: 1PRG) active (chain A) and inactive (chain B) structures. The 
energy of each trajectory snapshot was calculated and overlaid on the 2D RMSD to produce the 
displayed potential energy landscapes. b and g) The aMD trajectory structures within a 0.2 x 0.2 
angstroms RMSD square centered on the lowest energy wells were clustered using k-means 
clustering into 5 clusters using CPPTRAJ308. Arbitrary (i.e. CPPTRAJ chosen) representative 
structures are shown for the most prevalent clusters. The relative prevalence of the structure is 
indicated by the color of helix 12 ranging from dark green for the most prevalent to olive drab, 
light green, light blue and then deep sky blue for the least prevalent. For reference, an active 
structure (rosiglitazone bound PPARγ; 2PRG chain A) is shown with helix 12 colored dim grey. c) 
Representative structures from the third and second lowest energy wells in the inactive and active 
apo simulations respectively are shown in orange and dark green. Representative active and 
inactive crystal structures (PDB code 1PRG chain a and chain b) are shown in dim grey and light 
pink respectively.  d) Representative structures from active and inactive apo (white and green) are 
shown compared to an active crystal structure (light blue; PDB code 2PRG chain A). e) A 
representative structure from a low energy well (well 4 Supplementary Fig. 1; white; PPARγ LBD 
and gold; helix 11-12) is compared to the crystal structure of PPARα  bound to SMRT (PDB code 
1KKQ; white; PPARα LBD, green; helix 12 and light blue; SMRT peptide). Comparison of 
relative position of PPARγ helix 12 LXXLLXXXY residues with the SMRT corepressor motif 
residues is highlighted. h) Representative structures of PPARγ (green) bound to T0070907 and a 
peptide from NCoR (gold) from the lowest energy well. The orange lines indicate hydrogen bonds 
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between the helix 12 charge clamp (E499/471) and the NCoR peptide backbone of 1.7 and 2.0 
Angstroms as defined by Chimera for this particular trajectory snapshot. i) Comparison of the 
active structure (white; rosiglitazone; PDB code 2PRG) bound to a coactivator peptide (SRC2; 
grey) with the most prevalent conformation in the lowest energy well from the aMD simulation of 
T007-PPARγ-NCoR (green and gold). A shift in helix 12 relative to the active conformation is 
indicated by the pink arrow. 
4.3.3 aMD indicates that inverse agonists bias the structural ensemble towards 
helix 12 conformations favorable for NCoR binding. 
We next performed aMD of PPARγ bound to three inverse 
agonists/antagonists SR10221161, GW9662155 and T0070907 to determine how 
inverse agonist/antagonist structures differ from apo PPARγ and agonist bound 
structural ensembles (Figure 1a). These simulations were started from structures 
with helix 12 in the inactive conformation. T0070907 and GW9662 covalently 
attach to the sole cysteine in the ligand binding domain and differ by one atom; the 
benzene ring of GW9662 is a pyridine ring in T0070907, making T0070907 a more 
efficacious inverse agonist296. Both covalent ligands increase affinity for a NCoR 
peptide over apo while SR10221 does not (Supplementary Table 6), however only 
T0070907 and SR10221 act as inverse agonists in a in cell reporter assay296. 
Representative structures from the lowest energy wells demonstrate considerable 
conformational diversity in helix 3, 11 and 12. Three main low energy helix 12 
conformations are detected for the covalent ligands; 1) active-like conformations, 
2) active-like conformations with a shifted helix 12 that expands the coregulator 
binding surface, 3) conformations where helix 12 lies parallel to and near the n-
terminus of helix 3, (Figure 1b and Supplementary Figure 1). There is also an n-
terminal extension of helix 3 observed in some of these structures. Representative 
structures from the two lowest energy wells for these complexes feature expanded 
coregulator binding surfaces, in contrast helix 12 would sterically clash with NCoR 
binding in the lowest energy apo well (Figure 1b). The PPARγ-SR10221 complex 
displays distinct low energy conformations. The lowest energy conformation 
resembles the active conformation, however helix 12 is shifted along the helical 
axis toward helix 11 (Figure 1b). Thus, these simulations indicate that the covalent 
ligands select/induce helix 12 conformations expand the coregulator binding 
surface in several ways, allowing binding of the longer corepressor peptide. These 
simulations also indicate distinct helix 12 conformations are induced/selected by 
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SR10221 and GW9662/T0070907, which is supported by fluorine NMR (Figure 
3).   
To experimentally test these simulation-generated structural hypotheses we 
measured the effect of the K347A mutation on PPARγ bound to SR10221, 
T0070907, and GW9662. Bonding between K347 and helix 12 is more frequent in 
active-like conformations (Supplementary Figure 2e). The K347A mutation has 
a large effect on the PPARγ/GW9662 complex, a small effect on the PPARγ-
T0070907 complex and no apparent effect on the PPARγ-SR10221 complex 
(Supplementary Figure 2a). Both the GW9662 and T0070907 simulations 
indicate prevalent low energy conformations with helix 12 in an active-like 
conformation (Supplementary Figure 1) which result in relatively low levels of 
K347A to E499 bonding (Figure 2b). The protein NMR suggests that active-like 
conformations are more prevalent in the GW9662 complex than the T0070907 
complex and that these conformations result in more K347A to helix 12 bonding 
than observed in the simulations. This raises the possibility that one of the two 
major helix 12 conformations observed using fluorine282 and protein296 NMR 
(Supplementary Figure 2b) is similar to the active state. As shown below, fluorine 
NMR indicates that 36% of the T0070907 helix 12 structural ensemble is found in 
this active-like state while 83-88% of helix 12 in the PPARγ-GW9662 structural 
ensemble is in this active-like state282,296. The lack of change in the PPARγ-
SR10221 spectrum supports the idea that this ligand induces a distinct helix 12 
conformational ensemble from the other two inverse agonist/antagonist ligands. 
Which is also supported by the distinct PPARγ-SR10221 fluorine NMR spectrum 
(see below) and distinct low energy conformations observed in simulations 




Figure 2. The active apo simulation is inconsistent with NMR data. a) Examples of three classes 
of helix 4 to helix 12 binding observed in 31 randomly chosen crystal structures with helix 12 in the 
active conformation (PDB codes 1PRG, 2PRG and 3R5N). PPARγ LBD structures are commonly 
asymmetric homodimers with helix 12 in an active and inactive conformation. The salt bridge 
between K347/319 and E499/471 was only seen in 1/31 active structures, while 25/26 active 
structures showed bonding between K347/319 and the helix 12 backbone and none of the inactive 
conformations showed bonding between helix 4 and helix 12. b) Prevalence of helix 4 (K347/319) 
to helix 12 (E499/471) bonding (side chain and backbone), which dominated the helix 4 to helix 12 
bonding in active-like structures in simulations. The Boltzmann average is shown as a pink bar while 
individual values from cMD simulations started from representative structures in the lowest wells 
in the aMD generated energy landscape are shown as closed circles. Only prevalence of E499 to 
K347 interaction is shown as this interaction is a good indicator of the active-like conformation 
(Supplementary Figure 1g). c) Comparison of wt and K347/319A mutants bound to rosiglitazone 
or with no ligand. 
 4.3.4 Ligands induce/select functionally distinct helix 12 structural ensembles. 
We gathered solution structural information for diverse ligand-PPARγ 
complexes and apo PPARγ using a fluorine NMR probe, 3-bromo-1,1,1-
trifluoroacetone (BTFA)309, attached via an introduced cysteine at three locations; 
on helix 12 (K502/474C), on Q322/294C between the helix 3 charge clamp lysine 
(K329/301) and the site of simulation observed helical disruption (316/288-
320/292) and on a portion of the omega loop (Q299/271C) near helix 3. We BTFA 
label PPARγ ligand binding domain in the presence of bound ligand to minimize or 
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eliminate labeling of the only native cysteine (which points into the ligand binding 
pocket), alternatively for apo we also use a double mutant that includes a C313A 
mutation. Fluorescence polarization-based coregulator peptide recruitment assays 
demonstrated that the K502C-BTFA probe does not have a significant effect on 
peptide affinity282, Q299C has no apparent effect on NCoR or MED1 binding 
(Supplementary Table 2), and Q322C causes a 2 fold median increase in affinity 
for MED1 and no apparent change in affinity for NCoR peptide (Supplementary 
Table 3).  
19F NMR of the K502C-BTFA construct confirmed our previous 
observations282 that T0070907, GW9662 and the non-covalent inverse agonist 
SR10221161,296 induce distinct helix 12 structural ensembles from each other and 
from apo, although T0070907 and GW9662 differ only in relative populations of 
the two main structural ensembles (Figure 3a). Given that T0070907 induces 
higher affinity than GW9662 for a nuclear receptor interaction domain peptide 
from NCoR296 (Supplementary Table 2, 3 and 6) and the T0070907 spectrum 
has a larger left (i.e. downfield) population than GW9662, this narrower left peak 
likely represents an ensemble of closely related structures with high affinity for 
NCoR. This is supported by the fact that addition of SMRT or NCoR increases 
the population of the left peak in both GW9662 and T0070907 (Figure 3) as we 
previously reported282. Objective deconvolution219 of these spectra indicate that 
this left peak is relatively narrow (43 Hz) and similar in width to agonist bound 
PPARγ (rosiglitazone; 32 Hz) and the primary SR10221 bound PPARγ peak (41 
Hz) and much narrower than the broad deconvoluted apo peaks which range from 
97 to 144 Hz (Figure 3). The relatively narrow peaks are consistent with the 
hypothesis that these peaks represent structures exchanging on relatively fast 
timescales (e.g. ps to lower microsecond lifetimes) between similar helix 12 
conformations while the apo peaks indicate exchange between more distinct helix 
12 structures exchanging on the μs-ms time scale223. Clearly resolved separate 
peaks observed in these spectra indicate very slow exchange (ms-s time scale) 
which we previously confirmed for the two prominent PPARγ-T0070907 peaks282 
and which is consistent with exchange between conformations with larger 
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structural differences223. Together, these data with other NMR and HDX-
MS207,282,296 indicate that agonist (i.e. rosiglitazone) bound PPARγ has one 
primary narrow structural ensemble, while apo PPARγ and PPARγ bound to 
T0070907, GW9662 and SR10221 have at least two and very likely more distinct 
helix 12 structural ensembles. However, these data also support the idea that 
T0070907 and NCoR co-binding to PPARγ induce/select a primary helix 12 
structural state composed of similar structures with high affinity for NCoR and 
two or more other structural states with lower affinity for NCoR.  
 
4.3.5 The apo helix 3 structural ensemble is composed of structurally and 
functionally diverse structures. 
While the helix 12 conformational ensemble has a large impact on 
coregulator affinity282, we hypothesized that the helix 3 structural ensemble is 
influenced by ligands and also plays a role in coregulator affinity. The fluorine 
probe on helix 3 of apo PPARγ shows two distinct wide peaks, which chemical 
exchange saturation transfer (CEST310) indicates undergo slow exchange at a rate 
of less than 0.5 per second for both PPARγQ322C-BTFA (Figure 3 and 
Supplementary Figure 3) and PPARγC313A,Q322C-BTFA282. We routinely 
delipidate PPARγ, which binds E. coli lipids218. The right (upfield) apo peak 
originates, at least partially, from the E. coli lipid bound state and the observed 
exchange could be reflective of either lipid exchange or exchange between apo 
structural states. In contrast to apo, our previous work indicates that the structure 
and dynamics of PPARγ bound to the ligands utilized here is dominated by the 
ligands with any residual lipid causing minimal effects282. There is no indication 
that the two states have grossly different affinity for NCoR or CBP as both peaks 
are in clear slow exchange with the peptide bound peak (Supplementary Figure 
3). Regardless, the left apo peak is almost certainly lipid free and is wider (~70 
Hz) than spectral peaks for PPARγ bound to efficacious ligands (e.g. rosiglitazone 
and T0070907 primary peaks which are ~30 Hz) indicating that the left apo peak 
represents two or more distinct structures exchanging on the μs to ms timescale. 
The ratio of chemical shift separation between the states (350 Hz) to the rate of 
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exchange between states (<0.5 s-1) is <0.001, thus peak broadening is not due to 
exchange between the left and right states. Addition of coactivator, corepressor or 
a heterodimer partner of PPARγ (RXRα) all lead to peak consolidation (Figure 3 
and Supplementary Figure 3), indicating that the structural ensemble of the 
portion of helix 3 containing the charge clamp contains a mix of structures with 
no clear preference for binding coactivators or corepressors. 
Ligands induce/select functionally distinct helix 3 structural ensembles from 
the apo ensemble. 
 Addition of corepressors (NCoR or SMRT) to PPARγQ322C-BTFA led to 
narrowing of primary peaks in inverse agonist (T0070907) bound PPARγ spectra 
and broadening for labeled PPARγ bound to an agonist (rosiglitazone). Likewise, 
the binding of a coactivator peptide (MED1 or CBP) has little effect on the 
spectra from agonist bound labeled PPARγ but induces peak splitting and 
broadening in inverse agonist/antagonist bound labeled PPARγ (Figure 3 and 
Supplementary Figure 3). Heterodimerization with RXRα reduces the affinity of 
the PPARγ T0070907 complex for NCoR282 and thus would be expected to have a 
similar structural effect to coactivator binding on the PPARγQ322C-BTFA 
spectrum. This is what is observed (Supplementary Figure 7a). The 
MED1/PPARγQ322C-BTFA/T0070907 complex has the highest dissociation 
constant of any of these complexes (20 μM; Supplementary Table 2 and 3). 
PPARγ and RXRα have a very low dissociation constant (<10nM). At NMR 
concentrations (150 μM protein and 300 μM peptide) even the lowest affinity 
complex should be >90% bound. Therefore, peak splitting is not likely due to 
unbound and bound species in the case of the poorest affinity peptides and 
certainly not in the heterodimer. Rather it appears that binding of coactivators or 
RXRα to inverse agonist bound PPARγ shifts the equilibrium towards minor 
conformations. This argument is especially compelling in the case of PPARγ 
bound to GW9662, where CEST reveals exchange between downfield (left 
shifted) minor states with the major state and major downfield peaks appear upon 
addition of peptides or RXRα (Supplementary Figure 7). We confirmed 
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exchange between the two peaks in the PPARγ/GW9662/RXRα complex 
spectrum using CEST (1.7 s-1 95% CI=1.4-2.0; Supplementary Figure 7). 
Interestingly, in contrast to PPARγ bound to the most efficacious ligands 
(T0070907 and rosiglitazone), binding of either a coactivator or a corepressor 
peptide to both apo and a partial agonist (nTZDpa) cause similar changes (Figure 
3 and Supplementary Figure 7). These data indicate that efficacious ligands 
select/induce distinct states with a strong preference for coactivators or 
corepressors, while apo and partial agonist structural ensembles are composed of 
structures with no strong preference.  
4.3.6 Ligands narrow the energy well of the helix 3 c-terminus.  
Representative structures from the lowest energy wells of the inactive apo 
PPARγ simulations, with or without NCoR peptide, show more variability in the 
position of the c-terminal portion of helix 3, including Q322 and the charge 
clamp, than PPARγ bound to ligands with or without NCoR peptide (Figure 3b 
and c). The variability in this region is likely functionally significant as it varies 
the position of the backbone of the K329 charge clamp (Figure 3d). Simulations 
also indicate lower helix 3 helicity for some low energy apo PPARγ structures 
than ligand bound PPARγ with or without NCoR bound (Supplementary Figure 
3). Consistent with fluorine NMR and simulations, HDX-MS shows much faster 
exchange of amide protons in a peptide that spans residues 322 to 326 for the apo 
PPARγ/NCoR complex than the PPARγ/T0070907/NCoR complex and slightly 
faster exchange in the PPARγ/SR10221/NCoR complex compared to the 
T0070907 complex (Figure 4 and Supplementary Figure 8). These data indicate 
that ligands that induce the highest affinity for coregulators induce/select a c-
terminal helix 3 structural ensemble distinct from apo and less efficacious ligands. 
Together, these data imply the structure of the c-terminus of helix 3 is ligand 
dependent and functionally important; importance that likely lies in positioning 




Figure 3. 19F NMR, HDX-MS and simulations indicate that helix 3 has a ligand 
dependent diverse conformational ensemble that affects the helix 3 charge clamp position. a) 
19F NMR spectra of PPARγ labeled at the indicated residues with BTFA and bound to the 
indicated ligands. The lower rows of spectra included an 2x molar ratio of corepressor peptide 
derived from NCoR (unlabeled). Asterisk denotes what is likely unfolded PPARγ or BTFA 
labeled contaminating protein282. b) The c-terminal portion of helix 3 is highlighted in color. Dark 
green, olive drab and light green indicate that the structures are a representative structure from the 
lowest, second lowest and third lowest energy wells in the aMD energy landscape for the indicated 
PPARγ-ligand or PPARγ/ligand/NCoR complexes. A representative structure from the 
rosiglitazone PPARγ simulation is shown in yellow. The side chains of the charge clamp (K329) 
and the BTFA probe location (Q322) are shown. c) RMSD of residues 322-329 of individual cMD 
simulations that were started from representative structures from the lowest energy wells for the 
indicated complexes compared to the same residues in the crystal structure 1PRG (apo PPARγ). 
Boltzmann averages are shown as magenta bars. The Boltzmann average is shown as a magenta 
bar. d) Comparison of representative structures from the lowest (dark green) and second lowest 
(olive drab) energy wells of inactive apo PPARγ. The distance between the alpha carbon atoms for 




                      
Figure 4. HDX-MS of PPARγ co-bound to T0070907 and a NCoR peptide (2:1 molar ratio 
NCoR:PPARγ) compared to PPARγ  bound to NCoR alone (right) or cobound with SR10221 
(left). The difference in hydrogen deuterium exchange for peptides from the indicated regions of 
the protein is shown by the coloring as indicated. The dark grey regions showed no significant 
difference, while the white regions were not resolved in the assay.  
4.3.7 A single omega loop structure is selected/induced by inverse agonist and 
corepressor binding.  
The spectrum produced by a probe on the omega loop (Q299/272C) near 
the n-terminus of helix 3 of PPARγ produces a narrow peak (72% of signal) and a 
wider peak (28% of signal) for the PPARγ-T0070907 complex and more complex 
spectra for other complexes (Figure 3a). The dominant narrow peak indicates that 
the loop region is stabilized by T0070907 into a single structure in 72% of the 
population. Fifteen percent of the GW9662 and apo spectra originates from a peak 
with very similar chemical shift and width to this narrow T0070907 peak. 
Addition of NCoR or SMRT corepressor peptides drives the omega loop in the 
GW9662 and T0070907 complexes to a single peak, which is consistent with an 
ensemble of closely related structures, while the changes to apo are difficult to 
interpret because of native cysteine labeling (Figure 3a). These data indicate that 
the omega loop is allosterically linked to the coregulator binding surface in these 
complexes and suggest that a specific omega loop conformation is characteristic 
of a structural ensemble with the highest affinity for NCoR. In contrast, the 
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spectrum of Q299-BTFA PPARγ bound to the efficacious agonists rosiglitazone 
or GW1929 does not change upon addition of coactivators or corepressors 
indicating a lack of allosteric linkage between the omega loop and the coregulator 
binding surface for this complex (Figure 3a and Supplementary Figure 4). 
Simulations indicate that in some low energy apo, GW9662 and T0070907 
structures (with or without NCoR) helix 3 extends n-terminally to near the 
fluorine probe residue (299; Supplementary figure 4b), which would be 
consistent with the narrow PPARγQ299C-BTFA/T0070907 NMR spectrum (Figure 
3a). Three of 174 PPARγ crystal structures show a 4-residue helix 3 n-terminal 
extension; a few others show shorter extensions (Supplementary Figure 4d). 
However overall, there is not a good correlation between the Boltzmann average 
and the population of the narrow peak in the 19F NMR spectrum. In addition, 
Hydrogen deuterium exchange mass spectrometry (HDX-MS) of an omega loop 
peptide that covers this region does not show differences between 
PPARγ/T0070907/NCoR and PPARγ/SR10211/NCoR or apo PPARγ/NCoR 
complexes (Figure 4, Supplementary Figure 9). Indicating that helical extension 
may not be different between these three complexes. The overall helicity of the 
region included in the HDX-MS omega loop peptides appears different between 
the complexes in the simulations (Supplementary Figure 4f). Either this 
difference is not detected by HDX-MS or these simulation structures are 
representative of intermediates along the path to an as yet unsampled NCoR 
bound structure. One consequence of Helix 3 extension is reduction of the 
interaction between the omega loop (i.e. the large loop between helix 2 and helix 
3) and helix 3 and/or helix 12 (Supplementary Figure 6). Interaction of the 
omega loop with helix 3 residues has been shown to be important for the 
transcriptionally active state106,107. In fact, SR10221 may disrupt this helix 3 
omega loop interaction by pushing on Phe310161, essentially the same mechanism 
via different means. Thus helix 3 extension may free up helix 12 positioning as 
one step towards a final structure. Another consequence of helical extension in 
both the crystal structures and the simulations appears to be disruption of a critical 






Figure 5. The reconstructed physiologic ensemble (from aMD inspired cMD) indicates that 
helix 12 bonds to NCoR in the T0070907 complex but not the SR10221 complex. a) The 
prevalence of the indicated hydrogen and salt bridge bonds in individual 1μs conventional MD 
runs of representative structures from low energy wells (black circles) and the overall Boltzmann 
weighted average (pink) for the indicated complexes. b) The Boltzmann average prevalence of 
hydrogen bonding between the charge clamp residue (K329) and NCoR is significantly higher 
than between a helix 4 residue (N340) and NCoR. c) The decrease in affinity is greater for a 
mutation abolishing the helix 3 charge clamp (K329A) than for one abolishing the helix 4-NCoR 
bonding (N340A). d) Mutation of the helix 12 charge clamp (E499L) leads to ligand dependent 
decrease in affinity for NCoR, which correlates with simulation derived prevalence of bonding 
between E499 and both NCoR and helix 4 (K347). e) Abolishing the helix 4 to helix 12 and NCoR 
interaction through mutation (K347A) reduces affinity for NCoR in a ligand dependent manner, 
but only the prevalence of the K347-E499 bonding correlates with the decrease. Fits for panels d 
and e were done with a single exponential as this is the correlation expected between the ratio of 
dissociation constants and bond prevalence311. 
 
4.3.8 The structural mechanism of distinct corepressor bound affinities. 
The PPARγ-T0070907 complex has the highest affinity for the NCoR 
peptide out of all the simulated complexes, including the inverse agonist 
SR10221296 (Supplementary Table 6). To determine the underlying mechanism 
for how T0070907 induces a high affinity structure for NCoR we analyzed aMD 
simulations of apo PPARγ, and PPARγ bound to inverse agonist/antagonist 
(T0070907, GW9662 and SR10221) co-bound to a peptide from NCoR. These 
simulations were started from structures with helix 12 in the inactive conformation 
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because docking of NCoR onto PPARγ with helix 12 in the active conformation 
results in steric clash between NCoR and helix 12. Representative structures from 
the deepest wells indicate that the structure of these PPARγ NCoR complexes are 
ligand dependent, with the most prominent differences found in the omega loop, 
helices 3, 11 and 12 (Figure 1d and Supplementary Figure 5). As expected from 
the PPARα-SMRT structure200, Boltzmann average values indicate prevalent 
hydrogen bonding between the NCoR peptide and Lys329/301 of helix 3 and 
Asn340/312 of helix 4 (Figure 5a). Interestingly, low energy ensembles of 
T0070907/NCoR and GW9662/NCoR, but not SR10221/NCoR, show hydrogen 
bonding between the NCoR backbone and helix 12 similar to the active 
conformation, but with helix 12 shifted to allow binding of the longer corepressor 
helix (Figure 1 and 5 and Supplementary Figure 5). The importance of the charge 
clamp residues (Lys329/301 and E499/471) for coactivator binding has been shown 
extensively for several different nuclear receptors, including PPARγ22, however the 
helix 12 clamp (E499) has not been proposed before to be important for corepressor 
binding to nuclear receptors including PPARγ. The helix 12 charge clamp was 
shown to interact with, but not hydrogen bond to, NCoR in a glucocorticoid 
receptor antagonist structure301, where helix 12 is shifted in a similar manner to 
accommodate the longer compressor helix42. In addition, these simulations indicate 
that low energy helix 12 conformations include disordered and/or coregulator 
binding surface displaced helix 12 conformations similar to those previously 
observed in various other corepressor bound crystal structures20,200,299,300,302. 
As noted above, simulations indicate that residues K329/301 (Helix 3) and 
N340/312 (Helix 4) interact with NCoR, while E499/471 (Helix 12) and 
K347/319 (Helix 4) can interact both with NCoR and form a salt bridge with each 
other in a ligand dependent manner. A series of point mutants of the PPARγ-LBD 
were generated in these four residues to test these simulation-generated structural 
hypotheses. In addition we used a deletion mutant, L496stop (referred to herein as 
ΔH12), which deletes helix 12312,313 and increases affinity for corepressor 
proteins314. The change in affinity upon mutation of K329/301 or N340/312 
should correlate (exponentially) with hydrogen bond prevalence as simulations 
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indicate that the hydrogen bond partners to these residues on NCoR are solvent 
exposed in the mutants (Supplementary Table 4) and these residues do not 
interact with other PPARγ residues and are thus less likely to affect the native 
state structure (e.g. are non-disruptive315). Simulations indicate that the K329-
NCoR hydrogen bond is more prevalent than the N340-NCoR hydrogen bond 
across the tested complexes (Figure 5b). Consistent with the simulations, 
mutation of K329 has a significantly larger effect on affinity for NCoR than 
mutation of N340 (Figure 5c).  
Interpretation of the E499 and K347 mutation data is less straightforward 
because simulations indicate that these two residues not only hydrogen bond to 
NCoR but also form a salt bridge with each other in a ligand dependent manner. 
Mutation of these residues may impact PPARγ structure in addition to NCoR 
binding. The prevalence of both E499-K347 and E499-NCoR hydrogen bonding 
alone and summed correlates with the effects of E499L mutation on NCoR 
affinity indicating that both interactions contribute to NCoR affinity.  In contrast, 
the prevalence of K347-NCoR hydrogen bonding does not correlate with 
mutagenesis results. However there is the expected exponential correlation316 
between K347-E499 bonding prevalence and affinity changes in the K347A 
mutant across the four complexes. This suggests that either disruption of the 
K347-E499 salt bridge affects helix 12 conformation and may obscure the effects 
of K347-NCoR bonding or that the K347-NCoR bonding observed in simulations 
is absent or inconsequential in the actual complex.  The E499L mutant has 
increased affinity for NCoR in the ligand free (apo) and SR10221 bound forms 
which are dominated by structures with no hydrogen bonding between 
helix4/NCoR and helix 12 (Figure 5a). Thus, the increased affinity of the apo and 
SR10221 bound E499L mutant for NCoR is consistent with the E499L mutation 
lowering the energetic cost of helix 12 displacement through disruption of the 
E499-K347 salt bridge. Consistent with this model, deletion of helix 12 had no 
effect on the affinity of the PPARγ-T0070907 complex for NCoR but increased 
affinity of NCoR for GW9662 bound PPARγ and dramatically increased affinity 
for apo and PPARγ bound to SR10221 (Supplementary Table 5), which is a 
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pattern consistent with the prevalence of both the helix 4 to helix 12 (K347 to 
E499) salt bridge prevalence and the E499 to NCoR hydrogen bonding prevalence 
in these complexes. These data indicate that both displacement of helix 12 from 
the coregulator binding surface and positioning of helix 12 that allows direct 
binding to a corepressor (Figure 1d and Supplementary Figure 5) can both 
increase NCoR affinity.  
 
                 
Figure 6. A tripartite salt bridge that biases towards agonism is disrupted in the T0070907 
bound structural ensemble. Prevalence of the helix 6-7 loop to a) helix 11-12 loop and b) helix 3 
salt-bridges are shown for the indicated complexes for individual cMD simulations started from 
representative structures from the lowest energy wells in the aMD potential energy landscapes 
(black circles). The Boltzmann average is shown by a magenta bar. c) The change in affinity 
induced by mutation of the helix 3 salt bridge residue (E304) is shown for the indicated 
complexes. d) The tripartite salt bridge as detected by chimera in a PPARγ bound to rosiglitazone 
crystal structure (PDB code 2PRG). Blue indicate ideal hydrogen bonds, while orange lines 
indicate relaxed constraint hydrogen bonds (20 degrees and 0.4 angstroms). 
4.3.9 A salt bridge switch for inverse agonism. 
We next used the simulations to identify the possible mechanisms by 
which T0070907 induces higher affinity for NCoR peptide than apo PPARγ. A 
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tripartite salt bridge network was identified in active but not inactive structures in 
analysis of >200 PPARγ crystal structures294. A mutation (F388L) found in 
familial partial lipodystrophy disrupts this salt bridge network and reduces 
transcriptional activation potency for drugs303. This salt bridge network ties 
together a very mobile domain of the ligand binding domain140,207 which includes 
the n-terminal part of helix 3 (E304/276), the adjacent helix 6-7 loop (R385/357) 
and the helix 11-12 loop (E488/460; Figure 6d). The T0070907 complex with or 
without NCoR shows the lowest Boltzmann average prevalence for both these salt 
bridges (Figure 6 a,b). We analyzed the simulations and found a correlation 
between helix 3 extension and interaction of the omega loop with helix 3 and the 
integrity of this tripartite salt bridge (Supplementary Figure 6 a,b,e). In addition, 
analysis of all available PPARγ crystal structures indicates that this tripartite salt 
bridge is more prevalent when helix 12 is in the active conformation than when it 
is in an inactive conformation (Supplementary Figure 6d) . It appears that the 
PPARγ-T0070907 structural ensembles are biased against the helix 11-12 loop to 
helix 6-7 loop salt bridge formation in ways in addition to helix 3 extension as 3/7 
of the PPARγ-T0070907 ensembles without helix 3 extension lack this salt 
bridge. Thus, T0070907 disrupts this tripartite salt bridge network, which would 
be expected to allow alternative conformations of the helix 11-12 loop and 
thereby helix 12, impacting coregulator binding. 
To experimentally test the importance of E304/276 to coregulator affinity 
we generated an E304L mutant and tested the effect on affinity for a FITC-NCoR 
peptide using fluorescence polarization. These data confirm the importance of the 
E304/276-385/R357 salt bridge for the active high coactivator affinity state as 
disruption of this salt bridge increases NCoR affinity and decreases CBP affinity 
consistently for all complexes except the T0070907 complex (Figure 6c). These 
data are consistent with our simulation generated models which indicate that the 
inverse agonist T0070907 disrupts this salt bridge network, inducing a unique 
conformation with increased affinity for NCoR. 
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4.3.10 The distinct structural ensembles of SR10221 and T0070907 yield 
distinct function. 
19F NMR of helix 12 and helix 3 (Figure 3 and Supplementary Figure 4 
and 10), protein NMR (Supplementary Figure 2) and simulations (Figure 1 and 
5) indicate that the inverse agonists SR10221 and T0070907 induce/select distinct 
NCoR bound conformations. Comparison of PPARγ co-bound to T0070907 and 
NCoR peptide with the apo NCoR and SR10221-NCoR complexes using 
hydrogen deuterium exchange mass spectrometry (HDX-MS) also reveals major 
structural differences (Figure 4). The T0070907 complex shows much less 
exchange in helix 12 and less exchange in helix 10/11 and the 11-12 loop than 
both apo/NCoR and SR10221/NCoR co-bound to PPARγ. Together these data 
indicate that SR10221 and T0070907 induce different structures and may achieve 
inverse agonist effects via distinct mechanisms. 
An important functional effect of drug binding to PPARγ is a change in affinity 
for coregulators. We tested the effect of SR10221, T0070907 and other PPARγ 
ligands on PPARγ affinity for peptides from NCoR and SMRT using fluorescence 
polarization. Compared to apo PPARγ, T0070907 binding induces a dramatic 
increase in affinity for both NCoR (Supplementary Table 2, 3, 6 ) and SMRT 
(Supplementary Table 7) while SR10221 increases affinity for SMRT only 
(Supplementary Table 7). Thus, differences in the structural ensemble of helix 
12, 3 and possibly other regions of PPARγ lead to differential recruitment of these 
corepressor peptides. Differential recruitment of NCoR and SMRT would be 
expected to produce unique functional effects in vivo317.  
4.4 Discussion 
These fluorine and protein NMR, HDX-MS, mutagenesis and extensive enhanced 
sampling simulations reveal a very diverse ligand dependent PPARγ 
conformational ensemble. These data also demonstrate that helix 3 dynamics and 
structure is key to coregulator affinity. They also implicate a particular omega 
loop structural state as important for a structural ensemble with high affinity for 
the corepressor NCoR. Previous HDX-MS and NMR work indicated that 
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stabilization of PPARɣ helix 3 and the βsheet region, and not just helix 12, is 
important for transcriptional activity221,318. Remarkably, the PPARγQ299C-BTFA 
(omega loop) spectrum dramatically narrows upon binding the inverse agonist 
T0070907 or when co-bound to the antagonist GW9662 and NCoR or SMRT 
peptides. These narrow NCoR bound spectra are consistent with a helix 3/omega 
loop structural ensemble of similar conformations and indicate that T0070907 
induces/selects a helix3/omega loop structural ensemble that is well suited to 
NCoR binding as we have observed previously for helix 12282 and other areas of 
PPARγ296 (Figure 3). These data also indicate that changes to the AF2 surface 
can induce changes in the omega loop depending on the ligand bound to PPARγ, 
indicating that the omega loop conformation is important to function. These 
results, as well as previously obtained data on helix 12 and other areas of the 
PPARγ ligand binding domain suggest that T0070907 induces/selects a 
conformational ensemble that accommodates NCoR binding better than GW9662 
as the structural ensemble induced/selected by GW9662 changes more than that 
of T0070907 upon ligand binding282,296. This is consistent with the idea that less 
of the NCoR free energy of binding is used in altering the conformational 
ensemble of PPARγ-T0070907 than PPARγ-GW9662 resulting in a higher 
affinity of NCoR peptide for PPARγ-T0070907.  
Simulations indicate that Helix 3 extension would disrupt interaction of the 
omega loop with helix 3. Evidence for the importance of helix 3-omega loop 
bonding for the transcriptionally active state has been published previously107. In 
addition, mutation of F488/460, involved in the ionic bond network that is also 
disrupted by helix 3 extension, is associated with familial partial lipodystrophy303.  
In addition, one member of a tripartite salt-bridge network is located on the n-
terminus of helix 3 (near the omega loop). Simulations indicate that T0070907 
disrupts this network. Disruption of this network favors corepressor binding. 
These changes appear to free helix 3 and 12 to move to a new conformation with 
high affinity for NCoR. Together these data indicate that an important 
consequence of T0070907 binding is disruption of this tripartite salt bridge. 
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Surprisingly, the helix 12 charge clamp (E49922) appears to have some 
importance for NCoR binding to inverse agonist (T0070907) bound PPARγ. 
Simulations indicate that the lowest energy PPARγ-T0070907-NCoR structure is 
similar to the active structure with a shifted helix 12. HDX-MS (Figure 3) and 
mutagenesis (Figure 4) are consistent with this model. A similar helix 12 and 
corepressor position has been observed via crystallography for glucocorticoid 
receptor bound to an NCoR peptide301. This position allows hydrogen bonding 
between the helix 12 charge clamp (E499) and the NCoR peptide backbone in a 
similar manner to the coactivator helix 12 interaction. However, given that our 
aMD simulations are not completely converged, there may be other lower energy 
unsampled or poorly sampled structures that are also consistent with our 
experimental data. In that case this conformation could represent a minor helix 12 
conformation that composes 25% of the NCoR bound PPARγK502C-BTFA 
spectrum. 
Interestingly, another inverse agonist (SR10221) appears to work as an inverse 
agonist by inducing a distinct structural ensemble which does not involve 
interaction of helix 12 with NCoR or a single omega loop structure. The distinct 
structural ensembles induced by T0070907 and SR10221 produce different 
corepressor recruitment profiles. Compared to apo PPARγ T0070907 increases 
affinity for both SMRT and NCoR, while SR10221 increases affinity for only 
SMRT. This opens the possibility that SR10221 and T0070907 could have 
distinct repressive effects in animals and possibly selective physiological effects 
similar to what has been observed in selective PPARγ modulators such as MRL24 
and SR1664166,306. 
4.5 Methods 
4.5.1 Protein and ligand 3D-structure preparation 
The crystal structure of GW9662-bound PPARγ (PDB code 3B0R) was used as 
the initial structure in all simulations of GW9662 bound PPARγ in this study. 
This crystal structure was also used to construct the initial 3D structure of 
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T0070907 bound PPARγ. In this model, GW9662 was transformed to T0070907 
by converting benzene ring of GW9662 to the pyridine ring. In both models, the 
chain B conformation was used. In order to construct the 3D structure for nuclear 
receptor corepressor 1 (NCoR1) crystal structure with PDB code 2OVM was 
used. 1KKQ crystal structure which is the only structure with corepressor 
(SMART) was used as a template to design NCoR bound to PPARγ-T0070907. 
Both chain A and B of crystal structure with PDB code 1PRG were used for apo 
and 10221 (chain B) simulations. To build the initial structure for Rosiglitazone 
simulations chain A of 2PRG PDB code along with S enantiomer of Rosiglitazone 
at pH 7.2 which has the highest affinity for PPARɣ were used. UCSF Chimera 
modeler extension was used to model the missing residues in PDB files. 
4.5.2 Molecular Dynamics (MD) simulations 
Molecular Dynamics (MD) simulations were performed using two different 
methods: conventional (cMD) and accelerated molecular dynamics simulation 
(aMD). aMD simulations were performed in order to sample the conformational 
spaces better. Both cMD and aMD production runs were carried out using Amber 
16 molecular modeling package and the AMBER ff14SB force field and general 
Amber force field (GAFF2) parameters were used to describe protein and 
ligand241,319. Refined structures were submitted to h++ server 
(http://biophysics.cs.vt.edu/H++)237 to generate the protonated states of protein at 
pH 7.4. The resulting PDB files were modified using pdb4amber in 
AmberTools14238 for use with tleap. The R.E.D server (http://upjv.q4md-
forcefieldtools.org/REDServer-Development/)239 was used for the ligand 
parameterization and charge calculations. The structures were immersed in an 
octahedron box of TIP3P243 water molecules extended to 10 Å from the protein 
atoms.  Enough Na+ atoms were added to neutralize the structure and KCl  (K+ 
and Cl- ions) was added to 50 mM320. The resulting system was equilibrated using 
a nine-step of minimization and restrained simulations protocol as following. In 
the first step a force constant of 5 kcal mol–1 Å–2 was applied on the protein heavy 
atoms through 2000 steps. Then, the MD simulation was performed for 15 ps 
with shake under constant volume periodic boundary conditions (NVT). This was 
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followed by two rounds of 2000 steps of steepest descent minimization with 2 and 
0.1 kcal/mol Å2 spring constant. The system was then subjected to a simulation 
with no restraints followed by three rounds of simulations with 1, 0.5 and 0.5 
kcal/mol Å2 force constant on heavy atoms for 5 ps, 10 ps and 10 ps. Finally, a 
simulation without restraints was performed for 200 ps under NPT condition. 
Hydrogen mass repartitioning along with SHAKE algorithm were used to 
allow an integration time step of 4 fs.  Production MD runs of constant pressure 
replicates were performed from randomized initial velocities. The pressure was 
controlled by a Monte Carlo barostat with a pressure relaxation time (taup) of 2 
ps. The Langevin dynamics with a collision frequency (gamma_ln) of 3 ps-1 was 
used to keep the temperature at 310 K. The particle mesh Ewald41 with an 8.0 Å 
cutoff was carried out to treat electrostatic interactions. The time step of cMD 
simulations was 100 ps and three independent ~15-μs-long cMD production runs 
were performed on T0070907, GW9662 and SR10221bound PPARγ with and 
without NCoR. Three independent simulations with the same length were 
performed on Rosiglitazone bound PPARɣ. All of the aMD simulations were 
started from the equilibrated structures and average dihedral energy and total 
potential energy obtained from cMD simulations were used to calculate the boost 
parameters. In this study a dual boosting approach was carried out in which two 
separate boost potentials are applied to the torsional and the total potential terms. 
aMD simulations for ~2.5 µs with time step of 3fs were performed on T0070907 
and GW9662 bound PPARγ with and without NCoR.  
All production simulations were performed using pmemd.cuda or 
pmemd.cuda.MPI. The simulation results were analyzed using cpptraj program in 
the AmberTools 14 Toolbox308. A toolkit of Python scripts “PyReweighting” was 
used to reweight the biased aMD frames and to calculate free energy profiles321.  
4.5.3 Protein purification 
A pET45b plasmid containing the PPARγ-LBD, residues 230-505 as well as an N-
terminal 6x His tag and tobacco etch virus nuclear inclusion protease (TEV) 
recognition site was transformed into BL21 (DE3) gold cells (Invitrogen). Cells 
were grown in either terrific broth or ZYP-5052 autoinduction media. In the case 
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of autoinduction media cells were grown for 10 hours at 37°C and then allowed to 
induce for an additional 12 hours at 22°C and 180 rpm. Cells in terrific broth were 
grown at 37°C and 170 rpm until OD600 of between 0.6-1 was reached. Following 
this the incubator was dropped to 20°C for one hour and cells were induced 
overnight by the addition of 500µM IPTG. Cells were pelleted by centrifugation 
and stored at -20°C until ready for use. Cell pellets were resuspended in 50mM 
KPO4, 300mM KCl, 1mM TCEP and 1mM EDTA pH 8.0 and lysed using a C-5 
Emulsiflex high pressure homogenizer (Avestin). Initial protein purification was 
performed on either an AKTA start (GE Healthcare) or a NGC Scout (Bio Rad) 
FPLC using 2 His Trap FF 5ml columns in series (GE Healthcare). Following this 
the 6x his tag was removed by the addition of approximately 1:40 w/w 6x his tagged 
TEV and overnight incubation. Cleaved tag and TEV protease was removed by 
again passing through His Trap FF columns. Size exclusion chromatography was 
then performed using a Hiload 16/600 Superdex 75 pg column (GE Healthcare). 
Protein purity in excess of 95% was confirmed by SDS-PAGE. 
4.5.4 Site-directed mutagenesis 
Site-directed mutagenesis was performed using the Quikchange Lightning 
mutagenesis kit (Agilent Technologies). All mutations as well as the absence of 
spurious mutations were confirmed by Sanger sequencing (Eurofins). Primers used 










4.5.5 Preparation of NMR samples 
All NMR samples were prepared to a final volume of 470µL and a final 
concentration of 150µM. Samples of PPARγC313A,Q322C and PPARγQ322C were 
loaded with ligands to a final concentration of 165µM for all ligands except 
Pioglitazone, Troglitazone and BVT.13 which were loaded to a final concentration 
of 225µM or GW9662 and T0070907 which were added to a final concentration of 
300µM. Ligand concentration was varied to fix the DMSO addition to each sample 
at 7.8µL, 1.66% final v/v. In the case of PPARγC313A,Q322C the protein was labeled 
with a 10-fold excess of BTFA during purification. However, the single mutant 
PPARγQ322C was labeled with a 2-fold molar excess of BTFA following drug 
addition, with the following exceptions, samples loaded with the covalent ligands 
were labeled with a 10-fold molar excess of BTFA while the apo sample was 
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labeled with a stoichiometric concentration of BTFA to reduce labeling on the 
native cysteine in the ligand binding pocket. Following labeling samples were 
incubated for 30 minutes when loaded with ligand or 2 hours for the apo sample 
and then buffer exchanged >100x using an amicon ultra centrifugal filter 
(Millipore) with a 10kDa molecular weight cut off to remove excess BTFA label. 
All peptides were added to NMR samples at a final concentration of 300µM from 
stocks of approximately 1mM in the same buffer as the NMR samples. Following 




Chapter 5: Conclusions 
 Presented in this work were a wide variety of experiments to increase the 
understanding of a fundamental property of the significant nuclear receptor 
PPARγ. All data in this work revolved around the central theme towards 
elucidating the conformational mechanisms by which very diverse ligands cause 
their functional outcomes. From this we were able to expand the available 
knowledge in this area, but the picture is still incomplete. However, a substantial 
contribution is made towards the understanding of this area of study which will 
help guide future research. 
 This work demonstrates that the two-state “on-off” model for PPARγ, and 
likely other nuclear receptors, does not appear to be correct. We observed that the 
conformations induced by the majority of ligands were highly complex. Even in 
the highly efficacious ligands such as the inverse agonist T0070907 or the FDA 
approved full agonist pioglitazone there appeared to be two or more significantly 
populated conformational states of the protein. In fact, when probing helix 12, 
considered the most important region of the AF-2 surface, it was seen that only a 
small number of ligands, GW1929, rosiglitazone and SR10221, were generating 
only a single dominant conformation. Results were similar when probing the 
conformational ensemble of helix 3 which is another portion of the AF-2 surface. 
In this case all efficacious agonists or inverse agonists selected for a more specific 
local conformation, but the majority of ligands showed multiple conformations 
present at high population. Interestingly, it was seen that both agonists and inverse 
agonists seemed to select for the same conformation in this region. This has not 
previously been observed but is not completely surprising as the helix 3 charge 
clamp is significant in the binding of all coregulators.  
 Additionally, we observed that inverse agonism does not operate through a 
single mechanism. This has long been thought to occur in NR through a 
displacement of helix 12 which then allows room for the larger footprint of the 
CoRNR box to bind on the AF-2 surface. This hypothesis was due to the fact that 
when nuclear receptors were crystallized with corepressor peptides helix 12 was 
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always unresolved and appeared to point into space. Such a mechanism does 
appear to be relevant in PPARγ inverse agonists, namely SR10221 and nTZDpa, 
but does not appear to be the exclusive conformation. We identified a second 
inverse agonist induced conformation which appears to be unique to the covalent 
ligands, T0070907 and GW9662. In this mechanism the small covalent ligand 
remodels helix 3 which then exerts allosteric effect on helix 12 through the 
disruption of intra-protein non-covalent interactions. This allows helix 12 to 
reposition into a new conformation which allows for the binding of a CoRNR box 
while retaining productive interactions to the corepressor from the helix 12 charge 
clamp. Such a mechanism has not previously been reported and the presence of 
these productive helix 12 interactions is likely why T0070907 is the most 
efficacious known inverse agonist in this protein, approximately three times more 
efficacious than SR10221 in SMRT or NCoR recruitment. Though it should be 
noted that in the monomeric PPARγ SR10221 is a selective inverse agonist and 
only promotes the recruitment of SMRT not NCoR, while in the PPARγ-RxRα 
heterodimer it increases affinity for both corepressors. 
 Perhaps the most interesting finding in this work was the discovery of the 
helix 4 motif that seems to direct specificity in coactivator interactions. This 
eight-residue motif makes discriminatory hydrogen bonds from the terminal 
residues to the side chains of residues on the coactivator peptide that seem to be 
responsible for a large portion of the extreme specificity seen in coactivator 
interactions. They also seem to have some significance in corepressor interactions 
but not to nearly as large of a degree. It could be envisioned where this could be 
exploited towards the design of biased drugs to recruit only specific coactivators 
and thereby drive specific signaling events. An example of such would be in 
PPARγ where the moderate affinity PGC1α protein is relatively unaffected by 
ablation of helix 4 hydrogen bond interactions. This leads to the idea of the 
creation of a ligand that specifically alters the conformation of helix 4 while 
retaining other agonist characteristics. It is reasonable to hypothesize that this 
ligand would than preferentially recruit PGC1α. Such a design could be exploited 
similarly in other nuclear receptors to select for desired effects. The caveat would 
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be that such a design could lead to negative side effects. For example, it has been 
shown that overexpression of PGC1α in mice can lead to increased insulin 
resistance in the liver322. As such it would require special care in drug design to 
avoid such unforeseen effects. Another caveat is that this could only be exploited 
to preferentially recruit coactivators with lower affinity since the disruption of 
helix 4 would severely reduce the affinity for the high affinity coactivators, such 
as MED1 and CBP. So, while this may be a strategy in drug design which would 
be slightly limited it could still be of very significant value provided proper care 
was taken. 
 One interesting question this work was not able to resolve is the 
mechanism of action in partial agonists. Literature would suggest that the majority 
of the insulin sensitizing effects seen with these arises from the modulation of 
phosphorylation on S245/273 but this is not their only effect. Several of these 
ligands including MRL24323, INT131163 and SR2088282 have been shown reliably 
to increase coactivator recruitment, either through transactivation assays or in 
vitro peptide recruitment assays. However, it has previously been shown these 
make no interaction on helix 12164, consistent with our own data, and herein we 
show they do not generate a conformation in the helix 3 portion of the AF-2 
distinguishable from non-agonists. The only portion of the AF-2 this leaves they 
could exert an effect on is helix 4 but according to molecular dynamics and 
crystallography they do not make significant contacts in this region. It should be 
stated that there may be direct effects on this region which are not captured by 
these techniques. To verify this NMR studies similar to those performed in 
chapters 2 or 3 would need to be employed. Other two or three-dimensional NMR 
based techniques would likely not be successful in ascertaining these effects since 
partial agonist binding generally results in a very plastic state of the protein 
leading to a small amount of resolved peaks which makes assignment impractical 
and without assigned backbone residues it would not be possible to determine 
what changes are occurring. If as the initial data suggests there are no significant 
effects on helix 4 conformation induced by partial agonist binding that would 
imply that there must be a significant allosteric mechanism exerted by partial 
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agonists. This would be highly interesting to unravel but may be very challenging. 
The difficulty lies in the fact that partial agonists make only minimal direct 
contacts to the protein and those contacts are shared with non-agonists. However, 
a stepwise mutagenic screen may be able to parse these effects and solve the 
underlying mechanism. This would be of great value as these ligands are the 
current focus of active research despite having no real understanding of their 
mechanism. Such an understanding would allow for the more intelligent design of 
non-agonist ligands such as SR1664166, this ligand strongly increases insulin 
sensitivity but has very poor bioavailability making it unsuitable for medicinal 
use, which could increase insulin sensitivity but have no effect on other protein 
signaling pathways. Such drugs would be of great use as potential therapeutics 
which could yield the desired medical effects but avoid the very serious side-
effects associated with full agonist activation of PPARγ.  
 Through this work we have greatly expanded the knowledge base relating 
to how ligand binding leads to a functional effect in PPARγ. This is of great value 
in future guided studies to either create novel ligands or modify existing ligands 
in a more efficient way. Through this the current drug design for this protein 
which relies primarily on a somewhat scattershot method of creating hundreds if 
not thousands of ligands could be made more efficient leading to the more rapid 
release of potential therapeutics which target this important protein for metabolic 




Chapter 6: References 
1. Evans, R. The steroid and thyroid hormone receptor superfamily. Science (80-. ). 
240, 889–895 (1988). 
2. Mangelsdorf, D. J. et al. The Nuclear Receptor Superfamily: The Second Decade. 
83, 835–839 (1995). 
3. Krust, A. et al. The chicken oestrogen receptor sequence: homology with v-erbA 
and the human oestrogen and glucocorticoid receptors. EMBO J. 5, 891–897 
(1986). 
4. Nwachukwu, J. C. et al. Resveratrol modulates the inflammatory response via an 
estrogen receptor-signal integration network. Elife 2014, (2014). 
5. Srinivasan, S. et al. Ligand-binding dynamics rewire cellular signaling via Estrogen 
Receptor-α. Nat Chem Biol 9, 326–332 (2013). 
6. Arao, Y. & Korach, K. S. The F domain of estrogen receptor is involved in species-
specific, tamoxifen-mediated transactivation. J. Biol. Chem. 293, 8495–8507 
(2018). 
7. Patel, S. R. & Skafar, D. F. Modulation of nuclear receptor activity by the F 
domain. Mol. Cell. Endocrinol. 418, 298–305 (2015). 
8. Carter, E. L. & Ragsdale, S. W. Modulation of nuclear receptor function by cellular 
redox poise. J. Inorg. Biochem. 133, 92–103 (2014). 
9. Wang, Z. et al. Structure and function of Nurr1 identifies a class of ligand- 
independent nuclear receptors. Nature 423, 555–560 (2003). 
10. Zhao, Y. & Bruemmer, D. NR4A Orphan Nuclear Receptors: Transcriptional 
Regulators of Gene Expression in Metabolism and Vascular Biology. Arter. Thomb 
Vasc Biol 30, 1535–1541 (2010). 
11. de Vera, I. M. S. et al. Defining a canonical ligand-binding pocket in the orphan 
nuclear receptor Nurr1. bioRxiv 1–16 (2018). 
12. Zhang, Y. & Dufau, M. L. Gene Silencing by Nuclear Orphan Receptors. Vitam. 
Horm. 68, 1–48 (2004). 
13. Iyer, A. K. & McCabe, E. R. B. Molecular mechanisms of DAX1 action. Mol. Genet. 
Metab. 83, 60–73 (2004). 
14. Feng, W. et al. Hormone-Dependent Coactiva tor Binding to a surface. 
Hydrophobic Cleft on Nuclear Receptors. Science (80-. ). 280, 1747–1749 (1998). 
15. Heery, D. M., Kalkhoven, E., Hoare, S. & Parker, M. G. A signature motif in 
transcriptional co-activators mediates binding to nuclear receptors. Nature 387, 
733–736 (1997). 
16. Savkur, R. S. & Burris, T. P. The coactivator LXXLL nuclear receptor recognition 
motif. J Pept Res 63, 207–212 (2004). 
153 
 
17. Hu, X. & Lazar, M. A. The CoRNR motif controls the recruitment of corepressors 
by nuclear hormone receptors. Nature 402, 93–96 (1999). 
18. Hu, X., Li, Y. & Lazar, M. Determinants of CoRNR-dependent repression complex 
assembly on nuclear hormone receptors. Mol Cell Biol 21, 1747–1758 (2001). 
19. Perissi, V. & Rosenfeld, M. G. Controlling nuclear receptors: The circular logic of 
cofactor cycles. Nat. Rev. Mol. Cell Biol. 6, 542–554 (2005). 
20. Phelan, C. A. et al. Structure of Rev-erbα bound to N-CoR reveals a unique 
mechanism of nuclear receptor-co-repressor interaction. Nat. Struct. Mol. Biol. 
17, 808–814 (2010). 
21. Darimont, B. D. et al. Structure and specificity of nuclear receptor − coacNvator 
interactions Structure and specificity of nuclear receptor – coactivator 
interactions. 1, 3343–3356 (1998). 
22. Nolte, R. T. et al. Ligand binding and co-activator assembly of the peroxisome 
proliferator-activated receptor-gamma. Nature 395, 137–143 (1998). 
23. Huang, P., Chandra, V. & Rastinejad, F. Structural Overview of the Nuclear 
Receptor Superfamily: Insights into Physiology and Therapeutics. Annu Rev 
Physiol 71, 247–272 (2010). 
24. Khorasanizadeh, S. & Rastinejad, F. Visualizing the architectures and interactions 
of nuclear receptors. Endocrinology 157, 4212–4221 (2016). 
25. Bevan, C. L., Hoare, S., Claessens, F., Heery, D. M. & Parker, M. G. The AF1 and 
AF2 Domains of the Androgen Receptor Interact with Distinct Regions of SRC1. 
Mol. Cell. Biol. 19, 8383–8392 (1999). 
26. Benecke, A., Chambon, P. & Gronemeyer, H. Synergy between estrogen receptor 
a activation functions AF1 and AF2 mediated by transcription intermediary factor 
TIF2. EMBO Rep. 1, 151–157 (2000). 
27. Lin, S. J. et al. TR2 and TR4 Orphan Nuclear Receptors: An Overview. Current 
Topics in Developmental Biology 125, (Elsevier Inc., 2017). 
28. Lin, S.-J. et al. Minireview: Pathophysiological Roles of the TR4 Nuclear Receptor: 
Lessons Learned From Mice Lacking TR4. Mol. Endocrinol. 28, 805–821 (2014). 
29. Senali Abayratna Wansa, K. D., Harris, J. M. & Muscat, G. E. O. The activation 
function-1 domain of Nur77/NR4A1 mediates trans-activation, cell specificity, 
and coactivator recruitment. J. Biol. Chem. 277, 33001–33011 (2002). 
30. Codina, A. et al. Identification of a novel co-regulator interaction surface on the 
ligand binding domain of Nurr1 using NMR footprinting. J. Biol. Chem. 279, 
53338–53345 (2004). 
31. Horwitz, K. B. et al. Nuclear receptor coactivators and corepressors. Mol. 
Endocrinol. 10, 1167–1177 (1996). 
32. Ruan, X. Z., Varghese, Z., Powis, S. H. & Moorhead, J. F. Nuclear receptors and 
their coregulators in kidney. Kidney Int. 68, 2444–2461 (2005). 
154 
 
33. Xu, J. & Li, Q. Review of the in Vivo Functions of the p160 Steroid Receptor 
Coactivator Family. Mol. Endocrinol. 17, 1681–1692 (2003). 
34. Ngan, V. & Goodman, R. H. CBP and p300 in Transcriptional Regulation. 
Biochemistry 5, 1–42 (2003). 
35. Yao, T.-P., Ku, G., Zhou, N., Scully, R. & Livingston, D. M. The nuclear hormone 
receptor coactivator SRC-1 is a specific target of p300. Biochemistry 93, 10626–
10631 (1996). 
36. Koppen, A. et al. Nuclear Receptor-Coregulator Interaction Profiling Identifies 
TRIP3 as a Novel Peroxisome Proliferator-activated Receptor γ Cofactor. Mol. 
Cell. Proteomics 8, 2212–2226 (2009). 
37. Wallberg, A. E., Yamamura, S., Malik, S., Spiegelman, B. M. & Roeder, R. G. 
Coordination of p300-mediated chromatin remodeling and TRAP/mediator 
function through coactivator PGC-1α. Mol. Cell 12, 1137–1149 (2003). 
38. Charos, A. E. et al. A highly integrated and complex PPARGC1A transcription 
factor binding network in HepG2 cells. Genome Res. 22, 1668–1679 (2012). 
39. Puigserver, P. & Spiegelman, B. M. Peroxisome proliferator-activated receptor-γ 
coactivator 1α (PGC-1α): Transcriptional coactivator and metabolic regulator. 
Endocr. Rev. 24, 78–90 (2003). 
40. Martínez-Jiménez, C. P., Gómez-Lechón, M. J., Castell, J. V. & Jover, R. 
Underexpressed coactivators PGC1α and SRC1 impair hepatocyte nuclear factor 
4α function and promote dedifferentiation in human hepatoma cells. J. Biol. 
Chem. 281, 29840–29849 (2006). 
41. Viswakarma, N. et al. The Med1 subunit of the mediator complex induces liver 
cell proliferation and is phosphorylated by AMP kinase. J. Biol. Chem. 288, 
27898–27911 (2013). 
42. Perissi, V. et al. Molecular determinants of nuclear receptor – corepressor 
interaction. 3198–3208 (1999). 
43. Hörlein, A. J. et al. Ligand-independent repression by the thyroid hormone 
receptor mediated by a nuclear receptor co-repressor. Nature 377, 397 (1995). 
44. Chen, J. D. & Evans, R. M. A transcriptional co-repressor that interacts with 
nuclear hormone receptors. Nature 377, 454 (1995). 
45. Li, P. et al. Adipocyte NCoR Knockout Decreases PPARγ Phosphorylation and 
Enhances PPARγ Activity and Insulin Sensitivity. Cell 147, 815–826 (2011). 
46. Rosell, M., Jones, M. C. & Parker, M. G. Role of nuclear receptor corepressor 
RIP140 in metabolic syndrome. Biochim. Biophys. Acta - Mol. Basis Dis. 1812, 
919–928 (2011). 
47. Nautiyal, J., Christian, M. & Parker, M. G. Distinct functions for RIP140 in 




48. Frkic, R. L. et al. PPARγ in Complex with an Antagonist and Inverse Agonist: A 
Tumble and Trap Mechanism of the Activation Helix. iScience 5, 69–79 (2018). 
49. Wang, Y. X. PPARs: Diverse regulators in energy metabolism and metabolic 
diseases. Cell Res. 20, 124–137 (2010). 
50. Olivier, B., Aldridge, T. C., Norbert, L. & Stephen, G. PPAR-RXR HETERODIMER 
ACTIVATES A PEROXISOME PROLIFERATOR RESPONSE ELEMENT UPSTREAM OF 
THE BIFUNCTIONAL ENZYME GENE. Biochem. Biophys. Res. Commun. 192, 37–45 
(1993). 
51. Lam, V. Q., Zheng, J. & Griffin, P. R. Unique Interactome Network Signatures for 
Peroxisome Proliferator-activated Receptor Gamma (PPARγ) Modulation by 
Functional Selective Ligands. Mol. Cell. Proteomics 16, 2098–2110 (2017). 
52. Poulsen, L. la C., Siersbæk, M. & Mandrup, S. PPARs: Fatty acid sensors 
controlling metabolism. Semin. Cell Dev. Biol. 23, 631–639 (2012). 
53. Barish, G. D. et al. PPAR d : a dagger in the heart of the metabolic syndrome Find 
the latest version : Review series PPAR δ : a dagger in the heart of the metabolic 
syndrome. J. Clin. Invest. 116, 590–597 (2006). 
54. Katsiki, N. et al. The Role of Fibrate Treatment in Dyslipidemia: An Overview. 
Curr. Pharm. Des. 19, (2013). 
55. Chen, W. et al. A metabolomic study of the PPARδ agonist GW501516 for 
enhancing running endurance in Kunming mice. Sci. Rep. 5, 1–13 (2015). 
56. Cox, R. L. Rationally designed PPARδ-specific agonists and their therapeutic 
potential for metabolic syndrome. Proc. Natl. Acad. Sci. 114, 3284–3285 (2017). 
57. Li, L. et al. Expression patterns of peroxisome proliferator-activated receptor 
gamma 1 versus gamma 2, and their association with intramuscular fat in goat 
tissues. Gene 528, 195–200 (2013). 
58. Medina-Gomez, G. et al. PPAR gamma 2 prevents lipotoxicity by controlling 
adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 3, 
0634–0647 (2007). 
59. Saraf, N., Sharma, P. K., Mondal, S. C., Garg, V. K. & Singh, A. K. Role of PPARg2 
transcription factor in thiazolidinedione-induced insulin sensitization. J. Pharm. 
Pharmacol. 64, 161–171 (2012). 
60. Lee, J. E. & Ge, K. Transcriptional and epigenetic regulation of PPARγ expression 
during adipogenesis. Cell Biosci. 4, 1–11 (2014). 
61. Peter, T., Erding, H. & Spiegelman, B. M. Stimulation of Adipogenesis by PPARy2, 
a Lipid-Activated in Fibroblasts Transcription Factor. Cell 79, 1147–1156 (1994). 
62. Brun, R. P. et al. Differential activation of adipogenesis by multiple PPAR 
isoforms. Genes Dev. 10, 974–984 (1996). 
63. Barak, Y. et al. PPARγ is required for placental, cardiac, and adipose tissue 
development. Mol. Cell 4, 585–595 (1999). 
156 
 
64. He, W. et al. Adipose-specific peroxisome proliferator-activated receptor ␥ 
knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. 
Acad. Sci. 100, 15712–15717 (2003). 
65. Imai, T. et al. Peroxisome proliferator-activated receptor gamma is required in 
mature white and brown adipocytes for their survival in the mouse. Proc Natl 
Acad Sci U S A 101, 4543-4547 (2004)..pdf. 101, 4543–4547 (2004). 
66. Tang, W. et al. White Fat Progenitors Reside in the Adipose Vasculature. Science 
(80-. ). 322, 583–586 (2009). 
67. Petrovic, N. et al. Chronic peroxisome proliferator-activated receptor γ (PPARγ) 
activation of epididymally derived white adipocyte cultures reveals a population 
of thermogenically competent, UCP1-containing adipocytes molecularly distinct 
from classic brown adipocytes. J. Biol. Chem. 285, 7153–7164 (2010). 
68. Nedergaard, J. & Cannon, B. The Changed Metabolic World with Human Brown 
Adipose Tissue: Therapeutic Visions. Cell Metab. 11, 268–272 (2010). 
69. CANNON, B. Brown Adipose Tissue: Function and Physiological Significance. 
Physiol. Rev. 84, 277–359 (2004). 
70. Nedergaard, J., Petrovic, N., Lindgren, E. M., Jacobsson, A. & Cannon, B. PPARγ in 
the control of brown adipocyte differentiation. Biochim. Biophys. Acta - Mol. 
Basis Dis. 1740, 293–304 (2005). 
71. Ohno, H., Shinoda, K., Spiegelman, B. M. & Kajimura, S. PPAR agonists induce a 
white-to-brown fat conversion through stabilization of PRDM16 protein. Cell 
Metab. 15, 395–404 (2012). 
72. Qiang, L. et al. Brown Remodeling of White Adipose Tissue by SirT1-Dependent 
Deacetylation of Pparγ. Cell 150, 620–632 (2012). 
73. Armoni, M., Harel, C. & Karnieli, E. Transcriptional regulation of the GLUT4 gene: 
from PPAR-γ and FOXO1 to FFA and inflammation. Trends Endocrinol. Metab. 18, 
100–107 (2007). 
74. Wu, Z., Xie, Y., Morrison, R. F., Bucher, N. L. R. & Farmer, S. R. PPARγ induces the 
insulin-dependent glucose transporter GLUT4 in the absence of C/EBPα during 
the conversion of 3T3 fibroblasts into adipocytes. J. Clin. Invest. 101, 22–32 
(1998). 
75. Ribon, V., Johnson, J. H., Camp, H. S. & Saltiel, A. R. Thiazolidinediones and insulin 
resistance: peroxisome proliferatoractivated receptor gamma activation 
stimulates expression of the CAP gene. Proc. Natl. Acad. Sci. U. S. A. 95, 14751–
14756 (1998). 
76. Maeda, N. et al. PPARγ Ligands Increase Expression and Plasma Concentrations 
of Adiponectin, an Adipose-Derived Protein. Diabetes 50, 2094–2099 (2001). 
77. Hollenberg, A. N. et al. Functional antagonism between CCAAT/enhancer binding 
protein-α and peroxisome proliferator-activated receptor-γ on the leptin 
promoter. J. Biol. Chem. 272, 5283–5290 (1997). 
157 
 
78. Zhang, Y. et al. A noncanonical PPARγ/RXRα-binding sequence regulates leptin 
expression in response to changes in adipose tissue mass. Proc. Natl. Acad. Sci. 
115, E6039–E6047 (2018). 
79. Hofmann, C. et al. Altered gene expression for tumor necrosis factor-alpha and 
its receptors during drug and dietary modulation of insulin resistance. 
Endocrinology 134, 264–270 (1994). 
80. Borst, S. E. The role of TNF-α in insulin resistance. Endocrine 23, 177–182 (2004). 
81. Kim, J. K. et al. Differential effects of rosiglitazone on skeletal muscle and liver 
insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 52, 1311–1318 (2003). 
82. Berkowitz, K. et al. Effect of Troglitazone on Insulin Sensitivity and Pancreatic β-
Cell Function in Women at High Risk for NIDDM. Diabetes 45, 1572–1579 (1996). 
83. Kim, H. et al. Peroxisomal Proliferator-Activated Receptor-γ Upregulates 
Glucokinase Gene Expression in β-Cells. Diabetes 51, 676–685 (2002). 
84. Way, J. M. et al. Comprehensive messenger ribonucleic acid profiling reveals that 
peroxisome proliferator-activated receptor γ activation has coordinate effects on 
gene expression in multiple insulin-sensitive tissues. Endocrinology 142, 1269–
1277 (2001). 
85. Kallwitz, E. R., McLachlan, A. & Cotler, S. J. Role of peroxisome proliferators-
activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver 
disease. World J. Gastroenterol. 14, 22–28 (2008). 
86. Mayerson, A. B. et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, 
and hepatic and skeletal muscle triglyceride content in patients with type 2 
diabetes. Diabetes 51, 797–802 (2002). 
87. Bruedigam⁎ , C., Drabek, K., van de Peppel, J. & van Leeuwen, H. Peroxisome 
proliferator-activated receptor gamma controls human osteoblast differentiation 
celerity and life span – A novel concept for aging-related thiazolidinedione-
mediated bone loss. Bone 44, S297 (2009). 
88. Patel, J. J., Butters, O. R. & Arnett, T. R. PPAR agonists stimulate adipogenesis at 
the expense of osteoblast differentiation while inhibiting osteoclast formation 
and activity. Cell Biochem. Funct. 32, 368–377 (2014). 
89. Akune, T. et al. PPARγ insufficiency enhances osteogenesis through osteoblast 
formation from bone marrow progenitors. J. Clin. Invest. 113, 846–855 (2004). 
90. Wan, Y., Chong, L. W. & Evans, R. M. PPAR-γ regulates osteoclastogenesis in 
mice. Nat. Med. 13, 1496–1503 (2007). 
91. Liu, L. et al. Rosiglitazone Inhibits Bone Regeneration and Causes Significant 
Accumulation of Fat at Sites of New Bone Formation Lichu. Calcif Tissue Int. 91, 
139–148 (2012). 
92. Lu, M. et al. Brain PPARγ Promotes Obesity and is Required for the Insulin– 
Sensitizing Effect of Thiazolidinediones. Nat Med. 17, 618–622 (2011). 
158 
 
93. Karen K. Ryan, Bailing Li, Bernadette E. Grayson, Emily K. Matter, Stephen C. 
Woods,  and R. J. S. A role for CNS PPAR γ in the regulation of energy balance. 
Nat Med. 17, 623–626 (2011). 
94. Sarafidis, P. A., Georgianos, P. I. & Lasaridis, A. N. PPAR-γ Agonism for 
Cardiovascular and Renal Protection. Cardiovasc. Ther. 29, 377–384 (2011). 
95. Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS 
coronavirus-induced lung injury. Nat. Med. 11, 875–879 (2005). 
96. Guan, Y. F. et al. Thiazolidinediones expand body fluid volume through PPARγ 
stimulation of ENaC-mediated renal salt absorption. Nat. Med. 11, 861–866 
(2005). 
97. Zhang, H. et al. Collecting duct-specific deletion of peroxisome proliferator-
activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc. 
Natl. Acad. Sci. U. S. A. 102, 9406–9411 (2005). 
98. Son, N. et al. Cardiomyocyte expression of PPAR g leads to cardiac dysfunction in 
mice Find the latest version : Cardiomyocyte expression of PPAR γ leads to 
cardiac dysfunction in mice. 117, 2791–2801 (2007). 
99. Huang, J. V., Greyson, C. R. & Schwartz, G. G. PPAR-γ as a therapeutic target in 
cardiovascular disease: evidence and uncertainty. J. Lipid Res. 53, 1738–1754 
(2012). 
100. Duan, S. Z., Ivashchenko, C. Y., Russell, M. W., Milstone, D. S. & Mortensen, R. M. 
Cardiomyocyte-specffic knockout and agonist of peroxisome proliferator-
activated receptor-γ both induce cardiac hypertrophy in mice. Circ. Res. 97, 372–
379 (2005). 
101. Ahmadian, M. et al. Pparγ signaling and metabolism: The good, the bad and the 
future. Nat. Med. 19, 557–566 (2013). 
102. Waite, K. J., Floyd, Z. E., Arbour-Reily, P. & Stephens, J. M. Interferon-γ-induced 
Regulation of Peroxisome Proliferator-activated Receptor γ and STATs in 
Adipocytes. J. Biol. Chem. 276, 7062–7068 (2001). 
103. Chang, A. J., Song, D. H. & Wolfe, M. M. Attenuation of peroxisome proliferator-
activated receptor γ (PPARγ) mediates gastrin-stimulated colorectal cancer cell 
proliferation. J. Biol. Chem. 281, 14700–14710 (2006). 
104. Kliewer, S. A. et al. A prostaglandin J2 metabolite binds peroxisome proliferator-
activated receptor γ and promotes adipocyte differentiation. Cell 83, 813–819 
(1995). 
105. Forman, B. M. et al. 15-Deoxy-Δ12,14-Prostaglandin J2is a ligand for the 
adipocyte determination factor PPARγ. Cell 83, 803–812 (1995). 
106. Waku, T., Shiraki, T., Oyama, T. & Morikawa, K. Atomic structure of mutant 
PPARγ LBD complexed with 15d-PGJ2: Novel modulation mechanism of 




107. Waku, T. et al. Structural Insight into PPARγ Activation Through Covalent 
Modification with Endogenous Fatty Acids. J. Mol. Biol. 385, 188–199 (2009). 
108. Itoh, T. et al. Structural basis for the activation of PPARgamma by oxidized fatty 
acids. Nat. Struct. Mol. Biol. 15, 924–31 (2008). 
109. Erlemann, K. R., Rokach, J. & Powell, W. S. Oxidative stress stimulates the 
synthesis of the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic 
acid by inflammatory cells. J. Biol. Chem. 279, 40376–40384 (2004). 
110. O’Flaherty, J. T. et al. 5-Oxo-ETE analogs and the proliferation of cancer cells. 
Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 1736, 228–236 (2005). 
111. Sheu, S. H., Kaya, T., Waxman, D. J. & Vajda, S. Exploring the binding site 
structure of the PPARγ ligand-binding domain by computational solvent 
mapping. Biochemistry 44, 1193–1209 (2005). 
112. Hughes, T. S. et al. An alternate binding site for PPARγ ligands. Nat Commun 359, 
1018–1026 (2015). 
113. Jang, J. Y. et al. Structural basis for differential activities of enantiomeric PPARγ 
agonists: Binding of S35 to the alternate site. Biochim. Biophys. Acta - Proteins 
Proteomics 1865, 674–681 (2017). 
114. Pan, T. & Coleman, J. E. Structure and function of the Zn(II) binding site within 
the DNA-binding domain of the GAL4 transcription factor. Proc. Natl. Acad. Sci. U. 
S. A. 86, 3145–9 (1989). 
115. Shao, D. et al. Interdomain communication regulating ligand binding by PPAR-
gamma. Nature 396, 377–380 (1998). 
116. Luckert, C., Hessel, S., Lampen, A. & Braeuning, A. Utility of an appropriate 
reporter assay: Heliotrine interferes with GAL4/upstream activation sequence-
driven reporter gene systems. Anal. Biochem. 487, 45–48 (2015). 
117. Nishikawa, J. et al. New screening methods for chemicals with hormonal 
activities using interaction of nuclear hormone receptor with coactivator. Toxicol. 
Appl. Pharmacol. 154, 76–83 (1999). 
118. Luo, Y., Batalao, A., Zhou, H. & Zhu, L. Mammalian two-hybrid system: A 
complementary approach to the yeast two- hybrid system. Biotechniques 22, 
350–352 (1997). 
119. Delerive, P. et al. Peroxisome Proliferator-activated Receptor α Negatively 
Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with 
Transcription Factors NF- κ Peroxisome Proliferator-activate. J. Biol. Chem. 274, 
32048–32054 (1999). 
120. IJpenberg, A. et al. In vivo activation of PPAR target genes by RXR homodimers. 
EMBO J. 23, 2083–2091 (2004). 
121. Michel, M. C. & Charlton, S. J. Biased agonism in drug discovery - is it too soon to 




122. Rankovic, Z., Brust, T. F. & Bohn, L. M. Biased agonism: An emerging paradigm in 
GPCR drug discovery. Bioorganic Med. Chem. Lett. 26, 241–250 (2016). 
123. Brust, R. et al. A structural mechanism for directing inverse agonism of PPARγ. 
bioRxiv (2018). doi:10.1101/245852 
124. de Vera, I. M. S. et al. Synergistic Regulation of Coregulator/Nuclear Receptor 
Interaction by Ligand and DNA. Structure 25, 1506–1518.e4 (2017). 
125. Bramlett, K. S., Wu, Y. & Burris, T. P. Ligands Specify Coactivator Nuclear 
Receptor (NR) Box Affinity for Estrogen Receptor Subtypes. Mol. Endocrinol. 15, 
909–922 (2001). 
126. Igor, G., Flores, A. M. & Aneskievich, B. J. Corepressors of Agonist-Bound Nuclear 
Receptors. Toxicol Appl Pharmacol 223, 288–298 (2007). 
127. Comley, J. TR-FRET based assays - Getting better with age. Drug Discov. World 7, 
22–37 (2006). 
128. Taosheng, C., Wen, X., Michele, A. & Martin, B. Coactivators in Assay Design for 
Nuclear Hormone Receptor Drug Discovery. Assay Drug Dev. Technol. 1, (2004). 
129. Francois, D. et al. HTRF: A Technology Tailored for Drug Discovery –A Review of 
Theoretical Aspects and Recent Applications. Curr. Chem. Genomics 3, 22–32 
(2009). 
130. Du, Y. in Protein-Protein Interactions 529–544 (Humana Press, 2015). 
131. Teichert, A. et al. Quantification of the Vitamin D Receptor # Coregulator 
Interaction Quantification of the Vitamin D Receptor-Coregulator InteracNon †. 
Society 1454–1461 (2009). doi:10.1021/bi801874n 
132. Moore, J. M. R. et al. Quantitative proteomics of the thyroid hormone receptor-
coregulator interactions. J. Biol. Chem. 279, 27584–27590 (2004). 
133. Zhang, C., Nordeen, S. K. & Shapiro, D. J. Fluorescence anisotropy microplate 
assay to investigate the interaction of full-length steroid receptor coactivator-1a 
with steroid receptors. Methods Mol Biol 977, 339–351 (2013). 
134. Houtman, R. et al. Serine-305 Phosphorylation Modulates Estrogen Receptor 
Alpha Binding to a Coregulator Peptide Array, with Potential Application in 
Predicting Responses to Tamoxifen. Mol. Cancer Ther. 11, 805–816 (2012). 
135. Broekema, M. F. et al. Profiling Of 3696 Nuclear Receptor-Coregulator 
Interactions: A Resource For Biological And Clinical Discovery. Endocrinology 9, 
397 (2018). 
136. Corso-Díaz, X. et al. Co-activator candidate interactions for orphan nuclear 
receptor NR2E1. BMC Genomics 17, 1–11 (2016). 
137. Rosenfeld, M. G., Lunyak, V. V & Glass, C. K. integrating signal-dependent 
programs of transcriptional response Sensors and signals : a coactivator / 
161 
 
corepressor / epigenetic code for integrating signal-dependent programs of 
transcriptional response. Genes Dev. 20, 1405–1428 (2006). 
138. Nagy, L. & Schwabe, J. W. R. Mechanism of the nuclear receptor molecular 
switch. Trends Biochem. Sci. 29, 317–324 (2004). 
139. Tontonoz, P. & Spiegelman, B. M. Fat and Beyond: The Diverse Biology of PPARγ. 
Annu. Rev. Biochem. 77, 289–312 (2008). 
140. Johnson, B. A. et al. Ligand-induced stabilization of PPARγ monitored by NMR 
spectroscopy: implications for nuclear receptor activation. J. Mol. Biol. 298, 187–
194 (2000). 
141. Day, C. Thiazolidinediones: A new class of antidiabetic drugs. Diabet. Med. 16, 
179–192 (1999). 
142. Brown, K. K. et al. A novel N-aryl tyrosine activator of peroxisome proliferator-
activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty 
rat. Diabetes 48, 1415–1424 (1999). 
143. Patel, H. et al. Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ 
agonist for treatment of dyslipidemia and metabolic disorders. Xenobiotica 0, 1–
10 (2017). 
144. Jaeschke, H. Troglitazone hepatotoxicity: Are we getting closer to understanding 
idiosyncratic liver injury? Toxicol. Sci. 97, 1–3 (2007). 
145. Ikeda, T. Drug-induced Idiosyncratic Hepatotoxicity: Prevention Strategy 
Developed after the Troglitazone Case. Drug Metab. Pharmacokinet. 26, 60–70 
(2011). 
146. Bach, R. G. et al. Rosiglitazone and outcomes for patients with diabetes mellitus 
and coronary artery disease in the bypass angioplasty revascularization 
investigation 2 diabetes (BARI 2D) Trial. Circulation 128, 785–794 (2013). 
147. Virk, I. S., Ruby, R. S. & Tepper, D. Rosiglitazone and heart failure: the 
controversy and clinical implications. Congest. Heart Fail. 13, 293–295 (2007). 
148. Komajda, M. et al. Heart failure events with rosiglitazone in type 2 diabetes: Data 
from the RECORD clinical trial. Eur. Heart J. 31, 824–831 (2010). 
149. Ryder, R. E. J. Pioglitazone has a dubious bladder cancer risk but an undoubted 
cardiovascular benefit. Diabet. Med. 32, 305–313 (2015). 
150. Korhonen, P. et al. Pioglitazone use and risk of bladder cancer in patients with 
type 2 diabetes: retrospective cohort study using datasets from four European 
countries. BMJ 354, i3903 (2016). 
151. An, Z., Muthusami, S., Yu, J.-R. & Park, W.-Y. T0070907, a PPAR γ inhibitor 
induced G2/M Arrest Enhances the Effect of Radiation in Human Cervical Cancer 
Cells Through Mitotic Catastrophe. Reprod. Sci. 1–10 (2014). 
doi:10.1177/1933719114525265 
152. Zaytseva, Y. Y., Wallis, N. K., Southard, R. C. & Kilgore, M. W. The PPARgamma 
162 
 
antagonist T0070907 suppresses breast cancer cell proliferation and motility via 
both PPARgamma-dependent and -independent mechanisms. Anticancer Res. 31, 
813–823 (2011). 
153. Wang, X., Sun, Y., Wong, J. & Conklin, D. S. PPARγ maintains ERBB2-positive 
breast cancer stem cells. Oncogene 32, 5512–5521 (2013). 
154. Seargent, J. M., Yates, E. A. & Gill, J. H. GW9662, a potent antagonist of PPAR??, 
inhibits growth of breast tumour cells and promotes the anticancer effects of the 
PPAR?? agonist rosiglitazone, independently of PPAR?? activation. Br. J. 
Pharmacol. 143, 933–937 (2004). 
155. Leesnitzer, L. M. et al. Functional consequences of cysteine modification in the 
ligand binding sites of peroxisome proliferator activated receptors by GW9662. 
Biochemistry 41, 6640–6650 (2002). 
156. Lee, G. et al. T0070907, a selective ligand for peroxisome proliferator-activated 
receptor γ, functions as an antagonist of biochemical and cellular activities. J. 
Biol. Chem. 277, 19649–19657 (2002). 
157. Fehlberg, S., Trautwein, S., Göke, A. & Göke, R. Bisphenol A diglycidyl ether 
induces apoptosis in tumour cells independently of peroxisome proliferator-
activated receptor-gamma, in caspase-dependent and -independent manners. 
Biochem. J. 362, 573–8 (2002). 
158. Marciano, D. P. et al. Pharmacological Repression of PPARγ Promotes 
Osteogenesis. Nat Commun 6, (2015). 
159. Xu, H. E. et al. Structural basis for antagonist mediated recruitment of nuclear co-
repressors by PPARalpha. Nature 415, 813–817 (2002). 
160. Rangwala, S M; Lazar, M. A. The dawn of the SPPARMs? Sci STKE 121, (2002). 
161. Marciano, D. P. D. P. et al. Pharmacological repression of PPARγ promotes 
osteogenesis. Nat. Commun. 6, 7443 (2015). 
162. Berger, J. P. et al. Distinct Properties and Advantages of a Novel Peroxisome 
Proliferator-Activated Protein γ Selective Modulator. Mol. Endocrinol. 17, 662–
676 (2003). 
163. Motani, A. et al. INT131: A Selective Modulator of PPARγ. J. Mol. Biol. 386, 1301–
1311 (2009). 
164. Bruning, J. B. et al. Partial Agonists Activate PPAR?? Using a Helix 12 Independent 
Mechanism. Structure 15, 1258–1271 (2007). 
165. Kroker, A. J. & Bruning, J. B. Review of the Structural and Dynamic Mechanisms 
of PPARgamma Partial Agonism. PPAR Res. 2015, 816856 (2015). 
166. Choi, J. H. et al. Anti-Diabetic Actions of a Non-Agonist PPARγ Ligand Blocking 
Cdk5-Mediated Phosphorylation. Nature 477, 477–481 (2012). 
167. Acton, J. J. et al. Benzoyl 2-methyl indoles as selective PPARγ modulators. 
Bioorganic Med. Chem. Lett. 15, 357–362 (2005). 
163 
 
168. Rangwala, S. M. et al. Genetic modulation of PPARγ phosphorylation regulates 
insulin sensitivity. Dev. Cell 5, 657–663 (2003). 
169. Burns, K. A. & Vanden Heuvel, J. P. Modulation of PPAR activity via 
phosphorylation. Biochim Biophys Acta 1771, 952–960 (2007). 
170. Ohshima, T., Koga, H. & Shimotahno, K. Transcriptional activity of peroxisome 
proliferator-activated receptor γ is modulated by SUMO-1 modification. J. Biol. 
Chem. 279, 29551–29557 (2004). 
171. Katafuchi, T. et al. PPAR{gamma}-K107 SUMOylation regulates insulin sensitivity 
but not adiposity in mice [Physiology]. Proc. Natl. Acad. Sci. U. S. A. (2018). 
doi:10.1073/pnas.1814522115 
172. Pascual, G. et al. A sumoylation-dependent pathway mediating transrepression 
of inflammatory response genes by PPARγ. Nature 437, 759–763 (2005). 
173. Diezko, R. & Suske, G. Ligand Binding Reduces SUMOylation of the Peroxisome 
Proliferator-activated Receptor γ (PPARγ) Activation Function 1 (AF1) Domain. 
PLoS One 8, (2013). 
174. Choi, J. H. et al. Obesity-linked phosphorylation of PPARγ by cdk5 is a direct 
target of the anti-diabetic PPARγ ligands. Nature 466, 451–456 (2010). 
175. Bórquez, D. A. et al. Bioinformatic survey for new physiological substrates of 
Cyclin-dependent kinase 5. Genomics 101, 221–228 (2013). 
176. Mottin, M., Souza, P. C. T. & Skaf, M. S. Molecular Recognition of PPAR?? by 
Kinase Cdk5/p25: Insights from a Combination of Protein-Protein Docking and 
Adaptive Biasing Force Simulations. J. Phys. Chem. B 119, 8330–8339 (2015). 
177. Choi, J. H. et al. Thrap 3 docks on phosphoserine 273 of PPAR γ and controls 
diabetic gene programming. Genes Dev. 28, 2361–2369 (2014). 
178. Choi, S. S. et al. A novel non-agonist peroxisome proliferator-activated receptor γ 
(PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 
(CDK5) and improves insulin sensitivity. J. Biol. Chem. 289, 26618–26629 (2014). 
179. Eaton, S. L. et al. A Guide to Modern Quantitative Fluorescent Western Blotting 
with Troubleshooting Strategies. J. Vis. Exp. 1–10 (2014). doi:10.3791/52099 
180. Filho, H. V. R. et al. Screening for PPAR non-agonist ligands followed by 
characterization of a hit, AM-879, with additional no-adipogenic and cdk5-
mediated phosphorylation inhibition properties. Front. Endocrinol. (Lausanne). 9, 
(2018). 
181. Prokoph, N. et al. Development of an ELISA for High-Throughput Screening of 
Inhibitors of Cdk5-Mediated PPAR? Phosphorylation. Assay Drug Dev. Technol. 
14, 261–272 (2016). 
182. Li, X., Xu, B., Wang, Y. & Wei, L. Anti-inflammatory effect of peroxisome 
proliferator-activated receptor-γ (PPAR-γ) on non-obese diabetic mice with 
Sjogren’s syndrome. Int. J. Clin. Exp. Pathol. 7, 4886–4894 (2014). 
164 
 
183. Yang, S. et al. Pioglitazone ameliorates Aβ42 deposition in rats with diet-induced 
insulin resistance associated with AKT/GSK3β activation. Mol. Med. Rep. 15, 
2588–2594 (2017). 
184. Kapadia, R. Mechanisms of anti-inflammatory and neuroprotective actions of 
PPAR-gamma agonists. Front. Biosci. 13, 1813 (2008). 
185. Chung, S. W. et al. Oxidized Low Density Lipoprotein Inhibits Interleukin-12 
Production in Lipopolysaccharide-activated Mouse Macrophages via Direct 
Interactions between Peroxisome Proliferator-activated Receptor-γ and Nuclear 
Factor-κB. J. Biol. Chem. 275, 32681–32687 (2000). 
186. Annese, V., Rogai, F., Settesoldi, A. & Bagnoli, S. PPAR γ in inflammatory bowel 
disease. PPAR Res. 2012, (2012). 
187. Dammann, K. et al. PAK1 modulates a PPARγ/NF-κB cascade in intestinal 
inflammation. Biochim. Biophys. Acta - Mol. Cell Res. 1853, 2349–2360 (2015). 
188. Scirpo, R. et al. Stimulation of nuclear receptor PPAR- γ limits NF-kB-dependent 
inflammation in mouse cystic fibrosis biliary epithelium. Hepatology 62, 1551–
1562 (2015). 
189. Karmakar, S., Jin, Y. & Nagaich, A. K. Interaction of glucocorticoid receptor (GR) 
with estrogen receptor (ER) ?? and activator protein 1 (AP1) in dexamethasone-
mediated interference of ER?? activity. J. Biol. Chem. 288, 24020–24034 (2013). 
190. Ohshima, K., Mogi, M. & Horiuchi, M. Role of Peroxisome Proliferator-Activated 
Receptor-gamma in Vascular Inflammation. Int J Vasc Med 2012, 508416 (2012). 
191. Carta, A. R. PPAR-γ: Therapeutic Prospects in Parkinson’s Disease. Curr. Drug 
Targets 14, 743–751 (2013). 
192. Breidert, T. et al. Protective action of the peroxisome proliferator-activated 
receptor-γ agonist pioglitazone in a mouse model of Parkinson’s disease. J. 
Neurochem. 82, 615–624 (2002). 
193. Nicolakakis, N. et al. Complete Rescue of Cerebrovascular Function in Aged 
Alzheimer’s Disease Transgenic Mice by Antioxidants and Pioglitazone, a 
Peroxisome Proliferator-Activated Receptor   Agonist. J. Neurosci. 28, 9287–9296 
(2008). 
194. Steinmetz, A. C., Renaud, J. P. & Moras, D. Binding of ligands and activation of 
transcription by nuclear receptors. Annu. Rev. Biophys. Biomol. Struct. 30, 329–
359 (2001). 
195. Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are 
there? Nat. Rev. Drug Discov. 5, 993–996 (2006). 
196. Nettles, K. W. & Greene, G. L. Ligand Control of Coregulator Recruitment To 
Nuclear Receptors. Annu. Rev. Physiol. 67, 309–333 (2005). 
197. Brzozowski,  a M. et al. Molecular basis of agonism and antagonism in the 
oestrogen receptor. Nature 389, 753–758 (1997). 
165 
 
198. Shiau, A. K. et al. The structural basis of estrogen receptor/coactivator 
recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927–
937 (1998). 
199. Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H. & Moras, D. Crystal 
structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. 
Nature 375, 377–382 (1995). 
200. Xu, H. E. et al. Structural basis for antagonist-mediated recruitment of nuclear 
co-repressors by PPARα. Nature 415, 813–817 (2002). 
201. Bain, D. L., Heneghan, A. F., Connaghan-Jones, K. D. & Miura, M. T. Nuclear 
Receptor Structure: Implications for Function. Annu. Rev. Physiol 69, 201–20 
(2007). 
202. Kroker, A. J. & Bruning, J. B. Review of the Structural and Dynamic Mechanisms 
of PPARγ Partial Agonism. PPAR Res. 2015, 816856 (2015). 
203. Kojetin, D. J. & Burris, T. P. Small molecule modulation of nuclear receptor 
conformational dynamics: implications for function and drug discovery. Mol. 
Pharmacol. 83, 1–8 (2013). 
204. Choi, J. H. et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of 
PPARgamma by Cdk5. Nature 466, 451–456 (2010). 
205. Wright, E. et al. Helix 11 dynamics is critical for constitutive androstane receptor 
activity. Structure 19, 37–44 (2011). 
206. Zhang, J. et al. DNA binding alters coactivator interaction surfaces of the intact 
VDR-RXR complex. Nat. Struct. Mol. Biol. 18, 556–63 (2011). 
207. Hughes, T. S. et al. Ligand and receptor dynamics contribute to the mechanism of 
graded PPARγ agonism. Structure 20, 139–150 (2012). 
208. Hughes, T. S. et al. An alternate binding site for PPARγ ligands. Nat. Commun. 5, 
3571 (2014). 
209. Berger, J. P. et al. Distinct properties and advantages of a novel peroxisome 
proliferator-activated protein [gamma] selective modulator. Mol Endocrinol 17, 
662–676 (2003). 
210. Sharaf, N. G. & Gronenborn, A. M. in Methods in Enzymology 565, 67–95 (2015). 
211. Kim, T. H. et al. The role of ligands on the equilibria between functional states of 
a G protein-coupled receptor. J. Am. Chem. Soc. 135, 9465–9474 (2013). 
212. Nygaard, R. et al. The dynamic process of ??2-adrenergic receptor activation. Cell 
152, 532–542 (2013). 
213. Manglik, A. et al. Structural Insights into the Dynamic Process of β2-Adrenergic 
Receptor Signaling. Cell 161, 1101–11 (2015). 
214. Liu, J. J., Horst, R., Katritch, V., Stevens, R. C. & Wüthrich, K. Biased signaling 




215. Kitevski-LeBlanc, J. L. & Prosser, R. S. Current applications of 19F NMR to studies 
of protein structure and dynamics. Prog. Nucl. Magn. Reson. Spectrosc. 62, 1–33 
(2012). 
216. Lehmann, J. M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for 
peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 
270, 12953–12956 (1995). 
217. Brust, R. et al. Modification of the Orthosteric PPARγ Covalent Antagonist 
Scaffold Yields an Improved Dual-Site Allosteric Inhibitor. ACS Chem. Biol. 12, 
969–978 (2017). 
218. Liberato, M. V. et al. Medium chain fatty acids are selective peroxisome 
proliferator activated receptor (PPAR) gamma activators and Pan-PPAR partial 
agonists. PLoS One 7, e36297 (2012). 
219. Hughes, T. S., Wilson, H. D., De Vera, I. M. S. & Kojetin, D. J. Deconvolution of 
complex 1D NMR spectra using objective model selection. PLoS One 10, 
e0134474 (2015). 
220. Evanics, F. et al. Tryptophan solvent exposure in folded and unfolded states of an 
SH3 domain by 19F and 1H NMR. Biochemistry 45, 14120–14128 (2006). 
221. Bruning, J. B. et al. Partial Agonists Activate PPARγ Using a Helix 12 Independent 
Mechanism. Structure 15, 1258–1271 (2007). 
222. Evanics, F., Kitevski, J. L., Bezsonova, I., Forman-Kay, J. & Prosser, R. S. 19F NMR 
studies of solvent exposure and peptide binding to an SH3 domain. Biochim. 
Biophys. Acta - Gen. Subj. 1770, 221–230 (2007). 
223. Henzler-Wildman, K. & Kern, D. Dynamic personalities of proteins. Nature 450, 
964–972 (2007). 
224. Hwan Bae, Jun Young Jang, Sun-Sil Choi, Jae-Jin Lee, Heejun Kim, Ala Jo, Kong-Joo 
Lee, Jang Hyun Choi, S. W. S. and S. B. P. Mechanistic elucidation guided by 
covalent inhibitors for the development of anti-diabetic PPARγ ligands. Chem. 
Sci. 7, 5523–5529 (2016). 
225. Nielsen, R. et al. Genome-wide profiling of PPARγ:RXR and RNA polymerase II 
occupancy reveals temporal activation of distinct metabolic pathways and 
changes in RXR dimer composition during adipogenesis. Genes Dev. 22, 2953–
2967 (2008). 
226. Song, Y. & Dai, L. L. The shear viscosities of common water models by non-
equilibrium molecular dynamics simulations. Mol. Simul. 36, 560–567 (2010). 
227. Batista, M. R. B. & Martínez, L. Conformational Diversity of the Helix 12 of the 
Ligand Binding Domain of PPARγ and Functional Implications. J. Phys. Chem. B 
119, 15418–15429 (2015). 
228. Ye, L., Van Eps, N., Zimmer, M., Ernst, O. P. & Scott Prosser, R. Activation of the 
167 
 
A2A adenosine G-protein-coupled receptor by conformational selection. Nature 
533, 1–15 (2016). 
229. Staus, D. P. et al. Allosteric nanobodies reveal the dynamic range and diverse 
mechanisms of G-protein-coupled receptor activation. Nature 535, 448–452 
(2016). 
230. Kojetin, D. J. et al. Structural mechanism for signal transduction in RXR nuclear 
receptor heterodimers. Nat Commun 6, 8013 (2015). 
231. Glasoe, P. K. & Long, F. A. USE OF GLASS ELECTRODES TO MEASURE ACIDITIES IN 
DEUTERIUM OXIDE1,2. J. Phys. Chem. 64, 188–190 (1960). 
232. Motulsky, H. J. & Brown, R. E. Detecting outliers when fitting data with nonlinear 
regression – a new method based on robust nonlinear regression and the false 
discovery rate. BMC Bioinformatics 7, 123 (2006). 
233. Owen, S. C. et al. Colloidal drug formulations can explain ‘bell-shaped’ 
concentration-response curves. ACS Chem. Biol. 9, 777–784 (2014). 
234. Helgstrand, M., Härd, T. & Allard, P. Simulation of NMR pulse sequences during 
equilibrium and non-equilibrium chemical exchange. J. Biomol. NMR 18, 49–63 
(2000). 
235. Fernandez-Fuentes, N. & Fiser, A. Modeling Loops in Protein Structures. Introd. 
to Protein Struct. Predict. 279–298 (2010). doi:10.1002/9780470882207.ch13 
236. Pettersen, E. F. et al. UCSF Chimera—A visualization system for exploratory 
research and analysis. J. Comput. Chem. 25, 1605–1612 (2004). 
237. Anandakrishnan, R., Aguilar, B. & Onufriev, A. V. H++ 3.0: Automating pK 
prediction and the preparation of biomolecular structures for atomistic 
molecular modeling and simulations. Nucleic Acids Res. 40, 537–541 (2012). 
238. D.A. Case, V. Babin, J.T. Berryman, R.M. Betz, Q. Cai, D.S. Cerutti, T.E. Cheatham, 
III, T.A. Darden, R. E., Duke, H. Gohlke, A.W. Goetz, S. Gusarov, N. Homeyer, P. 
Janowski, J. Kaus, I. Kolossváry, A. K., T.S. Lee, S. LeGrand, T. Luchko, R. Luo, B. 
Madej, K.M. Merz, F. Paesani, D.R. Roe, A. Roitberg, C. S., R. Salomon-Ferrer, G. 
Seabra, C.L. Simmerling, W. Smith, J. Swails, R.C. Walker, J. Wang, R.M. Wolf, X. & 
Kollman, W. and P. A. AMBER 14. (2014). 
239. Vanquelef, E. et al. R.E.D. Server: A web service for deriving RESP and ESP 
charges and building force field libraries for new molecules and molecular 
fragments. Nucleic Acids Res. 39, W511-7 (2011). 
240. Cornell, W. D., Cieplak, P., Bayly, C. I. & Kollman, P. A. Application of RESP 
Charges To Calculate Conformational Energies, Hydrogen Bond Energies, and 
Free Energies of Solvation. J. Am. Chem. Soc. 115, 9620–9631 (1993). 
241. Wang, J. M., Wolf, R. M., Caldwell, J. W., Kollman, P. a & Case, D. a. Development 




242. Maier, J. A. et al. ff14SB: Improving the Accuracy of Protein Side Chain and 
Backbone Parameters from ff99SB. J. Chem. Theory Comput. 11, 3696–3713 
(2015). 
243. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. 
Comparison of simple potential functions for simulating liquid water. J. Chem. 
Phys. 79, 926–935 (1983). 
244. Joung, I. S. & Cheatham, T. E. Determination of alkali and halide monovalent ion 
parameters for use in explicitly solvated biomolecular simulations. J. Phys. Chem. 
B 112, 9020–9041 (2008). 
245. Roe, D. R. & Cheatham, T. E. PTRAJ and CPPTRAJ: Software for processing and 
analysis of molecular dynamics trajectory data. J. Chem. Theory Comput. 9, 3084–
3095 (2013). 
246. Trott, O. & Olson, A. AutoDock Vina: inproving the speed and accuracy of docking 
with a new scoring function, efficient optimization and multithreading. J. 
Comput. Chem. 31, 455–461 (2010). 
247. Ryckaert, J. P., Ciccotti, G. & Berendsen, H. J. C. Numerical integration of the 
cartesian equations of motion of a system with constraints: molecular dynamics 
of n-alkanes. J. Comput. Phys. 23, 327–341 (1977). 
248. Govindan, M. V, Devic, M., Green, S., Gronemeyer, H. & Chambon, P. Cloning of 
the human glucocorticoid receptor cDNA. Nucleic Acids Res. 13, (1985). 
249. Chan, J. S. K. et al. Targeting nuclear receptors in cancer-associated fibroblasts as 
concurrent therapy to inhibit development of chemoresistant tumors. Oncogene 
37, 160–173 (2018). 
250. Dhiman, V. K., Bolt, M. J. & White, K. P. Nuclear receptors in cancer - Uncovering 
new and evolving roles through genomic analysis. Nat. Rev. Genet. 19, 160–174 
(2018). 
251. Jin, H. S., Kim, T. S. & Jo, E. K. Emerging roles of orphan nuclear receptors in 
regulation of innate immunity. Arch. Pharm. Res. 39, 1491–1502 (2016). 
252. Sonoda, J., Pei, L. & Evans, R. M. Nuclear receptors: Decoding metabolic disease. 
FEBS Lett. 582, 2–9 (2008). 
253. Hong, C. & Tontonoz, P. Coordination of inflammation and metabolism by PPAR 
and LXR nuclear receptors. Curr. Opin. Genet. Dev. 18, 461–467 (2008). 
254. Bernal, J. Thyroid hormone receptors in brain development and function. Nat. 
Clin. Pract. Endocrinol. &Amp; Metab. 3, 249 (2007). 
255. Zanaria, E. et al. An unusual member of the nuclear hormone receptor 
superfamily responsible for X-linked adrenal hypoplasia congenita. Nature 372, 
635 (1994). 
256. Haider, N. B. et al. Mutation of a nuclear receptor gene, NR2E3, causes enhanced 
S cone syndrHaider, N. B., Jacobson, S. G., Cideciyan, a V, Swiderski, R., Streb, L. 
169 
 
M., Searby, C., … Sheffield, V. C. (2000). Mutation of a nuclear receptor gene, 
NR2E3, causes enhanced S cone . Nat. Genet. 24, 127–131 (2000). 
257. Burris, T. P. & McCabe, E. R. B. Nuclear Receptors and Genetic Disease. (2000). 
258. Achermann, J. C., Schwabe, J., Fairall, L. & Chatterjee, K. Genetic disorders of 
nuclear receptors. J. Clin. Invest. 127, 1181–1192 (2017). 
259. Gurnell, M., Krishna, V. & Chatterjee, K. Nuclear receptors in disease: thyroid 
receptor beta, peroxisome-proliferator-activated receptor gamma and orphan 
receptors. Essays Biochem. 40, 169–189 (2004). 
260. Petrosino, M. et al. Single-nucleotide polymorphism of PPARγ, a protein at the 
crossroads of physiological and pathological processes. Int. J. Mol. Sci. 18, 1–20 
(2017). 
261. Overington, J. P., Al-lazikani, B. & Hopkins, A. L. How many drug targets are 
there? Nat. Rev. Drug Discov. 5, 993–996 (2006). 
262. Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug 
Discov. 16, 19–34 (2016). 
263. Lonard, D. M. & O’Malley, B. W. Nuclear receptor coregulators: modulators of 
pathology and therapeutic targets. Nat. Rev. Endocrinol. 8, 598 (2012). 
264. Dasgupta, S., Lonard, D. M. & O’Malley, B. W. Nuclear Receptor Coactivators: 
Master Regulators of Human Health and Disease. Annu. Rev. Med. 65, 279–292 
(2014). 
265. Plevin, M. J., Mills, M. M. & Ikura, M. The LxxLL motif: a multifunctional binding 
sequence in transcriptional regulation. Trends Biochem. Sci. 30, 66–69 (2005). 
266. Chang, C. et al. Dissection of the LXXLL Nuclear Receptor-Coactivator Interaction 
Motif Using Combinatorial Peptide Libraries: Discovery of Peptide Antagonists of 
Estrogen Receptors α and β. Mol. Cell. Biol. 19, 8226–8239 (1999). 
267. Webb, P. et al. The nuclear receptor corepressor (N-CoR) contains three 
isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs). Mol. 
Endocrinol. 14, 1976–1985 (2000). 
268. Nagy, L. et al. Mechanism of corepressor binding and release from nuclear 
hormone receptors. Genes Dev. 13, 3209–3216 (1999). 
269. Bunce, C. M. & Campbell, M. J. Nuclear Receptors: Current Concepts and Future 
Challenges. (Springer Science and Business Media, 2010). 
270. Leers, J., Treuter, E. & Gustafsson, J. A. Mechanistic principles in NR box-
dependent interaction between nuclear hormone receptors and the coactivator 
TIF2. Mol. Cell. Biol. 18, 6001–13 (1998). 
271. Wansa, K. D. S. A., Harris, J. M., Yan, G., Ordentlich, P. & Muscat, G. E. O. The AF-
1 Domain of the Orphan Nuclear Receptor NOR-1 Mediates Trans-activation, 
Coactivator Recruitment, and Activation by the Purine Anti-metabolite 6-
Mercaptopurine. J. Biol. Chem. 278, 24776–24790 (2003). 
170 
 
272. Weatherman, R. V, Fletterick, R. J. & Scanlan, T. S. NUCLEAR-RECEPTOR LIGANDS 
AND LIGAND-BINDING DOMAINS Ross. Annu. Rev. Biochem. 68, 559–581 (1999). 
273. Moras, D. & Gronemeyer, H. The nuclear receptor ligand-binding domain: 
Structure and function. Curr. Opin. Cell Biol. 10, 384–391 (1998). 
274. Wang, L. et al. X-ray crystal structures of the estrogen-related receptor-γ ligand 
binding domain in three functional states reveal the molecular basis of small 
molecule regulation. J. Biol. Chem. 281, 37773–37781 (2006). 
275. Wu, Y., Chin, W. W., Wang, Y. & Burris, T. P. Ligand and coactivator identity 
determines the requirement of the charge clamp for coactivation of the 
peroxisome proliferator-activated receptor ?? J. Biol. Chem. 278, 8637–8644 
(2003). 
276. Crooks, G., Hon, G., Chandonia, J. & Brenner, S. WebLogo: a sequence logo 
generator. Genome Res 14, 1188–1190 (2004). 
277. Holt, J. A. et al. Helix 1/8 interactions influence the activity of nuclear receptor 
ligand-binding domains. J. Control. Release 17, 1704–1714 (2003). 
278. Agostini, M. et al. Tyrosine agonists reverse the molecular defects associated 
with dominant-negative mutations in human peroxisome proliferator-activated 
receptor γ. Endocrinology 145, 1527–1538 (2004). 
279. Salentin, S., Schreiber, S., Haupt, V. J., Adasme, M. F. & Schroeder, M. PLIP: Fully 
automated protein-ligand interaction profiler. Nucleic Acids Res. 43, W443–
W447 (2015). 
280. Gelin, M. et al. Combining ‘dry’ co-crystallization and in situ diffraction to 
facilitate ligand screening by X-ray crystallography. Acta Crystallogr. Sect. D Biol. 
Crystallogr. 71, 1777–1787 (2015). 
281. Haffner, C. D. et al. Structure-Based Design of Potent Retinoid X Receptor α 
Agonists. J. Med. Chem. 47, 2010–2029 (2004). 
282. Chrisman, I. M. et al. Defining a conformational ensemble that directs activation 
of PPARγ. Nat. Commun. 9, 1–16 (2018). 
283. Torchia, J. et al. The transcriptional co-activator p/CIP binds CBP and mediates 
nuclear- receptor function. Nature 387, 677–684 (1997). 
284. Otwinoski, Z. & Minor, W. Processing of X-ray diffraction data collected in 
oscillation mode. Methods Enzymol. 276, 307–326 (1997). 
285. Adams, P. D. et al. PHENIX: A comprehensive Python-based system for 
macromolecular structure solution. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 
213–221 (2010). 
286. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of 
Coot. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 486–501 (2010). 
287. Read, R. J. Improved Fourier Coefficients for Maps Using Phases from Partial 
Structures with Errors By. Acta Cryst. 42, 140–149 (1986). 
171 
 
288. Kawai, M. & Rosen, C. J. PPARγ: a circadian transcription factor in adipogenesis 
and osteogenesis. Nat. Rev. Endocrinol. 6, 629–36 (2010). 
289. Bookout, A. L. et al. Anatomical profiling of nuclear receptor expression reveals a 
hierarchical transcriptional network. Cell 126, 789–799 (2006). 
290. Holzer, G., Markov, G. V. & Laudet, V. Evolution of Nuclear Receptors and Ligand 
Signaling: Toward a Soft Key–Lock Model? Current Topics in Developmental 
Biology 125, (Elsevier Inc., 2017). 
291. Millard, C. J., Watson, P. J., Fairall, L. & Schwabe, J. W. R. An evolving 
understanding of nuclear receptor coregulator proteins. J. Mol. Endocrinol. 51, 
(2013). 
292. Burris, T. P. et al. Nuclear Receptors and Their Selective Pharmacologic 
Modulators. Pharmacol. Rev. Pharmacol Rev 65, 710–778 (2013). 
293. Huang, P., Chandra, V. & Rastinejad, F. Structural overview of the nuclear 
receptor superfamily: insights into physiology and therapeutics. Annu. Rev. 
Physiol. 72, 247–272 (2010). 
294. Kaupang, Å., Laitinen, T., Poso, A. & Hansen, T. V. Structural review of PPARγ in 
complex with ligands: Cartesian- and dihedral angle principal component 
analyses of X-ray crystallographic data. Proteins Struct. Funct. Bioinforma. 85, 
1684–1698 (2017). 
295. Trump, R. P. et al. Co-crystal structure guided array synthesis of PPARgamma 
inverse agonists. Bioorg. Med. Chem. Lett. 17, 3916–20 (2007). 
296. Brust, R. et al. A structural mechanism for directing corepressor-selective inverse 
agonism of PPARγ. Nat. Commun. 9, 4687 (2018). 
297. Zhi, X. et al. Structural basis for corepressor assembly by the orphan nuclear 
receptor TLX. Genes Dev. 29, 440–450 (2015). 
298. Kim, J. Y., Son, Y. L., Kim, J. S. & Lee, Y. C. Molecular Determinants Required for 
Selective Interactions between the Thyroid Hormone Receptor Homodimer and 
the Nuclear Receptor Corepressor N-CoR. J. Mol. Biol. 396, 747–760 (2010). 
299. Madauss, K. P. et al. A Structural and in Vitro Characterization of Asoprisnil: A 
Selective Progesterone Receptor Modulator. Mol. Endocrinol. 21, 1066–1081 
(2007). 
300. Zhang, H., Chen, L., Chen, J., Jiang, H. & Shen, X. Structural basis for retinoic X 
receptor repression on the tetramer. J. Biol. Chem. 286, 24593–24598 (2011). 
301. Schoch, G. A. et al. Molecular Switch in the Glucocorticoid Receptor: Active and 
Passive Antagonist Conformations. J. Mol. Biol. 395, 568–577 (2010). 
302. Noguchi, M. et al. Ternary complex of human RORγ ligand-binding domain, 
inverse agonist and SMRT peptide shows a unique mechanism of corepressor 
recruitment. Genes to Cells 22, 535–551 (2017). 
303. Lori, C. et al. Structural basis of the transactivation deficiency of the human 
172 
 
PPARγ F360L mutant associated with familial partial lipodystrophy. Acta 
Crystallogr. Sect. D Biol. Crystallogr. 70, 1965–1976 (2014). 
304. Batista, M. R. B., Mart??nez, L. & Martínez, L. Conformational Diversity of the 
Helix 12 of the Ligand Binding Domain of PPARγ and Functional Implications. J. 
Phys. Chem. B 119, 15418–15429 (2015). 
305. Pierce, L. C. T., Salomon-Ferrer, R., Augusto F. de Oliveira, C., McCammon, J. A. & 
Walker, R. C. Routine Access to Millisecond Time Scale Events with Accelerated 
Molecular Dynamics. J. Chem. Theory Comput. 8, 2997–3002 (2012). 
306. Choi, J. H. et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of 
PPARγ by Cdk5. Nature 466, 451–456 (2010). 
307. Pike, A. C. W. et al. Structure of the ligand-binding domain of oestrogen receptor 
beta in the presence of a partial agonist and a full antagonist. EMBO J. 18, 4608–
4618 (1999). 
308. Roe, D. R., Cheatham III, T. E. & Cheatham, T. E. PTRAJ and CPPTRAJ: software for 
processing and analysis of molecular synamics trajectory data. J Chem Theory 
Com 9, 3084–3095 (2013). 
309. Ye, L., Larda, S. T., Frank Li, Y. F., Manglik, A. & Prosser, R. S. A comparison of 
chemical shift sensitivity of trifluoromethyl tags: optimizing resolution in 19F 
NMR studies of proteins. J. Biomol. NMR 62, 97–103 (2015). 
310. Anthis, N. J. & Clore, G. M. Visualizing transient dark states by NMR 
spectroscopy. Q. Rev. Biophys. 48, 35–116 (2015). 
311. Lowe, D. M., Winter, G. & Fersht, A. R. Structure-Activity Relationships in 
Engineered Proteins: Characterization of Disruptive Deletions in the a-
Ammonium Group Binding Site of Tyrosyl-tRNA Synthetase. Biochemistry 26, 
6038–6043 (1987). 
312. Berger, J. et al. A PPARγ mutant serves as a dominant negative inhibitor of PPAR 
signaling and is localized in the nucleus. Mol. Cell. Endocrinol. 162, 57–67 (2000). 
313. Masugi, J., Tamori, Y. & Kasuga, M. Inhibition of adipogenesis by a COOH-
terminally truncated mutant of PPARγ2 in 3T3-L1 cells. Biochem. Biophys. Res. 
Commun. 264, 93–99 (1999). 
314. Zhang, J., Hu, X. & Lazar, M. a. A novel role for helix 12 of retinoid X receptor in 
regulating repression. Mol. Cell. Biol. 19, 6448–57 (1999). 
315. Fersht, A. R. Relationships between Apparent Binding Energies Measured in Site-
Directed Mutagenesis Experiments and Energetics of Binding and Catalysis. 
Biochemistry 27, 1577–1580 (1988). 
316. Creighton, T. E. Proteins: Structures and Molecular Properties. (1992). 
317. Mottis, A., Mouchiroud, L. & Auwerx, J. Emerging roles of the corepressors 
NCoR1 and SMRT in homeostasis. Genes Dev. 27, 819–835 (2013). 
318. Pochetti, G. et al. Structural insight into peroxisome proliferator-activated 
173 
 
receptor γ binding of two ureidofibrate-like enantiomers by molecular dynamics, 
cofactor interaction analysis, and site-directed mutagenesis. J. Med. Chem. 53, 
4354–4366 (2010). 
319. Maier, J. A. et al. ff14SB: Improving the Accuracy of Protein Side Chain and 
Backbone Parameters from ff99SB. J. Chem. Theory Comput. 11, 3696–3713 
(2015). 
320. Joung, S. & Cheatham, T. E. Molecular dynamics simulations of the dynamic and 
energetic properties of alkali and halide ions using water-model-specific ion 
parameters. J. Phys. Chem. B 113, 13279–13290 (2009). 
321. Miao, Y. et al. Improved reweighting of accelerated molecular dynamics 
simulations for free energy calculation. J. Chem. Theory Comput. 10, 2677–2689 
(2014). 
322. Liang, H. et al. Whole body overexpression of PGC-1  has opposite effects on 
hepatic and muscle insulin sensitivity. AJP Endocrinol. Metab. 296, E945–E954 
(2009). 
323. Acton, J. J. et al. Benzoyl 2-methyl indoles as selective PPARγ modulators. 




Chapter 7: Appendices 
7.1 Supplementary material for chapter 2 
Data in this section has been published in Nature Communications DOI: 
10.1038/s41467-018-04176-x 
Supplementary Information for 
 
Defining a conformational ensemble that directs activation of PPARγ 
 
 
Ian M. Chrisman, Michelle D. Nemetchek, Ian Mitchelle S. de Vera, Jinsai Shang,  
Zahra Heidari, Yanan Long, Hermes Reyes-Caballero, Rodrigo Galindo-Murillo, 
Thomas E. Cheatham III, Anne-Laure Blayo, Youseung Shin, Jakob Fuhrmann, 







Supplementary Figure 1 | The fluorine NMR spectrum of Y505C C313S PPARγ LBD is 
largely ligand independent. a) Y505C C313S PPARγ LBD was labeled with BTFA and fluorine 
NMR was performed at ~376 MHz at room temperature either in apo form (blue spectrum) or in 
the presence of two agonists (rosiglitazone; red and MRL20; green). b) Y505 is located at the 
unstructured C-terminus of the PPARγ LBD, which likely contributes to the relative lack of 






Supplementary Figure 2 | Influence of crystal packing on PPARγ LBD helix 12 
conformation. The PPARγ LBD often crystalizes as a homodimer where helix 12 of the 
symmetry-related B chain (helix 12*) associates with the AF-2 surface of the A chain (a), adopting 
a conformation similar to a coactivator peptide bound to the AF-2 surface (b). This crystallization 
artifact distorts the conformation of the B chain helix 12* and influences the conformation of the 
A chain helix 12 through the formation of “charge clamp” hydrogen bonds with a positively 
charged (Lys301) of A chain helix 3 and negatively charged (Glu471) residues of A chain helix 
12. This creates a dipolar coactivator mimicking protein-protein interaction (δ+/δ-) between 
monomeric subunits that is further stabilized by hydrophobic interactions originating from Leu468 
and Ile472 of B chain helix 12*, which biases the observed structure into an “active” (A chain) or 
“pseudo-inactive” (B chain) helix 12 conformation. (c) Chain A and (d) chain B forms of PPARγ 





Supplementary Figure 3 | Molecular dynamics simulations indicate that the “agonist” helix 
12 crystal conformation results in a solvent exposed side chain zeta nitrogen of residue K502 
and terminal carbon of K502C-BTFA. (a) PPARγK502C-BTFA bound to GW1929 was simulated 
in explicit water and salts for ~12 μs and clustered into five clusters by label (cysteine-BTFA) 
position. Representative structures from the two most populated clusters (1 and 2 89% of total 
frames) are shown. The percent of the total simulation time spent in each cluster is highlighted.  
The trifluoromethyl of the BTFA label and the ligand are highlighted. Fluorine atoms are green. 
The remaining 11% of the frames are similar to those in cluster 1 and 2 except for a cluster of 3% 
of the frames where the BTFA is near the ligand and has very low solvent exposure. (b) The CF3 
group of K502C-BTFA is on the surface of the protein in these two clusters (c) Solvent exposure 
analysis of the PPARγK502C-BTFA simulation. The number of solvent molecules (water and ions) 
within 5 angstroms of the trifluoromethyl carbon of BTFA, and terminal carbons on the indicated 
amino acids and a randomly chosen water molecule are shown. (d) Three independent simulations 
were performed of GW1929 bound to PPARγ LBD totaling ~25 μs. The number of solvent 
molecules (water and ions) within 5 angstroms of the zeta Nitrogen of K502, other control lysines, 
including one pointing into the ligand binding pocket (buried Lysine), and a randomly chosen 
water molecule are also shown. (e) Representative structures from clustering of the PPARγK502C-
BTFA simulation according to helix 12 RMSD into five clusters along with a crystal structure of 




Supplementary Figure 4 | 19F NMR indicates that K502C is preferentially labeled over C313 
by BTFA and PPARγK502C without BTFA label is not active in TR-FRET. PPARγK502C which 
contains a native cysteine (C313), and an introduced cysteine (K502C) was incubated with either 
(a) 10x or (b) 2x molar ratio of BTFA. (c) PPARγC313A,K502C which contains a single cysteine 
(K502C) was incubated with 10x BTFA. The PPARγC313A,K502C-BTFA  spectrum is very similar to 
the 2x BTFA treated PPARγK502C in panel b indicating that K502C is labeled preferentially. The 
spectra shown in panel b and c are shown in other figures in this manuscript (d) PPARγK502C was 
prepared for use in functional assays (TR-FRET and FP) or NMR and loaded with either 1.1 to 
1.25 molar equivalents of MRL24 (which contains a CF3 group; left peak). The signal from 
MRL24 (left peak) and BTFA (right peak) were integrated (red numbers in figure). The integral of 
the left peak indicates the amount of protein, while the right peak indicates the fraction labeled. (e) 
Ligand dependent recruitment of NCOR or MED1 peptide to PPARγK502C (no BTFA) or 
PPARγK502C-BTFA was measured using TR-FRET for select ligands. The failure of non-BTFA 
labeled PPARγK502C to produce a TR-FRET signal was also seen in two other separate TR-FRET 
experiments using GW1929. Mean of two technical replicates and standard deviation are shown. 
(f) The non-BTFA labeled PPARγK502C used in panel e has the expected affinity for NCOR as 
measured by fluorescence polarization (also see Supplementary Figure 7b) (g) Comparison of 
PPARγC313A,K502C-BTFA (green; only labeled on C502) with PPARγK502C-BTFA2x that was loaded 
first with indicated ligands and then exposed to a 2x molar ratio of BTFA (blue; presumably 
labeled only on C502) and PPARγK502C-BTFA10x that was exposed to a 10x molar ratio and then 
loaded with the indicated ligands (red; presumably labeled on both C502 and C313). PPARγK502C-
BTFA2x is more similar to PPARγC313A,K502C-BTFA than PPARγK502C-BTFA10x in all cases 
except for the ligands which covalently attach to C313. (Dimethylformamide; DMF and Dimethyl 
sulfoxide; DMSO). The narrow peak at ~-83.3 ppm is free BTFA. All spectra displayed in panel g 





Supplementary Figure 5 | Covalent ligands do not bind to C502, DMSO has a minimal effect 
on TR-FRET, and signal from any BTFA labeled contaminating protein is undetectable. (a-
b) The indicated molar ratios of a) T0070907 or b) GW9662 were added to PPARγK502C followed 
by labeling with 10x BTFA. The percent of the total signal area found in the left peak is indicated 
in panel a. (c) TR-FRET demonstrates that ligand vehicle (DMSO) has negligible impact on 
coregulator recruitment to apo PPARγ LBD. Three technical replicates are shown along with the 
mean. (d) PPARγC313A LBD (no cysteines) without (purple) or with (red) 6x histidine tag was 
treated with 10x molar ratio of BTFA and measured with fluorine NMR using the same processing 
and acquisition parameters as PPARγC313A,K502C-BTFA not bound to ligand (blue) or bound to 
GW1929 (green). Cleavage of the 6x histidine tag increases the purity of the protein because after 
cleavage the prep is re-run over the nickel column and contaminating proteins stick to the column 
while PPAR flows through. The difference in purity that histidine cleavage makes is large, with 
virtually no contaminating protein detected after cleavage. All spectra shown in this work except 
supplementary figure 2 used proteins with the histidine tag cleaved off, thus, NMR signal from 
impurities would not be expected to be observed, however any signal from protein impurities 
would be expected to be broad and centered at ~-84.35ppm as shown here. A small broad upfield 
shifted peak around ~-84.35 ppm appears inconsistently in deconvolutions of some spectra. As 
demonstrated by this control, it is possible, but not likely, that this signal near -84.35 ppm 
originates from a small amount of contaminating protein that is labeled with BTFA. Inset displays 
zoomed view of main figure. The * denotes signal from free BTFA. The blue and green spectra in 





Supplementary Figure 6 | TR-FRET indicates that labeled proteins are functional, that 
PPARγK502C-BTFA is most functionally similar to PPARγ. (a) Titration of PPARγC313A,K502C-
BTFA and PPARγK502C-BTFA with a diverse set of ligands in the TR-FRET assay using NCoR or 
MED1 biotinylated peptides and His-tagged PPARγ LBD (EC50 values are shown in 
Supplementary Table 3). (b) Titration of PPARγ, PPARγC313A,K502C-BTFA and PPARγK502C-BTFA 
with a subset of ligands in the TR-FRET assay using CBP biotinylated peptides and His-tagged 
PPARγ LBD (EC50 values are shown in Supplementary Table 4). (c) Titration of the ligands into 
protein (as labeled) preloaded with fluorescently labeled ligand (Fluormone Pan-PPAR Green) 
was used to determine Ki values for ligands to the proteins. Fitted Ki values are displayed in 
Supplementary Table 1. Mean and standard deviation (n=2) are shown along with fitted curve (see 
methods). Error bars represent the standard deviation between two technical replicates in a single 
experiment. The competition assay to determine Ki values was performed a single time. The TR-
FRET with PPARγK502C-BTFA and PPARγC313A,K502C-BTFA was performed three times with 
similar results. TR-FRET with CBP was performed two times with similar results. (d-f) 
Comparison of PPARγ, PPARγK502C-BTFA and PPARγC313A,K502C-BTFA TR-FRET ratios at 
saturating ligand concentrations for (d) MED1 (e) CBP and (f) NCoR. Correlation coefficient is 




Supplementary Figure 7 | Fluorescence polarization indicates that labeled proteins are 
functional, that PPARγK502C-BTFA is most similar to PPARγ and that SMRT binding is 
perturbed by labeling. (a) Comparison of PPARγ with PPARγK502C-BTFA and PPARγC313A,K502C-
BTFA affinity for MED1, NCoR and SMRT peptides either without ligand or saturated with 
T0070907, GW1929 or INT-131 as measured by fluorescence polarization. Assays involving 
SMRT peptide recruitment also included rosiglitazone and MRL24. Error bars represent standard 
deviation of 2 (SMRT and wt NCoR) or 3 (PPARγC313A,K502C-BTFA NCoR and MED1) 
independently run assays. Correlation coefficient is indicated (R2). (b) Comparison of peptide 
affinities for wt and labeled/mutant versions of PPARγ either ligand free or saturated with the 
indicated ligands. Significant differences between wt and the labeled/mutant PPARγ are indicated 





Supplementary Figure 8 | 19F NMR spectra of PPARγC313A,K502C-BTFA bound to 16 
pharmacologically distinct ligands is similar to PPARγK502C-BTFA. The PPARγC313A,K502C-
BTFA spectra are higher signal to noise than the PPARγK502C-BTFA spectra because the C313A 
mutation allows complete labeling with higher BTFA concentrations without spurious labeling of 
C313 (Supplementary Fig. 4). GQ16 used DMF for a vehicle. All other ligands used DMSO. 
DMSO and DMF concentrations are the same in all spectra. This DMSO spectrum is also 
displayed in other figures in this manuscript. The estimated degree of saturation with ligand in 
these spectra is shown in Supplementary Table 2. Some of these spectra were replicated 





Supplementary Figure 9 | NMR indicates that delipidation produces a small difference in 
backbone structure and in coregulator recruitment. (a-b) Protein was delipidated (red spectra) 
or not (blue spectra) and then loaded with the indicated ligand or not loaded with ligand (Apo). 2D 
[1H,15N]-TROSY-HSQC NMR spectra (Bruker pulse program trosyf3gpphsi19.2) of (a) 15N-
labeled PPARγ LBD or (b) 15N-labeled PPARγC313A-BTFA. Apo spectra are shown at two 
different contour levels in panel a for clarity of changes vs. liganded states. Insets in panel b show 
19F NMR spectra of the same sample. Sharp upfield shifted peaks marked with an asterisk in panel 
b are likely misfolded protein or another artifact. (c) PPARγ LBD was delipidated or not 
delipidated prior to measuring coregulator recruitment in response to ligand titration via TR-
FRET. No significant difference is observed. Mean ± SE shown. Error bars represent the standard 
deviation of two technical replicates. TR-FRET was repeated in two independent experiments with 





Supplementary Figure 10 | NMR samples are stable over time and replicate samples from 
different protein preparations produce very similar spectra.  Fluorine NMR was collected on 
(a) PPARγK502C-BTFA or (b) PPARγC313A,K502C-BTFA loaded with the indicated ligands initially 
(blue) and then after two to nine days of storage at room temperature (red). The changes in the E. 
coli lipid panel are likely due to lipid precipitation after unbinding from PPARγ. The blue spectra 
are displayed in other figures in this manuscript. (c-d) Replicate samples from the same or 
different protein preparations. (c) replicate samples using PPARγK502C-BTFA and (d) 
PPARγC313A,K502C-BTFA (* denote samples from different protein preparations). Spectra are scaled 
relative to each other for ease of comparison. All of the spectra in panels c and d are shown 
elsewhere in this manuscript except for one of the spectra each of pioglitazone and nTZDpa bound 





Supplementary Figure 11 | PPARγC313A,Q322C-BTFA recruits coregulators with similar 
efficacy to that of wild type PPARγ and the apo PPARγC313A,Q322C-BTFA spectrum is stable 
over time. (a) TR-FRET ratio change with increased ligand concentration indicates a change in 
affinity between the indicated peptide and delipidated PPARγC313A,Q322C-BTFA induced by ligand 
binding. (b) 19F NMR spectra of delipidated apo PPARγC313A,Q322C-BTFA initially and then after 3 
days at ambient temperature. The * indicates free BTFA signal. Error bars represent the standard 
deviation of two technical replicates in a single experiment. TR-FRET was performed twice in two 






Supplementary Figure 12 | Chemical exchange occurs between 19F NMR resolved peaks. 
Chemical Exchange Saturation Transfer (CEST) was performed on probes on helix 12 (a,d,e) and 
on helix 3 (c). (a) Both on (-83.062 ppm) and off (-85.052 ppm) resonance selective saturating 
pulses were performed and the height of the smaller peak (-84.07 ppm) in the 19F spectrum of 
T0070907-bound PPARγK502C-BTFA was monitored (left panel). The p value of a two-tailed t-
test comparing the mean intensity (shown) of the smaller peak with on and off resonance selective 
pulses is shown. While exchange is detected, the exchange is likely very slow, resulting in very 
small changes in intensity of the small peak. (b) Calculation to determine the detection limits of 
CEST in our system. The intensity of a peak (peak A) as a function of the rate of exchange with a 
peak that is selectively saturated (peak B) normalized by the intensity of peak A in the absence of 
exchange (Ao). Calculations are shown using T1 values of 400 ms (red) and 350 ms (black) and a 
1.6 second selective saturation pulse (which is what was used in the CEST figures). Calculation 
was done using Equation 50 from (Journal of Biomolecular NMR 2000 18:49-63). Given 
experimental noise and peak A and B sharpness in our experiments exchange may be difficult to 
reliably detect with exchange rates less than ~0.4 s-1 (I/Io>0.86; indicated by dotted vertical line in 
graph). In addition, exchange rates faster than 10 s-1 can be detected but may be difficult to 
quantify given that we used 50 ms selective pulses. (c-e) Exchange rates are indicated with 95% 
confidence interval in parentheses. An off resonance soft pulse equidistant from the peak of 
interest (green) was subtracted from an on resonance soft pulse (red) to yield Veff (purple). Fits 
were carried out fixing T1 at the experimentally verified rate (Supplementary Table 5) and 
experimentally obtained non-exchange intensity. Thus, only one parameter was fit leaving 6 






Supplementary Figure 13 | 19F NMR was performed on samples of the indicated protein and 
ligand complexes in the presence of 10% (upper panel), 50% (middle panel), or 100% (lower 
panel) deuterium oxide (D2O). Vertical lines indicate the chemical shift of select peaks at 10% 
D2O concentration and are included to aid in comparison of peak position between different D2O 





Supplementary Figure 14 | Ligand-directed helix 12 ensemble dictates PPARγC313A,K502C-
BTFA-coregulator interaction. (a) Plot of mean 19F NMR chemical shift values 
(PPARγC313A,K502C-BTFA) versus TR-FRET endpoint data for the recruitment of MED1, NCoR 
and CBP peptides to PPARγC313A,K502C-BTFA (top panels) and wt PPARγ LBD (bottom panels) for 
the set of 16 pharmacologically distinct synthetic PPARγ ligands and apo-protein (select ligands 
for CBP). TR-FRET was performed in three separate experiments for MED1 and NCoR 
recruitment and two separate experiments for CBP with similar results. b) Plot of mean 19F NMR 
chemical shift values (PPARγC313A,K502C-BTFA) versus MED1, NCoR and SMRT peptide 
dissociation constant (Kd) for PPARγK502C-BTFA (top panels) and wt PPARγ LBD (bottom 
panels) as measured by fluorescence polarization (FP) for a subset of the ligands in panel a. Mean 
and standard deviation for FP represent 2 (NCOR binding to PPARγC313A,K502C-BTFA and SMRT) 
or 3 (NCOR binding to wt and MED1) independent replications. Linear regression fit is shown as 
a solid line and the correlation coefficient (R2) for the fitted line is indicated. Covalent ligands, 
which require C313 for binding are not included in the wt graphs as the NMR chemical shift 






Supplementary Figure 15 | Molecular simulations of PPARγ LBD bound to (a) T0070907 
(covalent inverse agonist) alone or co-bound to the corepressor peptide NCoR (lower panel) 
or (b) apo or apo bound to NCoR (lower panel). The root mean square deviation of helix 12 
compared to the conformation of helix 12 in the crystal structure that was used to build these 
molecules (chain B of 3B0R and 1PRG). Each color represents an independent simulation started 
from the same coordinates but with different initial atom velocities. Apo without NCoR stays the 
closest to the starting crystal structure.  




























































Supplementary Figure 16 | Synthetic PPARγ ligands and 19F label used in this study. a-q) 
Chemical structures of the ligands used in this study. r) Chemical structure of the 3-bromo-1,1,1-




Supplementary Table 1 | Effect of labeling on ligand affinity 















Pioglitazone 247 428 412 121 696 1137 6 9 
Rosiglitazone 32 81 516 16 132 1422 8 92 
Ciglitazone 9930 >50uM 9034 4875 >50uM 24921 36 5 
Troglitazone 4699 8723 6387 2306 14177 17619 6 8 
INT-131 5 66 22 3 107 60 41 23 
nTZDpa 21 19 44 10 31 123 3 12 
GQ-16 8481 2171 8873 4163 3528 24477 1 6 
BVT.13  10105 7087 7641 4960 11518 21079 2 4 
SR10221 292 282 314 143 458 866 3 6 
GW1929 2 3 5 1 5 13 5 12 
SR2088 33 45 68 16 74 189 5 12 
SR2595 110 80 352 54 130 972 2 18 
^GW9662 6 14 33204 NA NA NA similar EC50 large change in 
EC50 
^T0070907 15 25 >50uM NA NA NA similar EC50 large change in 
EC50 
SR1664 131 74 551 64 120 1519 2 24 
MRL24 0.9 1.3 1.4 0.5 2 4 5 8 
      median 5 11 
      mean 9 17 
 NA = Not applicable 
 
#Given that 8nM protein was used in determining EC50 values in this table any EC50 less than 4 nM indicates that the true EC50 
is ≤ 4 nM. 
 




Supplementary Table 2 | Fraction of protein bound by ligand for NMR samples 
 
Assumes all added 
ligand is soluble. 
Assumes 10 µM 


















Pioglitazone 1.00 0.99 0.96 0.94 1.00 0.89 
Rosiglitazone 1.00 0.94 0.99 0.93 1.00 0.95 
Ciglitazone 0.55 0.81 0.37 0.69 *1.00 *0.96 
Troglitazone 0.92 0.85 0.76 0.74 0.74 0.81 
INT-131 1.00 1.00 0.99 0.99 1.00 1.00 
nTZDpa 1.00 0.99 1.00 0.99 1.00 1.00 
GQ-16 0.93 0.71 0.89 0.69 #0.57 #0.29 
BVT.13 
Pentahydrate 
0.84 0.73 0.79 0.71 0.65 0.69 
SR10221 0.99 0.96 0.97 0.95 1.00 1.00 
GW1929 1.00 1.00 1.00 1.00 1.00 1.00 
SR2088 1.00 0.99 0.99 0.98 1.00 ND 
SR2595 1.00 0.96 0.99 0.95 1.00 1.00 
^GW9662 1.00 NA 1.00 NA 0.90 NA 
^T0070907 1.00 NA 1.00 NA 1.00 NA 
SR1664 1.00 0.94 0.99 0.93 1.00 1.00 
MRL24 1.00 1.00 1.00 1.00 1.00 0.86 
Vehicle (DMSO) 
    
##0.21 ##0.25 
 
Fraction bound is calculated using Ki values for ligands. 
*Discrepancy between NMR and calculation is likely a combination of inaccurate deconvolution and 
good solubility of ciglitazone (Cayman Chemical states that ciglitazone is soluble to 1.2mM in 25% 
DMSO). 
^Covalent ligands were added at 2x and so are assumed to be fully bound based on EC50 values, this 
is supported by LC-ESI MS data. 
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# GQ16 has very poor solubility, which would explain the low bound fraction observed via NMR. 




Supplementary Table 3 | EC50 values for MED1 and NCOR recruitment 
Coregulat
or 
















190 420 2 970 5 350 2200 6 1,200 3 
Rosiglitaz
one 
13 29 2 99 8 21 96 5 1,200 57 
Ciglitazon
e 
4200 7400 2 1800 <1 2,70
0 
15,000 6 14,000 5 
Troglitazo
ne 
580 2600 4 1400 2 1,10
0 
6,600 6 4,600 4 
INT-131 7 1 <1 18 2 2 3 1 38 19 
nTZDpa* 8 <1 <1 <1 <1 4 8 2 47 12 
GQ-16 730 1600 2 NC NA 1,90
0 










9,300 <1 19,000 <1 
SR10221 8 NC N
A 
4 <1 2 28 14 28 14 
GW1929 3 4 1 3 1 2 10 5 91 46 
SR2088 23 50 2 37 1 13 34 3 120 9 
SR2595 100 NC N
A 
680 7 75 34 <1 590 8 
GW9662# 4 NC N
A 





>50,000 NA 13 66 5 NC NA 
SR1664 180 NC N
A 
5600 31 NC 99 N
A 
535 NA 





  2  1   5  9 
Mean 
change§  




  5  15 
 NA=not applicable 
NC=no significant change in TR-FRET ratio was observed, which does not 
allow curve fitting, which is expected for non-agonists and for non-agonists and 
inverse agonists in the MED1 assay. 
*Data indicates two recruitment events. The EC50 is shown for the initial 
peptide recruitment event only. The second recruitment event likely is caused by 
binding of a second ligand to the same PPARγ molecule208. 
# these ligands form a covalent adduct to C313 and should not bind to 
PPARγC313A,K502C-BTFA. 
**Given that 8nM protein was used in determining EC50 values in this table any 
EC50 less than 4 nM indicates that the true EC50 is ≤ 4 nM. 





Supplementary Table 4 | EC50 values for CBP recruitment  
Coregulator CBP EC50 (nM)** 
PPARγ 
variant 
wt PPARγK502C-BTFA Fold 
change 
PPARγC313A,K502C-BTFA Fold change 
Rosiglitazon
e 
2 4 2 11 8 
INT-131 <1 <1 1 <1 1 
GW1929 <1 <1 1 <1 1 
T0070907# 2 4 2 41,000 21,000 













 *Data indicates two recruitment events. The EC50 is shown for the initial peptide recruitment 
event only. The second recruitment event likely is caused by binding of a second ligand to the 
same PPARγ molecule208. 
# this ligand forms a covalent adduct to C313 and should not bind to PPARγC313A,K502C-BTFA. 
**Given that 8nM protein was used in determining EC50 values in this table any EC50 less than 4 
nM indicates that the true EC50 is ≤ 4 nM. 


















from T2 value 











4.9 (4.6 to 
5.3) 




 -84.33 ppm 
6.2 (5.7 to 
6.7) 




 -84.38 ppm 
17.6 (16.9 
to 18.4) 




-84.06 ppm  
3.1 (2.9 to 
3.4) 





2.2 (2.0 to 
2.3) 
135 to 152 174 415 (396 to 
434) 
*Decovoluted peak widths are all slightly wider than the T2 predicted linewidth — if they were narrower, this 
would indicate over-fitting of the data. Thus, the deconvolution provides a fit with the least number of 
possible peaks (i.e. the number of chemical environments, or conformations) sampled by the BTFA probe 






Parameters used in simulations 
 
&cntrl                                                                         
  imin = 0, nstlim = 250000000, dt=0.004,                                       
  ntx = 5, irest = 1,                                                           
  ntwx = 25000, ioutfm = 1, ntxo =2, ntpr = 25000, ntwr = 25000,                
  iwrap = 1, nscm = 1000,                                                       
  ntc = 2, ntf = 2, ntb = 2, cut = 8.0,                                         
  ntt = 3, ig = -1, gamma_ln = 3, temp0 = 310, tempi = 310,                     
  ntp = 1, taup = 2.0, barostat = 2,                                            
  igb = 0, saltcon = 0.0,                                                       




    0    0    2 
 
This is a remark line 
molecule.res 
CYB   INT  0 
CORRECT     OMIT DU   BEG 
  0.0000 
   1  DUMM  DU    M    0  -1  -2     0.000      .0        .0      .00000 
   2  DUMM  DU    M    1   0  -1     1.449      .0        .0      .00000 
   3  DUMM  DU    M    2   1   0     1.523   111.21       .0      .00000 
199 
 
   4  N     N     M    3   2   1     1.540   111.208  -180.000 -0.415700 
   5  H     H     E    4   3   2     1.001   128.253    75.116  0.271900 
   6  CA    CT    M    4   3   2     1.453    46.684    -6.789  0.021300 
   7  HA    H1    E    6   4   3     1.085   106.975   -51.989  0.112400 
   8  CB    CT    3    6   4   3     1.532   114.777    70.403 -0.052400 
   9  HB2   H1    E    8   6   4     1.083   111.004   -48.445  0.125000 
  10  HB3   H1    E    8   6   4     1.080   109.153    70.321  0.125000 
  11  SG    S     S    8   6   4     1.820   113.917  -171.908 -0.275000 
  12  CD    CT    3   11   8   6     1.812    99.158    84.434 -0.125700 
  13  HD2   H1    E   12  11   8     1.085   111.557   -58.090  0.067200 
  14  HD3   H1    E   12  11   8     1.085   110.619    60.963  0.067200 
  15  CE    C     B   12  11   8     1.510   111.238  -178.762  0.509200 
  16  O1    O     E   15  12  11     1.181   125.861    -0.134 -0.397100 
  17  CZ    CT    3   15  12  11     1.537   114.766   179.713  0.511800 
  18  F3    F     E   17  15  12     1.323   109.977    58.455 -0.191500 
  19  F1    F     E   17  15  12     1.305   111.986   179.382 -0.191500 
  20  F2    F     E   17  15  12     1.324   109.860   -59.791 -0.191500 
  21  C     C     M    6   4   3     1.534   104.761  -167.409  0.597300 






   CD   CZ   CE   O1 







AMBER parameter database derived frcmod file 
 
Remark line goes here 
MASS 
N  14.010        0.530 
H  1.008         0.161 
CT 12.010        0.878 
H1 1.008         0.135 
S  32.060        2.900 
C  12.010        0.616 
O  16.000        0.434 
F  19.000        0.320 
 
BOND 
H -N   434.00   1.010 
CT-N   337.00   1.449 
CT-H1  340.00   1.090 
CT-CT  310.00   1.526 
C -CT  317.00   1.522 
CT-S   227.00   1.810 
C -O   570.00   1.229 





H1-CT-N    50.000     109.500 
CT-CT-N    80.000     109.700 
C -CT-N    63.000     110.100 
CT-N -H    50.000     118.040 
CT-CT-H1   50.000     109.500 
CT-CT-S    50.000     114.700 
CT-C -O    80.000     120.400 
C -CT-H1   50.000     109.500 
C -CT-CT   63.000     111.100 
CT-S -CT   62.000      98.900 
H1-CT-H1   35.000     109.500 
H1-CT-S    50.000     109.500 
CT-C -CT   63.000     117.000 
F -CT-F    77.000     109.100 
 
DIHE 
H1-CT-CT-N    9    1.400         0.000           3.000 
N -CT-CT-S    9    1.400         0.000           3.000 
O -C -CT-N    6    0.000         0.000           2.000 
H1-CT-N -H    6    0.000         0.000           2.000 
CT-CT-N -H    6    0.000         0.000           2.000 
C -CT-N -H    6    0.000         0.000           2.000 
CT-CT-S -CT   3    1.000         0.000           3.000 
H1-CT-CT-H1   9    1.400         0.000           3.000 
H1-CT-CT-S    9    1.400         0.000           3.000 
O -C -CT-H1   1    0.800         0.000          -1.000 
O -C -CT-H1   1    0.000         0.000          -2.000 
202 
 
O -C -CT-H1   1    0.080       180.000           3.000 
O -C -CT-CT   6    0.000         0.000           2.000 
H1-CT-S -CT   3    1.000         0.000           3.000 
C -CT-S -CT   3    1.000         0.000           3.000 
C -CT-CT-H1   9    1.400         0.000           3.000 
C -CT-CT-S    9    1.400         0.000           3.000 
O -C -CT-S    6    0.000         0.000           2.000 
CT-C -CT-S    6    0.000         0.000           2.000 
CT-C -CT-F    6    0.000         0.000           2.000 
CT-C -CT-H1   6    0.000         0.000           2.000 
O -C -CT-F    6    0.000         0.000           2.000 
 
IMPROPER 
CT-CT-C -O         10.5          180.0         2.0          Using general improper torsional 
angle  X- X- C- O, penalty score=  6.0) 
 
NONBON 
  N           1.8240  0.1700 
  H           0.6000  0.0157 
  CT          1.9080  0.1094 
  H1          1.3870  0.0157 
  S           2.0000  0.2500 
  C           1.9080  0.0860 
  O           1.6612  0.2100 
  F           1.7500  0.0610       
 
GAFF parameter database derived frcmod file 
203 
 
Remark line goes here 
MASS 
N  14.010        0.530               same as n   
H  1.008         0.161               same as hn  
CT 12.010        0.878               same as c3  
H1 1.008         0.135               same as h1  
S  32.060        2.900               same as ss  
C  12.010        0.616               same as c   
O  16.000        0.434               same as o   
F  19.000        0.320               same as f   
 
BOND 
H -N   403.20   1.013       same as hn- n, penalty score=  0.0 
CT-N   328.70   1.462       same as c3- n, penalty score=  0.0 
CT-H1  330.60   1.097       same as c3-h1, penalty score=  0.0 
CT-CT  300.90   1.538       same as c3-c3, penalty score=  0.0 
C -CT  313.00   1.524       same as  c-c3, penalty score=  0.0 
CT-S   215.90   1.839       same as c3-ss, penalty score=  0.0 
C -O   637.70   1.218       same as  c- o, penalty score=  0.0 
CT-F   356.90   1.350       same as c3- f, penalty score=  0.0 
 
ANGLE 
H1-CT-N    49.840     108.880   same as h1-c3-n , penalty score=  0.0 
CT-CT-N    65.910     111.610   same as c3-c3-n , penalty score=  0.0 
C -CT-N    67.000     109.060   same as c -c3-n , penalty score=  0.0 
CT-N -H    45.800     117.680   same as c3-n -hn, penalty score=  0.0 
CT-CT-H1   46.390     109.560   same as c3-c3-h1, penalty score=  0.0 
204 
 
CT-CT-S    61.300     110.270   same as c3-c3-ss, penalty score=  0.0 
CT-C -O    67.400     123.200   same as c3-c -o , penalty score=  0.0 
C -CT-H1   47.040     108.220   same as c -c3-h1, penalty score=  0.0 
C -CT-CT   63.270     111.040   same as c -c3-c3, penalty score=  0.0 
CT-S -CT   60.240      99.240   same as c3-ss-c3, penalty score=  0.0 
H1-CT-H1   39.240     108.460   same as h1-c3-h1, penalty score=  0.0 
H1-CT-S    42.060     108.760   same as h1-c3-ss, penalty score=  0.0 
C -CT-S    61.850     108.840   same as c -c3-ss, penalty score=  0.0 
CT-C -CT   62.040     116.500   same as c3-c -c3, penalty score=  0.0 
C -CT-F    66.260     110.000   same as c -c3-f , penalty score=  0.0 
F -CT-F    70.890     107.360   same as f -c3-f , penalty score=  0.0 
 
DIHE 
H1-CT-CT-N    9    1.400         0.000           3.000      same as X -c3-c3-X , penalty 
score=  0.0 
N -CT-CT-S    9    1.400         0.000           3.000      same as X -c3-c3-X , penalty 
score=  0.0 
O -C -CT-N    6    0.000       180.000           2.000      same as X -c -c3-X , penalty 
score=  0.0 
H1-CT-N -H    6    0.000         0.000           2.000      same as X -c3-n -X , penalty 
score=  0.0 
CT-CT-N -H    6    0.000         0.000           2.000      same as X -c3-n -X , penalty 
score=  0.0 
C -CT-N -H    6    0.000         0.000           2.000      same as X -c3-n -X , penalty 
score=  0.0 
CT-CT-S -CT   3    1.000         0.000           3.000      same as X -c3-ss-X , penalty 
score=  0.0 
H1-CT-CT-H1   9    1.400         0.000           3.000      same as X -c3-c3-X , penalty 
score=  0.0 
205 
 
H1-CT-CT-S    9    1.400         0.000           3.000      same as X -c3-c3-X , penalty 
score=  0.0 
O -C -CT-H1   1    0.800         0.000          -1.000      same as h1-c3-c -o  
O -C -CT-H1   1    0.000         0.000          -2.000      same as h1-c3-c -o  
O -C -CT-H1   1    0.080       180.000           3.000      same as h1-c3-c -o , penalty 
score=  0.0 
O -C -CT-CT   6    0.000       180.000           2.000      same as X -c -c3-X , penalty 
score=  0.0 
H1-CT-S -CT   3    1.000         0.000           3.000      same as X -c3-ss-X , penalty 
score=  0.0 
C -CT-S -CT   3    1.000         0.000           3.000      same as X -c3-ss-X , penalty 
score=  0.0 
C -CT-CT-H1   9    1.400         0.000           3.000      same as X -c3-c3-X , penalty 
score=  0.0 
C -CT-CT-S    9    1.400         0.000           3.000      same as X -c3-c3-X , penalty 
score=  0.0 
O -C -CT-S    6    0.000       180.000           2.000      same as X -c -c3-X , penalty 
score=  0.0 
CT-C -CT-S    6    0.000       180.000           2.000      same as X -c -c3-X , penalty 
score=  0.0 
CT-C -CT-F    6    0.000       180.000           2.000      same as X -c -c3-X , penalty 
score=  0.0 
CT-C -CT-H1   6    0.000       180.000           2.000      same as X -c -c3-X , penalty 
score=  0.0 
O -C -CT-F    6    0.000       180.000           2.000      same as X -c -c3-X , penalty 
score=  0.0 
 
IMPROPER 





  N           1.8240  0.1700             same as n   
  H           0.6000  0.0157             same as hn  
  CT          1.9080  0.1094             same as c3  
  H1          1.3870  0.0157             same as h1  
  S           2.0000  0.2500             same as ss  
  C           1.9080  0.0860             same as c   
  O           1.6612  0.2100             same as o   
  F           1.7500  0.0610             same as f   




7.2 Supplementary material for chapter 3 
Data in this section is in final preparation for publication. 
Supplementary information for  
Helix 4 determines the specificity of coactivator interactions in 
nuclear receptors 
 





Figure S1. Consensus logos of the helix 4 motif in nuclear receptors. A: The consensus logo of 
the 8-residue motif on helix 4 for all 40 NR which are thought to bind coregulators on the AF-2 
surface. In one NR, DAX1, this motif has expanded to be 9-residues and cannot be aligned. Of the 
remaining seven the motif cannot be located in two and is degenerate in five others. All NR where 
the motif is degenerate are not thought to bind coregulators on the AF-2 surface. B: Consensus 
logo of the helix 4 motif for the NR1 family of NR. This shows a much higher degree of 
conservation in this family relative to other NR families. C: Consensus logo of the helix 4 motif 
for the NR2 family. D: Consensus logo of the helix 4 motif for the NR2 family with TR4 omitted. 
This protein has a highly degenerate sequence in this region and has been shown not to bind 
coregulators on the AF-2 surface. E: Consensus logo of the helix 4 motif for the NR3 family. This 
motif is the least conserved in this family which may indicate the least homology in coregulator 
interactions within an NR family. This is merely hypothetical however and would require further 






















Coup TF1 (NR2F1) TDQVSLLR 246-253 No structures  
Coup TF2 (NR2F2) TDQVSLLR 239-246 No coregulator  
ERBAL2 (NR2F6) ADQVALLR 229-236 No structures  
DAX1 (NR0B1) LDQQLVLVR 280-288 No coregulators  
Estrogen receptor 
α (NR3A1) 
HDQVHLLE 373-380 NCoA1, NCoA2 4TUZ, 5KR9 
Estrogen receptor 
β (NR3A2) 

















HEDQIALLK 318-325 NCoA2, NCoA1 5WZX/5Q0A/ 
3OOF 







NCoA2, NCoR 3MNR, 3H52,  
4CSJ, 3K22, 
3E7C 
HNFα (NR2A1) DDQVALLR 205-212 NCoA1 1PZL 
HNFγ (NR2A2) DDQVALLR 166-173 No coregulators  
LRH1 (NR5A2) DDQMKLLQ 372-379 Dax1, SRC2 4RWV, 3PLZ 
LXRα (NR1H3) EDQIALLK 284-291 NCoA1 3IPQ 
LXRβ (NR1H2) REDQIALLK 298-305 NCoA1 4DK7 
Mineralocorticoid 
receptor (NR3C2) 
EDQITLIQ 796-803 NCoA1 5L7E 
NOR1 (NR4A3) EDQTLLIE 464-471 No structures  
NURR1 (NR4A1) ADQDLLFE 433-440 No coregulators  
NUR77 (NR4A2) ADQDLLLE 433-440 No coregulators  
PGR (NR3C3) DDQITLIQ 745-752 SMRT 4OAR 
PNR (NR2E3) RDQVILLE 247-254 No coregulators  
PPARα (NR1C1) NDQVTLLK 303-310 NCoA1 3FEI, 3G8I 
PPARγ (NR1C3) NDQVTLLK 312-319 MED1  
PPARδ (NR1C2) NDQVTLLK 276-283 No coregulators  
PXR (NR1I2) EDQISLLK 270-277 NCoA1 5X0R, 2O9I 
RARα (NR1B1) ADQITLLK 255-262 SMRT, NCoA1- No 
interactions 
 




NCoA1 4DM6, 4JYI 




Figure S2. Conserved helix 4 motif in all nuclear receptors. For all human nuclear receptors, 
listed alphabetically in left column, the eight-residue helix 4 sequence is shown along with the 
residue numbers this motif covers. Bolded residues are those which are resolved to interact with 
coregulator peptides in crystal structures. The coregulators listed are those which show interaction 
and the PDB accession numbers for the crystal structures these interactions were identified in are 
provided. For those proteins which have been crystallized with coregulators but show no helix 4 
interactions (ERRγ, RARα, REV-ERBα and RXRβ) all coregulators that have been crystallized 
with this protein are listed. In one case, DAX1, this motif has expanded to include one extra 
residue. For the proteins GCNF and TR2 this motif is highly degenerate and cannot be located due 
to the lack of crystal structures. 
  
REV-ERBα (NR1D1) HDQVNLLK 466-473 NCoR- No interactions  
REV-ERBβ (NR1D2) HDQVNLLK 432-439 No coregulators  
RORα (NR1F1) QNDQIVLLK 349-357 NRIP1 4S15 
RORβ (NR1F2) QNDQILLLK 288-296 NCoA1 1NQ7 
RORγ (NR1F2) QNDQIVLLK 346-354 NCoA2, NRIP1, SMRT 5YP5, 3L0L, 
6FZU, 5NTI, 
5X8Q 
RxRα (NR2B1) DDQVILLR 295-302 NCoA2, TIF2 4RMC, 5MK4 
RXRβ (NR2B2) DDQVILLR 366-373 NCoA2- No interactions  
RXRγ (NR2B3) EDQVILLR 296-303 No coregulators  
SF1 (NR5A1) ADQMTLLQ 293-299 NCoA2, SHP, PGC1α 1ZDT 
SHP (NR0B2) QDQRRLLQ 82-89 No coregulators  
THRα (NR1A1) EDQIILLK 245-252 No coregulators  
THRβ (NR1A2) EDQIILLK 299-306 No coregulators  
TLX (NR2C2) QDQLMLLE 202-209 No coregulators  
TR2 (NR2C1)   No structures  
TR4 (NR2C2) DCNTSLVR 413-420 No coregulators  
VDR (NR1I1) DDQIVLLK 253-260 MED1 5AWK, 5B41 
211 
 






























































































Figure S3. Sequence conservation of the helix 4 motif. The sequence conservation of the 8-
residue helix 4 motif for several nuclear receptors was examined across several species which 
range from close relatives of humans to distantly related species. Total protein identity is shown in 
parentheses for each non-human sequence.  For all nuclear receptors shown this motif is fully 
conserved among mammals. The only sequences found to not be fully conserved are from proteins 
which do not meet the standard motif. Fully conserved residues are shown in bold while residues 





Figure S4. Experimental replicate of the LBD PPARγ-RxRα FP. A: Heatmap from an 
experimental replicate of the LBD PPARγ-RxRα. All values shown reflect the average value from 
two technical replicates within the single experimental replicate. B: Curve fits used to generate the 
heatmap shown in figure 2. C: Curve fits used to generate the heatmap shown in panel A. Error 





Figure S5. Experimental replicate of the FL PPARγ-RxRα-SULT2A1 FP. A: Heatmap from 
an experimental replicate of the FL PPARγ-RxRα-SULT2A1 PPRE. All values shown reflect the 
average value from two technical replicates within the single experimental replicate. B: Curve fits 
used to generate the heatmap shown in figure 2. C: Curve fits used to generate the heatmap shown 






Figure S6. CEST NMR indicates that the central peak observed in 19F NMR of PPARγQ294C-
BTFA arises from labeling of the native cysteine. A: Variable location CEST NMR of 
PPARγQ294C-BTFA reveals that in this variant that the rightmost peak is not in exchange with the 
central peak but does exchange with the leftmost. In this spectrum the peak for free BTFA, 
denoted with an asterisk, was truncated so as to not drown out the peaks from the protein. This 
truncation is why the observed peak is much wider than expected for a small molecule. B: Overlay 
of PPARγQ294C-BTFA (Blue) and a sample WT PPARγ-LBD labeled with a 40x molar excess of 
BTFA (Red). The WT PPARγ peak nearly perfectly overlays with the central peak of PPAγQ294C-






Figure S7. 19F NMR of PPARγC285A, Q294C-BTFA. A-L: The 19F NMR spectra of PPARγC285A, 
Q294C-BTFA in 12 distinct ligand bound states. The covalent ligands T0070907 and GW9662 were 





Figure S8. Curve fits of Mutant FP. A: The curve fits for FP of point mutants from a single 
experimental replicate. B: The curve fits for FP of point mutants from the second experimental 






Figure S9. TR-FRET evidences the same ligand behavior as is seen in FP data. A: TR-FRET 
data for MED1-2 association with  more ligands including a partial agonist, INT131, and an 
inverse agonist T0070907. This data shows the same pattern of ligand induced affinity as is seen 
in the FP assays with this peptide. Data in this panel is from the same experiment as is shown in 
figure 4. B: Experimental replicate of the MED1-2 TR-FRET data. Data in this experimental 
replicate was collected in a manner identical to that in panel A. C: Experimental replicate of the 
SRC1-2 TR-FRET shown in figure 4. Data in this panel was collected identically to that in figure 
4. D: Experimental replicate of the SRC1-2 TR-FRET shown in figure 4. Data in this experimental 
replicate was collected at a concentration of SRC1-2 half that used in figure 4. The pattern is 






Figure S10. Molecular dynamics of ERα. A: RMSD of ERα bound to SRC1-2 started from 
3UUD. B: : RMSD of ERα bound to SRC1-3 introduced to 3UUD. C: : RMSD of ERα bound to 
SRC202 started from 5DX3. D: : RMSD of ERα bound to SRC1-3 introduced to 5DX3. E: : 
RMSD of ERαY537S bound to SRC1-2 started from 3UUD. F: RMSD of ERαY537S bound to SRC1-
2 introduced to 3UUD. G: RMSD of ERαY537S bound to SRC2-2 started from 3UUD. H: RMSD of 
ERαY537S bound to SRC1-3 introduced to 5DX3. In panel H the first μs of data is omitted due to a 
saving error. To allow protein to reach a stable state only the data from 1.5-3.5μs was considered 
in this work. I: Fractional charge clamp interaction for all data in this work. In the WT ERα 
interaction is always between 100-200% indicating robust interaction and proper peptide location. 
In ERαY537S the interaction is not always well populated indicating there may be issues in the 





Figure S11. Chemical structures of the synthetic ligands and the 19F label used in this work. 
A-M: The chemical structures of all PPARγ ligands used in this work. N: The chemical structure 




 T0070907 GW9662 Apo SR1664 MRL24 Troglitazone Pioglitazone Rosiglitazone GW1929 
CBP-1 
1,118 520.7 414.5 601.7 381.2 280.8 182.2 131 81.8 
602.6 387.7 257.7 459.9 364.5 252.9 199.7 105.9 76.1 
MED1-
2 
2,953 1,492 861.9 2,093 1,814 641.4 462 347.5 145.5 
1,533 1,036 732.9 1,465 1,450 567.5 494.2 237.4 172 
PGC1α 
2,008 1,256 1,235 1,761 1,029 984 893.4 658.4 257.1 
1,586 1,230 1,110 1,868 1,149 1,264 1,042 648.9 363.6 
NCoR-1 
78.4 273.1 497.5 555.3 1,404 602.6 875.9 2087 2,374 
100 359.9 638.8 738.6 3,194 1,001 1,387 3,445 3,777 
 
Table S1. Kd  values for the LBD PPARγ-RxRα complex with coactivator peptides. The first 
experimental replicate is shown in blue while a second experimental replicate is shown in orange. 
All Kd values are in nanomolar and were obtained from non-linear curve fits of 12 data points 
ranging from 20-41600nM for the first experimental replicate or 21-43000nM for the second 




 T0070907 GW9662 Apo SR1664 MRL24 Troglitazone Pioglitazone Rosiglitazone GW1929 
CBP-1 
3,953 3,211 2,227 3,805 3,624 1,693 1,444 1,327 1,198 
5,431 2,385 1,791 2,579 2,020 1,375 1,134 1,161 1,015 
MED1-
2 
7,240 6,032 4,020 6,753 5,271 3,049 2,928 2,623 2,181 
3,390 2,592 2,149 2,795 2,869 1,893 1,507 1,311 1,185 
PGC1α 
8,844 8,203 7,425 10,144 7,720 6,408 5,571 5,340 4,034 
6,075 3,474 4,601 6,471 3,680 4,061 3,553 3,336 2,205 
NCoR-1 
1,055 2,628 3,022 3,324 3,692 4,444 6,015 6,877 6,875 
455 1,161 1,552 1,541 2,183 1,946 2,741 3,710 3,785 
 
Table S2. Kd  values for the full-length PPARγ-RxRα-DNA complex with coactivator 
peptides. The first experimental replicate is shown in blue while a second experimental replicate 
is shown in orange. All Kd values are in nanomolar and were obtained from non-linear curve fits of 
12 data points ranging from 26-53000nM for the first experimental replicate or 23-47600nM for 







Data collection   
Beamline                       APS 19BM APS 19BM 
Wavelength (Å)  0.979 0.979 
Ligand 1929 MED1+1929 
Resolution range (Å)*  
30.31  - 1.90 (1.97  
- 1.90) 
43.81  - 1.90  
(1.97  - 1.90) 
Space group  P 41 21 2 C 2 2 21 
Unit cell dimensions 
a, b, c (Å) 
α, β, γ (◦)                     
 
61.9 61.9 167.9 
 90 90 90 
 
55.4 87.6 121.6 
90 90 90 
Unique reflections*  26487 (2520) 23571 (2313) 
Redundancy* 8.0 (4.3) 9.8 (6.2) 
Completeness (%)* 99.22 (97.30) 99.26 (98.72) 
Mean I/σ (I)*  13.5 (2.3) 19.2 (7.6) 
Wilson B-factor  23.08 25.50 
Rsym
†,*  0.11 (0.65) 0.09 (0.56) 
Refinement   
Rwork
§,*                          0.2082 (0.3873) 0.2008 (0.3524) 
Rfree
§,*                           0.2446 (0.4103) 0.2574 (0.3881) 
Number of total atoms                   
protein 2217 2295 
1929 37 37 
Solvent 185 131 
Total protein residues  276 286 
RMS deviations 
Bonds lengths (Å) 









97.81/ 2.19/0.00 98.23/1.77/0.00 
Average B-factor                      
Macromolecules                   36.01 45.24 
GW1929 44.01 30.09 
water 38.05 45.26 
Number of TLS groups 0 1 
 
Table S3. Crystallography data collection and refinement statistics. 
* Data for highest resolution shell are given in brackets. † Rsym=∑hkl ∑i |Ii(hkl)-〈I(hkl)〉|/ ∑hkl ∑i 
Ii(hkl), where Ii(hkl) is the ith observation of the intensity of the reflection hkl. § Rwork=∑hkl || Fobs|-
|Fcalc||/ ∑hkl |Fobs|, where Fobs and Fcalc are the observed and calculated structure-factor amplitudes 
for each reflection hkl. Rfree was calculated with 5% of the diffraction data that were selected 




 CBP-1 MED1-2 PGC1α 
WT PPARγ-LBD 
Rosiglitazone 
82.12 226.80 884.00 
125.90 194.80 1966.0 
WT PPARγ-LBD 
GW1929 
48.71 180.80 413.7 
70.00 97.61 538.70 
PPARγK301A 
Rosiglitazone 
2,040 12,953 46,132 
2,135 10,894 >50,000 
PPARγK301A 
GW1929 
1,310 8,299 12,348 
1,853 8,177 12,310 
PPARγN312A 
Rosiglitazone 
4,787 1,674 1,590 
7,838 1,130 2,973 
PPARγN312A 
GW1929 
3,663 1,495 675 
4,886 1,127 1,306 
PPARγ-LBDK319A 
Rosiglitazone 
1,625 2,332 2,946 
1,247 1649 4,249 
PPARγ-LBDK319A 
GW1929 
839.5 2,407 1,484 
980.4 1,379 751.2 
PPARγ-LBDE499L 
Rosiglitazone 
>50,000 NBD >50,000 
>50,000 NBD >50,000 
PPARγE499L 
GW1929 
>50,000 NBD 34,686 
>50,000 NBD >50,000 
 
Table S4. Kd  values for the PPARγ mutants with coactivator peptides. The first experimental 
replicate is shown in blue while a second experimental replicate is shown in orange. All Kd values 
are in nanomolar and were obtained from non-linear curve fits of 12 data points ranging from 24-
49,500nM for both experimental replicates. Each curve was comprised of two technical replicates. 
A value of >50,000 indicates the affinity was lower than the highest concentration used so an 
accurate affinity cannot be determined. A value of NBD indicates that there was no indication of 
binding at the highest concentration used.  
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7.3 Supplementary material for chapter 4 
Data in this section is in final preparation for publication 
Supplementary material for 
Inverse agonists induce drug specific structure and function via 
distinct molecular mechanisms in the nuclear receptor PPARγ 
Zahra Heidari, Ian Chrisman, Scott Novick, Michelle Nemetchek, Theodore Kamenecka, 










Supplementary Figure 1. Accelerated MD reveals a more diverse structural 
ensemble for apo PPARγ and PPARγ bound to inverse agonists/antagonists 
compared to agonist bound PPARγ. a-f) Representative structures from clustering 
based on helix 12 RMSD of structures in the wells indicated in panel g. The identity of the 
energy well and the calculated prevalence of each well’s structures within the Boltzmann 
ensemble (see methods) is indicated by the number and percent in parentheses 
respectively. The prevalence of the structures within a particular well is indicated by the 
color of helix 12 ranging from dark green for the most prevalent to olive drab, light green, 
light blue and then deep sky blue for the least prevalent. For reference, an active 
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structure (rosiglitazone bound PPARγ; 2PRG chain A) is shown with helix 12 colored dim 
grey. g) The locations of the wells that were sampled to produce the representative 
structures in panels a-f is shown. Supplementary table 9 shows the relative energies of 
the wells indicated in panel g. 
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Supplementary Table 2. Comparison of coregulator peptide affinity for the ligand 




Supplementary Table 3. Comparison of coregulator peptide affinity for the ligand 







Supplementary Figure 2. Protein and 19F NMR of the helix 12 conformational 
ensemble. a-c) Comparison of K347A mutant, that would disrupt interaction between 
helix 4 and helix 12, and wt PPARγ LBD bound to the indicated ligands. Probable 
assignments, based on rosiglitazone bound PPARγ and apo PPARγ assignments, for 
residues affected by the mutation are indicated. The mutation consistently affects a 
resonance with shifts between 121 and 123 and 8.5 and 8.7 in all forms. Two 
rosiglitazone assigned residues are in this area, K347 and L463. L463 is far from the 
coregulator binding surface so we assume this resonance is K347 (the residue we 
mutated). d) The Boltzmann average values for interaction of the terminal side chain 
protons on K347 (i.e. NH3) and all other residues was calculated for PPARγ alone (apo) 
or bound to T0070907. When K347 is not interacting with helix 12 it interacts almost 
solely with solvent. c) all 58 representative structures shown in Supplementary Figure 1 
were subjectively classified as having active-like or inactive-like helix 12 conformations 
and prevalence of bonding between helix 12 residues and K347 were calculated from 





Supplementary Figure 3. The c-terminal portion of helix 3 is composed of a diverse 
structural ensemble in apo that consolidates upon binding coregulators, RXRα or 
ligands. a) The spectrum of wt PPARγ-BTFA (red) overlays well with the middle peak of 
PPARγQ322C-BTFA, indicating that the middle peak originates from labeling of the native 
cysteine (C313). The green arrow indicates signal from C313. b) Examples of spectra 
from delipidated PPARγC313A,Q322C-BTFA from different purifications and from non-
delipidated PPARγC313A,Q322C-BTFA (bottom panel). The delipidation efficacy is variable 
and affects the relative population of apo peaks with delipidation increasing the 
population of the left peak. This variability is also observed with spectra of apo bound to 
peptides. These data indicate that the left peak in these spectra originates from apo. The 
right peak may also be representative of apo PPARγ or E. coli lipid bound PPARγ or the 
lipid may simply push the apo helix 3 structure equilibrium towards the right peak. c-d) 
Overlay of PPARγQ322C-BTFA (blue), which can be labeled at the native cysteine (C313), 
and PPARγC313A,Q322C-BTFA (red) which cannot, reveals the signal originating from C313 
when PPARγ is bound to either c) NCoR or d) RXRα (green arrows). NCoR and RXRα 
binding consolidate the Q322C-BTFA signal into one main peak. e) Either CBP or NCoR 
was titrated into ligand free PPARγC313A,Q322C-BTFA (apo) at the indicated molar ratios of 
peptide to PPARγ starting with just PPARγ (0.0). Titration of both peptides again leads to 
peak consolidation. f) CEST indicates exchange between the peak denoted by the 
orange arrow and the black arrow, but not the central peak (which originates from the 
native cysteine). The black circles indicate the location of the saturating peak, while the 
height of the circles represent the height of the right peak labeled with the black arrow. g) 
Saturating NMR pulses were applied at the orange peak (in panel f) and an off-target 
area equidistant from the peak of interest (the right peak labeled with the black arrow in 
panel f) and the height of the right peak (panel f) was measured after various durations of 
the saturating NMR pulse. The data were then fit to a single exponential, which indicates 
232 
 
0.5 s-1 exchange (0.3-0.7 95% CI), however this is at the limit of detection and the 
exchange rate may be lower. h) Boltzmann averages of the RMSD of helix 3 charge 
clamp (K329) indicate higher variance in the position of K329 compared to when bound 
to inverse agonists/antagonists or agonists. i) Boltzmann averages of the helicity of a 
section of helix 3 near the charge clamp and containing the Q322C BTFA probe shows 
higher variance in the helicity in apo PPARγ compared to when bound to inverse 





Supplementary Figure 4. The n-terminal portion of helix 3 shows diverse ligand 
dependent conformations. a-b) PPARγ-Q299C was labeled with BTFA bound to the 
indicated ligands (or apo) and peptides and fluorine NMR spectra were collected. c) The 
extent of helix 3 extension beyond the normally observed n-terminus (V305) is indicated 
for individual simulations along with the Boltzmann average (pink bar). d) Comparison of 
the crystal structure of rosiglitazone bound PPARγ (white; PDB code 2PRG) with 
simulation structures of rosiglitazone bound PPARγ (dim grey) and T0070907 bound 
PPARγ (gold). The location of the probe (Q299) and the usual n-terminus of helix 3 
(V305) is shown. e) Three crystal structures show n-terminal helix 3 extension to residue 
301/272 (khaki), which is different from the non-helical form usually observed in this 
region (light blue; PDB code 1PRG). The three structures with n-terminal extension are 
PPARγ bound to a partial agonist (PDB code 1ZEO) and PPARγ bound to two 
antagonists (6C5Q, 6C5T). f) Overall Boltzmann average (pink bars) and average helicity 
(black circles) of a region (291-306) where n-terminal extension is observed in some 
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simulations. This region was chosen for analysis as it is the same region as observed 
peptides from the HDX-MS analysis (Supplementary Figure 8) 
 
Supplementary Figure 5. Accelerated molecular simulations indicate that two 
inverse agonists induce different conformations when bound to a peptide from the 
corepressor peptide NCoR. aMD simulations were run of PPARγ bound to the indicated 
ligands and a NCoR peptide. a) Representative structures from clustering based on helix 
12 RMSD of structures in the wells indicated in panel g. The identity of the energy well 
and the calculated prevalence of each well’s structures within the Boltzmann ensemble 
(see methods) is indicated by the number and percent in parentheses respectively. The 
prevalence of the structures within a particular well is indicated by the color of helix 12 
ranging from dark green for the most prevalent to olive drab, light green, light blue and 
then deep sky blue for the least prevalent. For reference, an active structure 
(rosiglitazone bound PPARγ; 2PRG chain A) is shown with helix 12 colored dim grey. 














Fold change for each construct and ligand is shown relative to the same condition in WT 
PPARγ LBD. Significance is determined by T-test corrected for multiple comparison using 
the Holm-Sidak method      P ≤ 0.05. A blue arrow indicates a loss of affinity relative to 
WT while a red arrow indicates a higher affinity. NS indicates that the value is not 




Supplementary Table 6, Kd values for PPARγ constructs and NCoR when bound to 
each ligand used in this study 
 






     
Construct     
WT PPARγ 388.25±38.86 97.33±5.07 424.83±124.86 255.93±23.21 
Q314A 480.10±86.27 255.75±107.27 296.50±16.40 1114.20±307.73 
K329A 3474.35±18.88 703.05±90.16 2985.00±791.96 1556.50±40.31 
N340A 572.70±53.03 142.40±5.80 503.25±29.34 369.95±1.77 
K347A 1056.55±64.42 307.45±32.74 473.9±13.01 632.5±55.44 
E499L 318.43±5.80 158.93±16.05 104.82±15.24 396.80±84.00 
Deletion of 
Helix 12 
70.13±35.64 97.35±61.36 53.65±29.05 90.15±56.35 
 
Values are reported in nanomolar. Error represents the standard deviation of n separate 
experiments for each condition. For WT PPARγ n = 4, for Q314A n = 2, for K329A n = 2, 
for N340A n = 2, for K347A n = 2, for E499L n = 3, for Deletion of helix 12 n = 4. Kd 
values were determined from non-linear regression four-parameter variable slope fit of 12 
data points with concentrations ranging from 25 – 50,000nM ligand and protein. All fits 





Supplementary Figure 6. Helix 3 extension reduces omega loop-helix 3 interaction 
and salt-bridge interactions. a) Comparison of the total number of hydrogen bonds 
between the omega loop and helix 3 for simulations of various complexes and b) 
comparison between the Boltzmann average of the root mean square deviation between 
helix 3 and the omega loop and helix 3 extension. c) Comparison of the prevalence of 
hydrogen bonding between beta sheet residues for the indicated complexes. Bars 
represent Boltzmann averages, dots represent values of the individual aMD inspired cMD 
simulations. 
d) Analysis of the indicated salt bridge formation for all available crystal structures of 
PPARγ .e) Comparison of the prevalence of the indicated salt bridges and helical 
extension for the indicated complexes and for all available crystal structures. The helix 6-
7 loop (R385/357) to helix 11-12 loop (E488/460) salt bridge is not observed for the 13 
structural ensembles with an n-terminal helix 3 extension of 2 or more residues beyond 
V305/277 (i.e. the n-terminus of helix 3 normally observed in crystal structures) while it is 
observed in 22 of 27 structures that lack helix 3 extension. 12 of 13 structural ensembles 
with an extended helix 3 lack the R385 to E304 salt bridge while it is present in 26 of 27 






Supplementary Figure 7. 19F NMR reveals structurally and functionally distinct 
states in the charge clamp region of helix 3. 
a-b) PPARγQ322C covalently bound to T0070907 or GW9662 (which bind to the sole native 
cysteine, C313) was labeled with high concentration of BTFA (40x the protein 
concentration of ~150 μM) to yield high signal to noise spectra with no possibility of 
labeling the native cysteine. The indicated coregulators or RXRα were added at a 2:1 
molar ratio. These spectra yield evidence of multiple peaks even without other proteins or 
peptides bound, most obviously for PPARγQ322C-BTFA bound to GW9662 (panel b). d-f) 
PPARγQ322C-BTFA was loaded with the indicated ligands and 19F NMR spectra were 
acquired followed by deconvolution. g) Saturating pulses (circles) were applied at the 
minor peak chemical shift (on; black circles) and at a control location equidistant from the 
main peak (off; blue circles) for various durations. The normalized intensity of the main 
peak was monitored and plotted against the duration of the pulses and fit to determine 
the exchange rate (1.7 s-1; 95% CI=1.5-2.0). h) CEST indicates exchange between the 
240 
 
minor left peak and the major peak in PPARγQ322C-BTFA (top spectrum; panel b). The 
position of the black circles indicate the region of saturation and their y position indicates 
the height of the major peak (black arrow) upon saturation. A small deviation is noted 
when saturating near the minor peak (red arrow) indicating exchange between the minor 
and major peak. i) deconvolution of the GW9662 spectrum indicated the presence of 
signal downfield (left) of the readily visible peaks. We tested for exchange of these peaks 
with the major peak using selective saturating pulses in this region (orange arrows) and 
control upfield pulses equidistant from the major peak (black arrows). The intensity of the 
major peak was measured after saturating pulses at these locations and compared. This 
was repeated 4 times on the same sample at each location. A two-tailed t-test indicates 




Supplementary Figure 8. HDX-MS data of PPARγ bound to NCoR peptide alone or co-
bound to T0070907 or SR10221. Detected peptide sequences residue numbers and 
change in HDX is shown. A decrease in exchange in the T0070907 complex peptide 
compared to the indicated complexes is shown as a negative number while an increase 
is shown as a positive number. Standard deviation is shown in parantheses. Peptides 
with significant differences are shown in color, while insignificant are shown in grey and 














Supplementary Figure 9. Helix 12 binds to the coregulator surface in many crystal 
structures in a similar manner to NCoR and Helix 12 in simulations. Representative 
structures from the fifth lowest energy well in apo PPARγ where helix 12 binds to the 
coregulator binding surface (left; gold) and the second lowest energy well from the 
PPARγ cobound to SR10221 and NCoR (right; gold) simulations are aligned with the unit 





Supplementary Figure 10. SMRT induces similar changes to helix 12 as NCoR for 
PPARγ bound to the indicated ligands. PPARγK502C-BTFA was saturated with the 
indicated ligands and a 2:1 molar ratio of SMRT peptide was added. Fluorine NMR was 
then performed.  
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